東北大学研究者紹介 - 杉村　宏一郎

研究者詳細

ホーム

日本語 English

スギムラ　コウイチロウ

杉村　宏一郎

Koichiro Sugimura

所属

大学院医学系研究科　保健学専攻　臨床検査医科学講座（臨床生理検査学分野）

職名

教授

学位

博士（医学）（東北大学）

researchmap

https://researchmap.jp/ksugimura4120

J-GLOBAL ID

202101006757129606

e-Rad 研究者番号

60375079

ORCID

https://orcid.org/0000-0001-5354-9687

経歴 6

2020年4月～ 2026年3月

国際医療福祉大学医学部　循環器内科学　教授
2026年4月～継続中

東北大学大学院医学系研究科保健学専攻臨床生理検査学分野　健学専攻臨床生理検査学分野　教授
2017年4月～ 2020年3月

東北大学　循環器内科　講師
2012年4月～ 2017年3月

東北大学　循環器内科　院内講師
2007年4月～ 2012年3月

東北大学病院　循環器内科　助教
2006年10月～ 2007年3月

東北大学　高度救命救急センター　助教

︎全件表示 ︎最初の5件までを表示

学歴 2

東北大学　大学院医学系研究科

2000年4月～ 2004年3月
東北大学　医学部

1991年4月～ 1996年3月

研究キーワード 5

生理検査
腫瘍循環器
心不全
Fabry 病
肺高血圧症

研究分野 1

ライフサイエンス / 循環器内科学 / 腫瘍循環器肺高血圧症心不全心筋症

受賞 4

八巻賞

2019年6月　日本肺高血圧症・肺循環学会　非手術適応慢性血栓塞栓性肺高血圧症に対する新たな治療法の確立
奨励賞金賞

2017年12月　宮城県医師会
奨学賞金賞

2017年12月　東北大学医学部
Best poster award

2014年8月　ヨーロッパ心臓病学会

論文 252

Usefulness of cardiac magnetic resonance for early detection of cancer therapeutics-related cardiac dysfunction in breast cancer patients. 国際誌

Yosuke Terui, Koichiro Sugimura, Hideki Ota, Hiroshi Tada, Kotaro Nochioka, Haruka Sato, Yuko Katsuta, Junko Fujiwara, Narumi Harada-Shoji, Akiko Sato-Tadano, Yoshiaki Morita, Wenyu Sun, Satoshi Higuchi, Shunsuke Tatebe, Shigefumi Fukui, Saori Miyamichi-Yamamoto, Hideaki Suzuki, Nobuhiro Yaoita, Nobuhiro Kikuchi, Miku Sakota, Satoshi Miyata, Yasuhiko Sakata, Takanori Ishida, Kei Takase, Satoshi Yasuda, Hiroaki Shimokawa

International journal of cardiology　371　472-479　2022年9月14日

DOI： 10.1016/j.ijcard.2022.09.025 　

詳細を見る詳細を閉じる

BACKGROUND: Prognosis of breast cancer patients has been improved along with the progress in cancer therapies. However, cancer therapeutics-related cardiac dysfunction (CTRCD) has been an emerging issue. For early detection of CTRCD, we examined whether native T1 mapping and global longitudinal strain (GLS) using cardiac magnetic resonance (CMR) and biomarkers analysis are useful. METHODS: We prospectively enrolled 83 consecutive chemotherapy-naïve female patients with breast cancer (mean age, 56 ± 13 yrs.) between 2017 and 2020. CTRCD was defined based on echocardiography as left ventricular ejection fraction (LVEF) below 53% at any follow-up period with LVEF>10% points decrease from baseline after chemotherapy. To evaluate cardiac function, CMR (at baseline and 6 months), 12‑lead ECG, echocardiography, and biomarkers (at baseline and every 3 months) were evaluated. RESULTS: A total of 164 CMRs were performed in 83 patients. LVEF and GLS were significantly decreased after chemotherapy (LVEF, from 71.2 ± 4.4 to 67.6 ± 5.8%; GLS, from -27.9 ± 3.9 to -24.7 ± 3.5%, respectively, both P < 0.01). Native T1 value also significantly elevated after chemotherapy (from 1283 ± 36 to 1308 ± 39 msec, P < 0.01). Among the 83 patients, 7 (8.4%) developed CTRCD. Of note, native T1 value before chemotherapy was significantly higher in patients with CTRCD than in those without it (1352 ± 29 vs. 1278 ± 30 msec, P < 0.01). The multivariable logistic regression analysis revealed that native T1 value was an independent predictive factor for the development of CTRCD [OR 2.33; 95%CI 1.15-4.75, P = 0.02]. CONCLUSIONS: These results indicate that CMR is useful to detect chemotherapy-related myocardial damage and predict for the development of CTRCD in breast cancer patients.
Quantification of vortex flow in pulmonary arteries of patients with chronic thromboembolic pulmonary hypertension

Hiroki Kamada, Hideki Ota, Masanori Nakamura, Wenyu Sun, Tatsuo Aoki, Haruka Sato, Koichiro Sugimura, Kei Takase

European Journal of Radiology　148　2022年3月

DOI： 10.1016/j.ejrad.2021.110142 　

ISSN：0720-048X

eISSN：1872-7727
Systemic-pulmonary collateral supply associated with clinical severity of chronic thromboembolic pulmonary hypertension: a study using intra-aortic computed tomography angiography

Wenyu Sun, Hideki Ota, Haruka Sato, Saori Yamamoto, Shunsuke Tatebe, Tatsuo Aoki, Koichiro Sugimura, Junya Tominaga, Hiroaki Shimokawa, Takuya Ueda, Kei Takase

European Radiology　32　(11)　7668-7679　2022年

DOI： 10.1007/s00330-022-08768-6 　

ISSN：0938-7994

eISSN：1432-1084
乳癌患者における化学療法関連心機能障害の予測におけるNative T1 Mappingの有用性(Usefulness of Native T1 Mapping for Prediction of Chemotherapeutics-related Cardiac Dysfunction in Breast Cancer Patients)

照井洋輔, 杉村宏一郎, 大田英揮, 多田寛, 勝田祐子, 佐藤遥, 後岡広太郎, 建部俊介, 宮田敏, 坂田泰彦, 石田孝宜, 高瀬圭, 安田聡

日本循環器学会学術集会抄録集　85回　OJ29-5　2021年3月
出版者・発行元： (一社)日本循環器学会
Current Clinical Characteristics and Outcomes of Patients with Adult Congenital Heart Disease Associated with Pulmonary Hypertension(和訳中)

建部俊介, 紺野亮, 杉村宏一郎, 福井重文, 後岡広太郎, 山本沙織, 鈴木秀明, 矢尾板信裕, 佐藤遥, 照井洋輔, 岩澤伸哉, 松尾論志, 佐藤公雄, 齋木佳克, 下川宏明, 安田聡

日本循環器学会学術集会抄録集　85回　OJ34-6　2021年3月
出版者・発行元： (一社)日本循環器学会
Usefulness of Native T1 Mapping for Prediction of Chemotherapeutics-related Cardiac Dysfunction in Breast Cancer Patients(和訳中)

照井洋輔, 杉村宏一郎, 大田英揮, 多田寛, 勝田祐子, 佐藤遥, 後岡広太郎, 建部俊介, 宮田敏, 坂田泰彦, 石田孝宜, 高瀬圭, 安田聡

日本循環器学会学術集会抄録集　85回　OJ29-5　2021年3月
出版者・発行元： (一社)日本循環器学会
Identification of the Novel Variants in Patients With Chronic Thromboembolic Pulmonary Hypertension. 国際誌

Nobuhiro Yaoita, Kimio Satoh, Taijyu Satoh, Toru Shimizu, Sakae Saito, Koichiro Sugimura, Shunsuke Tatebe, Saori Yamamoto, Tatsuo Aoki, Nobuhiro Kikuchi, Ryo Kurosawa, Satoshi Miyata, Masao Nagasaki, Jun Yasuda, Hiroaki Shimokawa

Journal of the American Heart Association　9　(21)　e015902　2020年11月3日

DOI： 10.1161/JAHA.120.015902 　

詳細を見る詳細を閉じる

Background Although chronic thromboembolic pulmonary hypertension (CTEPH) and acute pulmonary embolism (APE) share some clinical manifestations, a limited proportion of patients with CTEPH have a history of APE. Moreover, in histopathologic studies, it has been revealed that pulmonary vasculature lesions similar to pulmonary arterial hypertension existed in patients with CTEPH. Thus, it remains unknown whether these 3 disorders also share genetic backgrounds. Methods and Results Whole exome screening was performed with DNA isolated from 51 unrelated patients with CTEPH of Japanese ancestry. The frequency of genetic variants associated with pulmonary arterial hypertension or APE in patients with CTEPH was compared with those in the integrative Japanese Genome Variation Database 3.5KJPN. Whole exome screening analysis showed 17 049 nonsynonymous variants in patients with CTEPH. Although we found 6 nonsynonymous variants that are associated with APE in patients with CTEPH, there was no nonsynonymous variant associated with pulmonary arterial hypertension. Patients with CTEPH with a history of APE had nonsynonymous variants of F5, which encodes factor V. In contrast, patients with CTEPH without a history of APE had a nonsynonymous variant of THBD, which encodes thrombomodulin. Moreover, thrombin-activatable fibrinolysis inhibitor, which is one of the pathogenic proteins in CTEPH, was significantly more activated in those who had the variants of THBD compared with those without it. Conclusions These results provide the first evidence that patients with CTEPH have some variants associated with APE, regardless of the presence or absence of a history of APE. Furthermore, the variants might be different between patients with CTEPH with and without a history of APE.
肺高血圧症を合併する成人先天性心疾患の臨床像

建部俊介, 紺野亮, 杉村宏一郎, 福井重文, 山本沙織, 鈴木秀明, 矢尾板信裕, 佐藤遥, 菊地順裕, 照井亮輔, 後岡広太郎, 佐藤公雄, 下川宏明

脈管学　60　(Suppl.)　S169-S169　2020年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty - A randomized controlled study. 国際誌

Tatsuo Aoki, Koichiro Sugimura, Yosuke Terui, Shunsuke Tatebe, Shigefumi Fukui, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Hideaki Suzuki, Haruka Sato, Katsuya Kozu, Ryo Konno, Satoshi Miyata, Kotaro Nochioka, Kimio Satoh, Hiroaki Shimokawa

International journal of cardiology. Heart & vasculature　29　100579-100579　2020年8月

DOI： 10.1016/j.ijcha.2020.100579 　

詳細を見る詳細を閉じる

Background: Although balloon pulmonary angioplasty (BPA) improves symptoms and pulmonary hemodynamics in patients with chronic thromboembolic pulmonary hypertension (CTEPH), the effects of riociguat on hemodynamics and exercise capacity in patients after BPA remain to be elucidated. Methods and Results: This study was a single-center, prospective, randomized, open-label trial. From November 2015 to November 2018, we prospectively examined 21 patients with CTEPH (65 ± 9 years old, M/F 2/19) who showed hemodynamic improvement with mean pulmonary arterial pressure (mPAP) < 30 mmHg after BPA without any vasodilators. We performed hemodynamic evaluation and expired gas analysis both at rest and during exercise in supine position using cycle ergometer. After right heart catheterization during exercise, they were randomly assigned to 2 groups with minimized method, using age, sex, and resting mPAP; riociguat (N = 10) and control (N = 11) groups. After 6 months, exercise capacity evaluated by 6-min walk distance and cardiopulmonary exercise testing, and resting hemodynamic parameters were comparable in both groups. However, cardiac output (CO) (6.0 ± 1.7-7.4 ± 1.6, P < 0.01) and pulmonary vascular resistance (4.8 ± 1.8-3.2 ± 0.7 Wood units, P = 0.02) at peak workload were significantly improved in the riociguat group as compared with the control group. The slope of linearized mPAP-CO relationship was significantly decreased in the riociguat group [14.5 (7.8, 14.7) to 6.41 (5.1, 11.4), P < 0.01] but not in the control group. Conclusions: These results indicate that riociguat exerts beneficial effects on hemodynamic response to exercise in CTEPH patients even after hemodynamic improvement by BPA.
循環器疾患患者の妊娠と出産心血管疾患を有する妊婦の現状(Current Status of Pregnant Women with Cardiovascular Disease)

山本沙織, 建部俊介, 杉村宏一郎, 齋藤昌利, 坂田泰彦, 佐藤公雄, 福井重文, 鈴木秀明, 佐藤遥, 紺野亮, 照井洋輔, 岩澤伸哉, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　84回　シンポジウム23-3　2020年7月
出版者・発行元： (一社)日本循環器学会
健康関連QOLによる成人先天性心疾患患者の心血管系アウトカムと予定外再入院の予測(Health-related Quality of Life Predicts Cardiovascular Outcomes and Unplanned Hospital Admissions in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 福井重文, 鈴木秀明, 山本沙織, 佐藤遥, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　84回　OJ32-5　2020年7月
出版者・発行元： (一社)日本循環器学会
Viral genome search in myocardium of patients with fulminant myocarditis. 国際誌

Giacomo Veronese, Enrico Ammirati, Michela Brambatti, Marco Merlo, Manlio Cipriani, Luciano Potena, Paola Sormani, Tatsuo Aoki, Koichiro Sugimura, Akinori Sawamura, Takahiro Okumura, Sean Pinney, Kimberly Hong, Palak Shah, Oscar Ö Braun, Caroline M Van de Heyning, Santiago Montero, Duccio Petrella, Florent Huang, Matthieu Schmidt, Claudia Raineri, Anuradha Lala, Marisa Varrenti, Alberto Foà, Ornella Leone, Piero Gentile, Jessica Artico, Valentina Agostini, Rajiv Patel, Andrea Garascia, Emeline M Van Craenenbroeck, Kaoru Hirose, Akihiro Isotani, Toyoaki Murohara, Yoh Arita, Alessandro Sionis, Enrico Fabris, Sherin Hashem, Victor Garcia-Hernando, Fabrizio Oliva, Barry Greenberg, Hiroaki Shimokawa, Gianfranco Sinagra, Eric D Adler, Maria Frigerio, Paolo G Camici

European journal of heart failure　22　(7)　1277-1280　2020年7月

DOI： 10.1002/ejhf.1738 　
Non-invasive screening using ventilatory gas analysis to distinguish between chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. 国際誌

Mina Akizuki, Koichiro Sugimura, Tatsuo Aoki, Takaaki Kakihana, Shunsuke Tatebe, Saori Yamamoto, Haruka Sato, Kimio Satoh, Hiroaki Shimokawa, Masahiro Kohzuki

Respirology (Carlton, Vic.)　25　(4)　427-434　2020年4月

DOI： 10.1111/resp.13618 　

詳細を見る詳細を閉じる

BACKGROUND AND OBJECTIVE: Clinical presentations associated with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) at rest are highly similar. Differentiating between CTEPH and PAH using non-invasive techniques remains challenging. Thus, we examined whether analysis of ventilatory gas in response to postural changes can be useful as a non-invasive screening method for pulmonary hypertension (PH), and help differentiate CTEPH from PAH. METHODS: We prospectively enrolled 90 patients with suspected PH and performed right heart catheterization, ventilation/perfusion scan and ventilatory gas analysis. Various pulmonary function parameters were examined in the supine and sitting postures, and postural changes were calculated (Δ(supine - sitting)). RESULTS: In total, 25 patients with newly diagnosed PAH, 40 patients with newly diagnosed CTEPH and 25 non-PH patients were included. ΔEnd-tidal CO2 pressure (PET CO2 ) was significantly lower in patients with CTEPH and PAH than in non-PH patients (both P < 0.001). ΔPET CO2 < 0 mm Hg could effectively differentiate PH from non-PH (area under the curve (AUC) = 0.969, sensitivity = 89%, specificity = 100%). Postural change from sitting to supine significantly increased the ratio of ventilation to CO2 production (VE/VCO2 ) in the CTEPH group (P < 0.001). By contrast, VE/VCO2 significantly decreased in the PAH group (P = 0.001). Notably, CTEPH presented with higher ΔVE/VCO2 than PAH, although no differences were observed in haemodynamic and echocardiographic parameters between the two groups (P < 0.001). Furthermore, ΔVE/VCO2 > 0.8 could effectively differentiate CTEPH from PAH (AUC = 0.849, sensitivity = 78%, specificity = 88%). CONCLUSION: Postural changes in ventilatory gas analysis are useful as a non-invasive bedside evaluation to screen for the presence of PH and distinguish between CTEPH and PAH.
Cyclophilin A as a biomarker for the therapeutic effect of balloon angioplasty in chronic thromboembolic pulmonary hypertension. 国際誌

Katsuya Kozu, Kimio Satoh, Tatsuo Aoki, Shunsuke Tatebe, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Hideaki Suzuki, Toru Shimizu, Haruka Sato, Ryo Konno, Yosuke Terui, Kotaro Nochioka, Nobuhiro Kikuchi, Taijyu Satoh, Koichiro Sugimura, Satoshi Miyata, Hiroaki Shimokawa

Journal of cardiology　75　(4)　415-423　2020年4月

DOI： 10.1016/j.jjcc.2019.09.010 　

詳細を見る詳細を閉じる

BACKGROUND: Although cardiac troponin and natriuretic peptide have been shown to decrease after balloon pulmonary angioplasty (BPA) with improved right ventricular afterload in chronic thromboembolic pulmonary hypertension (CTEPH), biomarkers to evaluate the effects of BPA independently of heart failure status remain to be developed. METHODS: In 39 consecutive CTEPH patients including 31 who underwent BPA, we measured plasma levels of cyclophilin A (CyPA), which we demonstrated is secreted from pulmonary vascular smooth muscle cells in response to mechanical stretch and hypoxia. RESULTS: CyPA levels were elevated in CTEPH patients (12.7, IQR: 7.6-16.0) compared with 8 thromboembolic controls with a history of venous thromboembolism (4.9, IQR: 2.4-11.2) or 18 healthy controls (4.1, IQR: 2.4-6.8) (both p< 0.05) and were linearly correlated with mean pulmonary arterial pressure (r=0.50, p = 0.0003) and pulmonary vascular resistance (r=0.32, p= 0.026). BPA reduced CyPA levels and tended to lower brain-type natriuretic peptide (BNP) levels (p< 0.01 and p = 0.07). When comparing the changes in CyPA before and after BPA in the two subgroups with higher (≥35pg/mL) and normal (<35pg/mL) BNP at baseline, CyPA decreased both in patients with higher BNP and those with normal BNP (both p< 0.05). In contrast, BNP decreased only in patients with higher BNP (p< 0.05). Also, CyPA decreased both in patients with lower (<25 kg/m2) and higher (≥25kg/m2) body mass index (BMI) at baseline (both p<0.05), whereas BPA tended to reduce BNP in patients with lower BMI (p = 0.12) but not in those with higher BMI (p = 0.55). CONCLUSIONS: CyPA could be a useful biomarker to evaluate the effects of BPA even in patients with normal BNP or high BMI.
Effect of riociguat from a different angle. 国際誌

Koichiro Sugimura

International journal of cardiology　304　156-157　2020年4月1日

DOI： 10.1016/j.ijcard.2019.12.017 　
4D-flow MRI assessment of blood flow before and after endovascular intervention in a patient with pulmonary hypertension due to isolated pulmonary artery involvement in large vessel vasculitis. 国際誌

Hiroki Kamada, Hideki Ota, Tatsuo Aoki, Koichiro Sugimura, Nobuhiro Yaoita, Hiroaki Shimokawa, Kei Takase

Radiology case reports　15　(3)　190-194　2020年3月

DOI： 10.1016/j.radcr.2019.11.019 　

詳細を見る詳細を閉じる

A 43-year-old woman presented with dyspnea during exertion and lower leg edema. Contrast-enhanced computed tomography images demonstrated extensive proximal narrowing in the right main pulmonary artery with thickening and enhancement. Right heart catheterization revealed the presence of precapillary pulmonary hypertension with a mean pulmonary arterial pressure of 45 mm Hg. The patient was diagnosed with large-vessel vasculitis with isolated pulmonary artery involvement. Takayasu's arteritis was suspected, but histological examination was not performed. Several sessions of pulmonary arterial intervention were stratified for the right main pulmonary artery. After treatment, mean pulmonary arterial pressure had decreased to 22 mm Hg with improvement in symptoms. Thoracic 4D-flow magnetic resonance imaging was performed before and after intervention to evaluate the volume flow rates of pulmonary arteries. The rates increased at the inlet of the right pulmonary artery (before: 23 mL/s vs after: 47.5 mL/s) and the main pulmonary artery (before: 71.2 mL/s vs after: 82.5 mL/s), and decreased at the inlet of the left pulmonary artery (before: 46.2 mL/s vs after: 31.7 mL/s). The split ratio of volume flow rate between the right and left pulmonary arteries improved after treatment (before. right:left = 33.1:66.9; after, right:left = 60.0:40.0), approaching normal values. This report quantitatively describes perioperative hemodynamic changes in a patient with pulmonary hypertension using 4D-flow magnetic resonance imaging. Stent placement for stenosis in the right pulmonary artery resulted in an increase in overall pulmonary blood flow and also improved blood flow balance between the right and the left pulmonary arteries.
Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. 国際誌

Katsuya Kozu, Koichiro Sugimura, Masaaki Ito, Ken-Ichi Hirata, Koichi Node, Takuya Miyamoto, Shuichi Ueno, Hiroshi Watanabe, Hiroaki Shimokawa

International journal of cardiology　300　228-235　2020年2月1日

DOI： 10.1016/j.ijcard.2019.11.139 　

詳細を見る詳細を閉じる

BACKGROUND: In the current era of treatment of pulmonary hypertension (PH) in Japan, combination therapy has been frequently used thanks to the medical insurance system. Additionally, pulmonary balloon angioplasty (BPA) is widely performed for chronic thromboembolic PH (CTEPH). METHODS: To elucidate the long-term prognosis and the prognostic factors among all five subtypes of PH in this new era, we examined the current status of management of PH from November 2012 to April 2016 in the multicenter registry by the Japanese Pulmonary Circulation Society. RESULTS: Among 1253 consecutive patients registered from 20 PH centers in Japan, we analyzed 997 patients with mean pulmonary arterial pressure ≥ 25 mmHg by right heart catheterization. Transplant-free survival at 5 years in pulmonary arterial hypertension (PAH), PH due to left-heart disease, PH due to lung diseases, CTEPH, and miscellaneous PH were 74.0, 69.3, 63.7, 92.0, and 55.3%, respectively. Of note, 32% of PAH patients were treated with double combination therapy and 42% of those with triple combination therapy, and 66% of CTEPH patients with BPA. Although PAH patients with triple combination therapy had worse hemodynamic parameters than those with other medications, triple combination therapy showed the best prognosis. BPA in CTEPH improved survival even when adjusted for the key background factors. CONCLUSIONS: In the current era of PH treatment in Japan, the five-year transplant-free survival rate in this study was 74% for PAH and 92% for CTEPH, in which active combination medical therapy for PAH and higher performance rate of BPA for CTEPH may be involved.
成人先天性心疾患患者における心血管イベントと緊急入院の予測因子としての健康関連QoL(Health-related Quality of Life Predicts Cardiovascular Outcomes and Unplanned Hospital Admissions in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 福井重文, 鈴木秀明, 山本沙織, 佐藤遥, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本成人先天性心疾患学会雑誌　9　(1)　243-243　2020年1月
出版者・発行元：日本成人先天性心疾患学会
Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody. 国際誌

Yusho Ishii, Hiroshi Fujii, Koichiro Sugimura, Tsuyoshi Shirai, Yosuke Hoshi, Yoko Fujita, Yuko Shirota, Tomonori Ishii, Hiroaki Shimokawa, Hideo Harigae

Case reports in rheumatology　2020　1926908-1926908　2020年

DOI： 10.1155/2020/1926908 　

詳細を見る詳細を閉じる

Systemic sclerosis (SSc) is characterized by skin sclerosis and multiple organ damages which may cause mortality and is usually accompanied with several specific autoantibodies, each of which is associated with characteristic complications. Among them, anticentriole antibody is recently reported to be highly associated with SSc-associated pulmonary arterial hypertension (SSc-PAH). In general, several vasodilators are used as therapeutic drugs for SSc-PAH, whereas immunosuppressive therapies are not. Here, we report the case of a 62-year-old female with anticentriole antibody-positive SSc-PAH treated with immunosuppressants and vasodilators. She presented with two-year exertional dyspnea and was diagnosed with PAH and SSc owing to the centriole staining pattern and other symptoms without digital sclerosis. Oral vasodilators were initially administered but were not sufficiently effective on dyspnea. Immunosuppressants such as prednisolone and cyclophosphamide were started. Both of them improved mean pulmonary arterial pressure and 6-minute walk distance, and the anticentriole antibody also disappeared. In this case, SSc-PAH with anticentriole antibody was properly diagnosed and immunosuppressants and vasodilators improved the hemodynamics of PAH with anticentriole antibody and stably maintained it and, in addition, reduced the titer of anticentriole antibody. This indicates that anticentriole antibody might represent a good responsive group to therapies among subgroups of patients with SSc-PAH.
Three cases of pulmonary tumor thrombotic microangiopathy (PTTM): Challenge in antemortem diagnosis using lung perfusion blood volume images by dual-energy computed tomography. 国際誌

Hiroki Kamada, Hideki Ota, Yosuke Terui, Koichiro Sugimura, Shigefumi Fukui, Hiroaki Shimokawa, Kei Takase

European journal of radiology open　7　100212-100212　2020年

DOI： 10.1016/j.ejro.2020.01.001 　

詳細を見る詳細を閉じる

Pulmonary tumor thrombotic microangiopathy (PTTM) is a specific type of tumor embolism in the small and medium pulmonary arteries, leading to rapid progressive pulmonary hypertension. Antemortem diagnosis of PTTM is extremely difficult. We encountered three patients who were histopathologically or clinically diagnosed with PTTM. In all cases, lung perfused blood volume (PBV) images on dual-energy computed tomography (CT) demonstrated multiple subpleural wedge-shaped defects with no evidence of pulmonary embolism on CT pulmonary angiography. The lung PBV images demonstrated small pulmonary arterial obstruction reflecting the pathology of PTTM. Therefore, lung PBV imaging would be useful for antemortem diagnosis of PTTM.
Usefulness of ventilatory gas analysis for the non-invasive evaluation of the severity of chronic thromboembolic pulmonary hypertension. 国際誌

Mina Akizuki, Koichiro Sugimura, Tatsuo Aoki, Takaaki Kakihana, Shunsuke Tatebe, Saori Yamamoto, Haruka Sato, Kimio Satoh, Hiroaki Shimokawa, Masahiro Kohzuki

International journal of cardiology　296　149-154　2019年12月1日

DOI： 10.1016/j.ijcard.2019.07.018 　

詳細を見る詳細を閉じる

BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by organic thrombotic obstructions in the pulmonary arteries with reduced pulmonary vascular reserve. This study aimed to examine whether postural changes in ventilatory gas analysis parameters are useful for assessing pulmonary hemodynamics in patients with CTEPH. METHODS: A total of 44 patients with newly diagnosed CTEPH (CTEPH group), 33 patients with improved CTEPH (mean pulmonary arterial pressure [mPAP] <25 mm Hg), and 25 controls were enrolled. Patients with improved CTEPH referred to patients without residual PH who were previously diagnosed with CTEPH and already received optimal therapies. Various pulmonary function parameters were examined in supine and sitting positions, and postural changes were calculated (Δ[supine - sitting]). In 32 patients with CTEPH, we examined hemodynamic and ventilatory gas analysis parameters before the first balloon pulmonary angioplasty (BPA) and during follow-up. RESULTS: Patients with CTEPH had significantly lower supine end-tidal carbon dioxide pressure (PETCO2) and ΔPETCO2 than controls (both P < 0.001), and these parameters were significantly correlated with mPAP (R2 = 0.507, P < 0.0001 and R2 = 0.470, P < 0.001, respectively). Supine PETCO2 and ΔPETCO2 were significantly lower in patients with improved CTEPH than in controls (both P < 0.001). Hemodynamic and echocardiographic parameters were comparable in both groups. Furthermore, significant correlation between the change in mPAP and change in supine PETCO2 by BPA was noted (R2 = 0.478, P < 0.001). CONCLUSION: These results indicate that postural changes in ventilatory gas analysis parameters are useful and non-invasive method for the evaluation of mPAP, which is one of the hemodynamic parameters of CTEPH severity.
肺高血圧に対する治療戦略 BPA治療後のCTEPH患者においてリオシグアトは運動負荷による血行動態反応を改善する

杉村宏一郎, 青木竜男, 建部俊介, 福井重文, 山本沙織, 佐藤遥, 紺野亮, 照井洋輔, 下川宏明

脈管学　59　(Suppl.)　S127-S127　2019年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
肺高血圧症の最新治療 BPA後のCTEPH患者におけるリオシグアトの有用性

青木竜男, 杉村宏一郎, 建部俊介, 山本沙織, 鈴木秀明, 佐藤遥, 後岡広太郎, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　67回　S12-2　2019年9月
出版者・発行元： (一社)日本心臓病学会
心房中隔欠損による肺高血圧症患者に脳膿瘍を併発した一例

照井洋輔, 杉村宏一郎, 建部俊介, 福井重文, 山本沙織, 佐藤遥, 紺野亮, 下川宏明

日本心臓病学会学術集会抄録　67回　O-121　2019年9月
出版者・発行元： (一社)日本心臓病学会
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. 国際誌査読有り

Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, Koichi Tamita, Toshihiro Kawasaki, Jun Kajihara, Akifumi Onishi, Hitoshi Sugiyama, Teiko Sakai, Ichijiro Murata, Takamasa Oda, Shigeru Toyoda, Kenichiro Hanawa, Takeo Fujimura, Shigehisa Ura, Mimiko Matsumura, Hideki Takano, Satoshi Yamashita, Gaku Matsukura, Ryushi Tazawa, Tsuyoshi Shiga, Mio Ebato, Hiroshi Satoh, Satoshi Ishii

Genetics in medicine : official journal of the American College of Medical Genetics　21　(8)　1900-1900　2019年8月

DOI： 10.1038/s41436-018-0258-3 　

ISSN：1098-3600

詳細を見る詳細を閉じる

The PDF and HTML versions of the article have been updated to include the Creative Commons Attribution 4.0 International License information.
Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. 国際誌

Enrico Ammirati, Giacomo Veronese, Michela Brambatti, Marco Merlo, Manlio Cipriani, Luciano Potena, Paola Sormani, Tatsuo Aoki, Koichiro Sugimura, Akinori Sawamura, Takahiro Okumura, Sean Pinney, Kimberly Hong, Palak Shah, Öscar Braun, Caroline M Van de Heyning, Santiago Montero, Duccio Petrella, Florent Huang, Matthieu Schmidt, Claudia Raineri, Anuradha Lala, Marisa Varrenti, Alberto Foà, Ornella Leone, Piero Gentile, Jessica Artico, Valentina Agostini, Rajiv Patel, Andrea Garascia, Emeline M Van Craenenbroeck, Kaoru Hirose, Akihiro Isotani, Toyoaki Murohara, Yoh Arita, Alessandro Sionis, Enrico Fabris, Sherin Hashem, Victor Garcia-Hernando, Fabrizio Oliva, Barry Greenberg, Hiroaki Shimokawa, Gianfranco Sinagra, Eric D Adler, Maria Frigerio, Paolo G Camici

Journal of the American College of Cardiology　74　(3)　299-311　2019年7月23日

DOI： 10.1016/j.jacc.2019.04.063 　

詳細を見る詳細を閉じる

BACKGROUND: Fulminant myocarditis (FM) is a form of acute myocarditis characterized by severe left ventricular systolic dysfunction requiring inotropes and/or mechanical circulatory support. A single-center study found that a patient with FM had better outcomes than those with acute nonfulminant myocarditis (NFM) presenting with left ventricular systolic dysfunction, but otherwise hemodynamically stable. This was recently challenged, so disagreement still exists. OBJECTIVES: This study sought to provide additional evidence on the outcome of FM and to ascertain whether patient stratification based on the main histologic subtypes can provide additional prognostic information. METHODS: A total of 220 patients (median age 42 years, 46.3% female) with histologically proven acute myocarditis (onset of symptoms <30 days) all presenting with left ventricular systolic dysfunction were included in a retrospective, international registry comprising 16 tertiary hospitals in the United States, Europe, and Japan. The main endpoint was the occurrence of cardiac death or heart transplantation within 60 days from admission and at long-term follow-up. RESULTS: Patients with FM (n = 165) had significantly higher rates of cardiac death and heart transplantation compared with those with NFM (n = 55), both at 60 days (28.0% vs. 1.8%, p = 0.0001) and at 7-year follow-up (47.7% vs. 10.4%, p < 0.0001). Using Cox multivariate analysis, the histologic subtype emerged as a further variable affecting the outcome in FM patients, with giant cell myocarditis having a significantly worse prognosis compared with eosinophilic and lymphocytic myocarditis. In a subanalysis including only adults with lymphocytic myocarditis, the main endpoints occurred more frequently in FM compared with in NFM both at 60 days (19.5% vs. 0%, p = 0.005) and at 7-year follow up (41.4% vs. 3.1%, p = 0.0004). CONCLUSIONS: This international registry confirms that patients with FM have higher rates of cardiac death and heart transplantation both in the short- and long-term compared with patients with NFM. Furthermore, we provide evidence that the histologic subtype of FM carries independent prognostic value, highlighting the need for timely endomyocardial biopsy in this condition.
Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder. 国際誌

Ming Li, Ken-Ichi Hirano, Yoshihiko Ikeda, Masahiro Higashi, Chikako Hashimoto, Bo Zhang, Junji Kozawa, Koichiro Sugimura, Hideyuki Miyauchi, Akira Suzuki, Yasuhiro Hara, Atsuko Takagi, Yasuyuki Ikeda, Kazuhiro Kobayashi, Yoshiaki Futsukaichi, Nobuhiro Zaima, Satoshi Yamaguchi, Rojeet Shrestha, Hiroshi Nakamura, Katsuhiro Kawaguchi, Eiryu Sai, Shu-Ping Hui, Yusuke Nakano, Akinori Sawamura, Tohru Inaba, Yasuhiko Sakata, Yoko Yasui, Yasuyuki Nagasawa, Shintaro Kinugawa, Kazunori Shimada, Sohsuke Yamada, Hiroyuki Hao, Daisaku Nakatani, Tomomi Ide, Tetsuya Amano, Hiroaki Naito, Hironori Nagasaka, Kunihisa Kobayashi

Orphanet journal of rare diseases　14　(1)　134-134　2019年6月11日

DOI： 10.1186/s13023-019-1087-4 　

詳細を見る詳細を閉じる

Triglyceride deposit cardiomyovasculopathy (TGCV) is a phenotype primarily reported in patients carrying genetic mutations in PNPLA2 encoding adipose triglyceride lipase (ATGL) which releases long chain fatty acid (LCFA) as a major energy source by the intracellular TG hydrolysis. These patients suffered from intractable heart failure requiring cardiac transplantation. Moreover, we identified TGCV patients without PNPLA2 mutations based on pathological and clinical studies. We provided the diagnostic criteria, in which TGCV with and without PNPLA2 mutations were designated as primary TGCV (P-TGCV) and idiopathic TGCV (I-TGCV), respectively. We hereby report clinical profiles of TGCV patients. Between 2014 and 2018, 7 P-TGCV and 18 I-TGCV Japanese patients have been registered in the International Registry. Patients with I-TGCV, of which etiologies and causes are not known yet, suffered from adult-onset severe heart disease, including heart failure and coronary artery disease, associated with a marked reduction in ATGL activity and myocardial washout rate of LCFA tracer, as similar to those with P-TGCV. The present first registry-based study showed that TGCV is an intractable, at least at the moment, and heterogeneous cardiovascular disorder.
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. 国際誌

Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, Koichi Tamita, Toshihiro Kawasaki, Jun Kajihara, Akifumi Onishi, Hitoshi Sugiyama, Teiko Sakai, Ichijiro Murata, Takamasa Oda, Shigeru Toyoda, Kenichiro Hanawa, Takeo Fujimura, Shigehisa Ura, Mimiko Matsumura, Hideki Takano, Satoshi Yamashita, Gaku Matsukura, Ryushi Tazawa, Tsuyoshi Shiga, Mio Ebato, Hiroshi Satoh, Satoshi Ishii

Genetics in medicine : official journal of the American College of Medical Genetics　21　(5)　1263-1263　2019年5月

DOI： 10.1038/s41436-019-0447-8 　

詳細を見る詳細を閉じる

The HTML version of this Article contained errors in Supplementary Figure S2 "Flowchart of the lyso-Gb3 screening and gene analysis in female patients", which have been detailed in the associated Correction.
Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017).

Keiichi Fukuda, Hiroshi Date, Shozaburo Doi, Yoshihiro Fukumoto, Norihide Fukushima, Masaru Hatano, Hiroshi Ito, Masataka Kuwana, Hiromi Matsubara, Shin-Ichi Momomura, Masaharu Nishimura, Hitoshi Ogino, Toru Satoh, Hiroaki Shimokawa, Keiko Yamauchi-Takihara, Koichiro Tatsumi, Hatsue Ishibashi-Ueda, Norikazu Yamada, Shunji Yoshida, Kohtaro Abe, Aiko Ogawa, Takeshi Ogo, Takatoshi Kasai, Masaharu Kataoka, Takashi Kawakami, Shigetoyo Kogaki, Mashio Nakamura, Tomotaka Nakayama, Mari Nishizaki, Koichiro Sugimura, Nobuhiro Tanabe, Ichizo Tsujino, Atsushi Yao, Takashi Akasaka, Motomi Ando, Takeshi Kimura, Takayuki Kuriyama, Norifumi Nakanishi, Toshio Nakanishi, Hiroyuki Tsutsui

Circulation journal : official journal of the Japanese Circulation Society　83　(4)　842-945　2019年3月25日

DOI： 10.1253/circj.CJ-66-0158 　
バルーン肺動脈形成術による血行動態改善後の慢性血栓塞栓性肺高血圧症(CTEPH)患者においてriociguatが運動に対する血行動態反応に及ぼす追加的な有益な作用(Additive Beneficial Effects of Riociguat on Hemodynamic Responses to Exercise in CTEPH Patients after Hemodynamic Improvement by Balloon Pulmonary Angioplasty)

青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 山本沙織, 鈴木秀明, 佐藤遥, 菊地順裕, 紺野亮, 照井洋輔, 迫田みく, 後岡広太郎, 佐藤公雄, 下川宏明

日本循環器学会学術集会抄録集　83回　OJ10-8　2019年3月
出版者・発行元： (一社)日本循環器学会
成人先天性心疾患患者においてMELD-XI(Model for End-Stage Liver Disease Excluding INR)スコアは心血管転帰を予測する(MELD-XI(Model for End-Stage Liver Disease Excluding INR) Score Predicts Cardiovascular Outcomes in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 三浦正暢, 鈴木秀明, 山本沙織, 佐藤遥, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　83回　OJ29-2　2019年3月
出版者・発行元： (一社)日本循環器学会
CTEPH患者においてNO吸入による急性肺血管反応性試験は肺血管拡張薬およびバルーン肺動脈形成術の有効性を予測する(Acute Pulmonary Vasoreactivity Test with Inhaled No Predicts the Efficacy of Pulmonary Vasodilators and Balloon Pulmonary Angioplasty in CTEPH Patients)

迫田みく, 青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 山本沙織, 鈴木秀明, 佐藤遥, 菊地順裕, 紺野亮, 照井洋輔, 後岡広太郎, 佐藤公雄, 下川宏明

日本循環器学会学術集会抄録集　83回　PJ054-3　2019年3月
出版者・発行元： (一社)日本循環器学会
Clinical Diversity in Patients with Anderson-fabry Disease with the R301Q Mutation.

Saori Yamamoto, Tasuku Nagasawa, Koichiro Sugimura, Atsuhiro Kanno, Shunsuke Tatebe, Tatsuo Aoki, Haruka Sato, Katsuya Kozu, Ryo Konno, Kotaro Nochioka, Kimio Satoh, Hiroaki Shimokawa

Internal medicine (Tokyo, Japan)　58　(4)　603-607　2019年2月15日

DOI： 10.2169/internalmedicine.0959-18 　

詳細を見る詳細を閉じる

Anderson-Fabry disease (AFD) is a rare X-linked disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A (α-GAL A). We herein report 10 cases of AFD in 5 families (3 men and 7 women) that were found to have a specific common mutation in R301Q [G-to-A transition in exon 6 (codon 301) resulting in the replacement of a glutamine with an arginine residue]. We evaluated their clinical characteristics, residual enzymatic activity, and plasma concentrations of globotriaosylsphingosine (Lyso-Gb3). Although all 10 cases had cardiac and renal manifestations in common, their clinical manifestations were markedly divergent despite the same genetic abnormality.
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. 国際誌査読有り

Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, Koichi Tamita, Toshihiro Kawasaki, Jun Kajihara, Akifumi Onishi, Hitoshi Sugiyama, Teiko Sakai, Ichijiro Murata, Takamasa Oda, Shigeru Toyoda, Kenichiro Hanawa, Takeo Fujimura, Shigehisa Ura, Mimiko Matsumura, Hideki Takano, Satoshi Yamashita, Gaku Matsukura, Ryushi Tazawa, Tsuyoshi Shiga, Mio Ebato, Hiroshi Satoh, Satoshi Ishii

Genetics in medicine : official journal of the American College of Medical Genetics　21　(2)　512-515　2019年2月

DOI： 10.1038/s41436-018-0125-2 　

ISSN：1098-3600

詳細を見る詳細を閉じる

In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows.
Who is the principal offender? 国際誌

Koichiro Sugimura

International journal of cardiology　276　293-294　2019年2月1日

DOI： 10.1016/j.ijcard.2018.10.109 　
Beneficial Effects of Imatinib in a Patient with Suspected Pulmonary Veno-Occlusive Disease.

Haruka Sato, Koichiro Sugimura, Masanobu Miura, Ryo Konno, Katsuya Kozu, Nobuhiro Yaoita, Toru Shimizu, Saori Yamamoto, Tatsuo Aoki, Shunsuke Tatebe, Kimio Satoh, Hiroaki Shimokawa

The Tohoku journal of experimental medicine　247　(2)　69-73　2019年2月

DOI： 10.1620/tjem.247.69 　

詳細を見る詳細を閉じる

Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH). The prognosis of PVOD patients remains poor, since no effective medical therapy is yet available. Imatinib is a tyrosine kinase inhibitor specific for platelet-derived growth factor receptor and is expected as a treatment option for pulmonary arterial hypertension (PAH). Recently, it has been reported that imatinib improved functional capacity of a patient with PVOD. We here report a patient with suspected PVOD who has been successfully treated with imatinib and is alive for 6 years after diagnosis. A 57-year-old woman was admitted to a hospital for severe dyspnea. Echocardiography suggested the presence of PH, because tricuspid regurgitation pressure gradient was elevated. The patient was then transferred to our hospital by an ambulance ahead of schedule due to fever and worsening dyspnea. Because the patient had no left heart disease, we diagnosed that she had PAH associated with severe right heart failure. We immediately started treatment with nitric oxide (NO) for her severe hypoxia; however, it caused pulmonary edema. We suspected PVOD from CT characteristics and pulmonary edema after PAH-targeted vasodilator therapy, and then started oral imatinib treatment. In response to imatinib, her pulmonary edema gradually improved. Since then, the patient has been alive for 6 years with imatinib and pulmonary vasodilators. At present, lung transplantation is the only effective therapy for PVOD with limited availability. We therefore propose that imatinib may be a treatment option for PVOD and a bridge to lung transplantation.
成人先天性心疾患患者の予後予測におけるMELD-XI Scoreの有用性(Prognostic Utility of Model for End-Stage Liver Disease Excluding INR(MELD-XI) Score in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 三浦正暢, 鈴木秀明, 山本沙織, 佐野遥, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本成人先天性心疾患学会雑誌　8　(1)　124-124　2019年1月
出版者・発行元：日本成人先天性心疾患学会
Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. 国際誌

Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, Koichi Tamita, Toshihiro Kawasaki, Jun Kajihara, Akifumi Onishi, Hitoshi Sugiyama, Teiko Sakai, Ichijiro Murata, Takamasa Oda, Shigeru Toyoda, Kenichiro Hanawa, Takeo Fujimura, Shigehisa Ura, Mimiko Matsumura, Hideki Takano, Satoshi Yamashita, Gaku Matsukura, Ryushi Tazawa, Tsuyoshi Shiga, Mio Ebato, Hiroshi Satoh, Satoshi Ishii

Genetics in medicine : official journal of the American College of Medical Genetics　21　(1)　44-52　2019年1月

DOI： 10.1038/gim.2018.31 　

詳細を見る詳細を閉じる

PURPOSE: Plasma globotriaosylsphingosine (lyso-Gb3) is a promising secondary screening biomarker for Fabry disease. Here, we examined its applicability as a primary screening biomarker for classic and late-onset Fabry disease in males and females. METHODS: Between 1 July 2014 and 31 December 2015, we screened 2,359 patients (1,324 males) referred from 168 Japanese specialty clinics (cardiology, nephrology, neurology, and pediatrics), based on clinical symptoms suggestive of Fabry disease. We used the plasma lyso-Gb3 concentration, α-galactosidase A (α-Gal A) activity, and analysis of the α-Gal A gene (GLA) for primary and secondary screens, respectively. RESULTS: Of 8 males with elevated lyso-Gb3 levels (≥2.0 ng ml-1) and low α-Gal A activity (≤4.0 nmol h-1 ml-1), 7 presented a GLA mutation (2 classic and 5 late-onset). Of 14 females with elevated lyso-Gb3, 7 displayed low α-Gal A activity (5 with GLA mutations; 4 classic and 1 late-onset) and 7 exhibited normal α-Gal A activity (1 with a classic GLA mutation and 3 with genetic variants of uncertain significance). CONCLUSION: Plasma lyso-Gb3 is a potential primary screening biomarker for classic and late-onset Fabry disease probands.
Prognostic value of the model for end-stage liver disease excluding INR score (MELD-XI) in patients with adult congenital heart disease. 国際誌

Ryo Konno, Shunsuke Tatebe, Koichiro Sugimura, Kimio Satoh, Tatsuo Aoki, Masanobu Miura, Hideaki Suzuki, Saori Yamamoto, Haruka Sato, Yosuke Terui, Satoshi Miyata, Osamu Adachi, Masato Kimura, Yoshikatsu Saiki, Hiroaki Shimokawa

PloS one　14　(11)　e0225403　2019年

DOI： 10.1371/journal.pone.0225403 　

詳細を見る詳細を閉じる

Patients with adult congenital heart disease (ACHD) are at increased risk of developing late cardiovascular complication. However, little is known about the predictive factors for long-term outcome. The Model for End-Stage Liver Disease eXcluding INR (MELD-XI) score was originally developed to assess cirrhotic patients and has the prognostic value for heart failure (HF) patients. In the present study, we examined whether the score also has the prognostic value in this population. We retrospectively examined 637 ACHD patients (mean age 31.0 years) who visited our Tohoku University hospital from 1995 to 2015. MELD-XI score was calculated as follows; 11.76 x ln(serum creatinine) + 5.11 x ln(serum total bilirubin) + 9.44. We compared the long-term outcomes between the high (≥10.4) and the low (<10.4) score groups. The cutoff value of MELD-XI score was determined based on the survival classification and regression tree (CART) analysis. The major adverse cardiac event (MACE) was defined as a composite of cardiac death, HF hospitalization, and lethal ventricular arrhythmias. During a mean follow-up period of 8.6 years (interquartile range 4.4-11.4 years), MACE was noted in 51 patients, including HF hospitalization in 37, cardiac death in 8, and lethal ventricular arrhythmias in 6. In Kaplan-Meier analysis, the high score group had significantly worse MACE-free survival compared with the low score group (log-rank, P<0.001). Multivariable Cox regression analysis showed that the MELD-XI score remained a significant predictor of MACE (hazard ratio 1.36, confidence interval 1.17-1.58, P<0.001) even after adjusting for patient characteristics, such as sex, functional status, estimated glomerular filtration rate, and cardiac function. Furthermore, CART analysis revealed that the MELD-XI score was the most important variable for predicting MACE. These results demonstrate that the MELD-XI score can effectively predict MACE in ACHD patients, indicating that ACHD patients with high MELD-XI score need to be closely followed.
Effects of Hepatitis C Virus Antibody-Positivity on Cardiac Function and Long-Term Prognosis in Patients With Adult Congenital Heart Disease. 国際誌

Ryo Konno, Shunsuke Tatebe, Koichiro Sugimura, Kimio Satoh, Tatsuo Aoki, Masanobu Miura, Saori Yamamoto, Haruka Sato, Katsuya Kozu, Yosuke Terui, Satoshi Miyata, Osamu Adachi, Masato Kimura, Yoshikatsu Saiki, Hiroaki Shimokawa

The American journal of cardiology　122　(11)　1965-1971　2018年12月1日

DOI： 10.1016/j.amjcard.2018.08.045 　

詳細を見る詳細を閉じる

It was reported that hepatitis C virus (HCV) antibody-positivity adversely affects cardiac function. As the screening for HCV began in 1992, we hypothesized that HCV antibody-positive rate would be high in adult congenital heart disease (ACHD) patients who underwent heart surgery before 1992 and adversely affected cardiac function and long-term prognosis. We retrospectively enrolled 243 ACHD patients (mean age 25.9 years) who underwent cardiac surgery before 1992 and visited our hospital from 1995 to 2015. We compared clinical characteristics including cardiac function and long-term prognosis between HCV antibody-positive (n = 48) and antibody-negative (n = 195) patients. The composite end point (CEP) included cardiac death, heart failure hospitalization, lethal ventricular arrhythmias, and cardiac reoperation. The prevalence of reduced systemic ventricular ejection fraction <50% was significantly higher in the HCV antibody-positive group compared with the HCV antibody-negative group (17 vs 5.4%, p = 0.014). During a mean follow-up period of 10.1 years (interquartile range 6 to 14 years), the CEP was noted in 51 patients. Kaplan-Meier analysis showed the HCV antibody-positive group had significantly poor event-free survival than the HCV antibody-negative group (log-rank, p = 0.002). In contrast, HCV ribonucleic acid-positivity was not a significant predictor of the CEP in the HCV antibody-positive group (log-rank, p = 0.442). Furthermore, the HCV antibody-positivity was significantly associated with the CEP in both univariable and multivariable Cox regression models (hazard ratio 2.37, 95% confident interval 1.32 to 4.15, p = 0.005 and 1.96, 1.06 to 3.63, p = 0.032, respectively). In conclusion, these results suggest that more attention should be paid to HCV antibody-positivity in the management of ACHD patients.
前毛細血管性肺高血圧症と後毛細血管性肺高血圧症合併例に対する治療戦略左心系心疾患による肺高血圧症の診断・治療の現状と問題点

杉村宏一郎, 建部俊介, 青木竜男, 三浦正暢, 山本沙織, 佐藤遥, 菊地順裕, 紺野亮, 照井洋輔, 下川宏明

日本心臓病学会学術集会抄録　66回　S9-4　2018年9月
出版者・発行元： (一社)日本心臓病学会
肺高血圧症のカテーテル治療の実際

杉村宏一郎, 青木竜男, 下川宏明

日本心臓病学会学術集会抄録　66回　EL8-EL8　2018年9月
出版者・発行元： (一社)日本心臓病学会
補助人工心臓待機時代における心臓移植について重症心不全患者における肺高血圧症合併の問題点

杉村宏一郎, 青木竜男, 秋山正年, 建部俊介, 三浦正暢, 山本沙織, 佐藤遥, 齋木佳克, 下川宏明

移植　53　(総会臨時)　243-243　2018年9月
出版者・発行元： (一社)日本移植学会
ISSN：0578-7947

eISSN：2188-0034
Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension.

Katsuya Kozu, Koichiro Sugimura, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Nobuhiro Yaoita, Toru Shimizu, Kotaro Nochioka, Haruka Sato, Ryo Konno, Kimio Satoh, Satoshi Miyata, Hiroaki Shimokawa

Heart and vessels　33　(8)　939-947　2018年8月

DOI： 10.1007/s00380-018-1140-6 　

詳細を見る詳細を閉じる

It is widely known that the incidence of pulmonary arterial hypertension (PAH) is higher in female, whereas prognosis is poorer in male patients. However, sex differences in hemodynamic response to and long-term prognosis with PAH-targeted treatment in the modern era remain to be fully elucidated. We examined the long-term prognosis of 129 consecutive PAH patients (34 males and 95 females) diagnosed in our hospital from April 1999 to October 2014, and assessed hemodynamic changes in response to PAH-targeted therapy. Female patients had better 5-year survival compared with male patients (74.0 vs. 53.4%, P = 0.003); however, higher age quartiles in females were associated with poor outcome. Follow-up examination after medical treatment showed significant decreases in mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), and pulmonary arterial capacitance (PAC) in both sexes (both P < 0.05), whereas only females had a significant improvement in right ventricular end-diastolic pressure (RVEDP), right atrial pressure (RAP), cardiac index, and mixed venous oxygen saturation (SvO2) (all P < 0.05). Baseline age significantly correlated with the hemodynamic changes only in female patients; particularly, there were significant sex interactions in RVEDP and RAP (both P < 0.10). The multivariable analysis showed that SvO2 at baseline and mPAP and SvO2 at follow-up were significant prognostic factors in males, whereas the changes in mPAP, PVR, and PAC and use of endothelin-receptor antagonist in females. These results indicate that female PAH patients have better long-term prognosis than males, for which better improvements of right ventricular functions and hemodynamics may be involved.
Treatment Effect of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension Quantified by Automatic Comparative Imaging in Computed Tomography Pulmonary Angiography. 国際誌

Zhiwei Zhai, Hideki Ota, Marius Staring, Jan Stolk, Koichiro Sugimura, Kei Takase, Berend C Stoel

Investigative radiology　53　(5)　286-292　2018年5月

DOI： 10.1097/RLI.0000000000000441 　

詳細を見る詳細を閉じる

OBJECTIVES: Balloon pulmonary angioplasty (BPA) in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) can have variable outcomes. To gain more insight into this variation, we designed a method for visualizing and quantifying changes in pulmonary perfusion by automatically comparing computed tomography (CT) pulmonary angiography before and after BPA treatment. We validated these quantifications of perfusion changes against hemodynamic changes measured with right-sided heart catheterization. MATERIALS AND METHODS: We studied 14 consecutive CTEPH patients (12 women; age, 70.5 ± 24), who underwent CT pulmonary angiography and right-sided heart catheterization, before and after BPA. Posttreatment images were registered to pretreatment CT scans (using the Elastix toolbox) to obtain corresponding locations. Pulmonary vascular trees and their centerlines were detected using a graph cuts method and a distance transform method, respectively. Areas distal from vessels were defined as pulmonary parenchyma. Subsequently, the density changes within the vascular centerlines and parenchymal areas were calculated and corrected for inspiration level differences. For visualization, the densitometric changes were displayed in color-coded overlays. For quantification, the median and interquartile range of the density changes in the vascular and parenchymal areas (ΔVD and ΔPD) were calculated. The recorded changes in hemodynamic parameters, including changes in systolic, diastolic, and mean pulmonary artery pressure (ΔsPAP, ΔdPAP, and ΔmPAP, respectively) and vascular resistance (ΔPVR), were used as reference assessments of the treatment effect. Spearman correlation coefficients were employed to investigate the correlations between changes in perfusion and hemodynamic changes. RESULTS: Comparative imaging maps showed distinct patterns in perfusion changes among patients. Within pulmonary vessels, the interquartile range of ΔVD correlated significantly with ΔsPAP (R = -0.58, P = 0.03), ΔdPAP (R = -0.71, P = 0.005), ΔmPAP (R = -0.71, P = 0.005), and ΔPVR (R = -0.77, P = 0.001). In the parenchyma, the median of ΔPD had significant correlations with ΔdPAP (R = -0.58, P = 0.030) and ΔmPAP (R = -0.59, P = 0.025). CONCLUSIONS: Comparative imaging analysis in CTEPH patients offers insight into differences in BPA treatment effect. Quantification of perfusion changes provides noninvasive measures that reflect hemodynamic changes.
症例から学ぶ肺高血圧症の病態〜From Bed to Bench〜免疫抑制療法は好酸球性多発血管炎性肉芽腫症患者の重症肺高血圧症と難治性血管攣縮性狭心症を改善する(Immunosuppressive Therapy Ameliorates Severe Pulmonary Hypertension and Refractory Vasospastic Angina in a Patient with Eosinophilic Granulomatosis with Polyangiitis)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 山本沙織, 佐藤遥, 神津克也, 下川宏明

日本循環器学会学術集会抄録集　82回　SY19-2　2018年3月
出版者・発行元： (一社)日本循環器学会
Anthracycline系による治療を受けた癌患者の管理における心臓MRIの有用性腫瘍循環器学の進歩(Usefulness of Cardiac MRI in the Management of Cancer Patients Treated with Anthracyclines: Progress in Cardiooncology)

照井洋輔, 杉村宏一郎, 大田英揮, 佐藤遥, 後岡広太郎, 建部俊介, 青木竜男, 山本沙織, 神津克也, 紺野亮, 高瀬圭, 下川宏明

日本循環器学会学術集会抄録集　82回　OJ02-4　2018年3月
出版者・発行元： (一社)日本循環器学会
成人先天性心疾患患者においてhepatitis C virus陽性は心機能および長期予後に悪影響を及ぼす(Hepatitis C Virus Positivity Adversely Impacts Cardiac Functions and Long-term Prognosis in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 山本沙織, 清水亨, 佐藤遥, 神津克也, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　82回　PJ043-4　2018年3月
出版者・発行元： (一社)日本循環器学会
慢性血栓塞栓性肺高血圧症の重症度評価における呼気ガス分析の有用性

秋月三奈, 杉村宏一郎, 青木竜男, 杉澤潤, 柿花隆昭, 下川宏明, 上月正博

日本循環器学会学術集会抄録集　82回　CP17-3　2018年3月
出版者・発行元： (一社)日本循環器学会
Diagnostic Criteria and Severity Score for Triglyceride Deposit Cardiomyovasculopathy

Hideyuki Miyauchi, Chikako Hashimoto, Yoshihiko Ikeda, Ming Li, Yusuke Nakano, Junji Kozawa, Eiryu Sai, Yasuyuki Nagasawa, Koichiro Sugimura, Shintaro Kinugawa, Katsuhiro Kawaguchi, Kazunori Shimada, Tomomi Ide, Tetsuya Amano, Masahiro Higashi, Tohru Inaba, Hiroshi Nakamura, Kunihisa Kobayashi, Ken-ichi Hirano

Annals of Nuclear Cardiology　4　(1)　94-100　2018年
出版者・発行元： The Japanese Society of Nuclear Cardiology
DOI： 10.17996/anc.18-00081 　

ISSN：2189-3926

eISSN：2424-1741
成人先天性心疾患患者におけるHCV陽性の心機能および予後に与える影響(Hepatitis C Virus Positivity Adversely Affects Cardiac Functions and Long-term Prognosis in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 山本沙織, 佐藤遥, 神津克也, 安達理, 木村正人, 齋木佳克, 下川宏明

日本成人先天性心疾患学会雑誌　7　(1)　143-143　2018年1月
出版者・発行元：日本成人先天性心疾患学会
The Efficacy of a Genetic Analysis of the BMPR2 Gene in a Patient with Severe Pulmonary Arterial Hypertension and an Atrial Septal Defect Treated with Bilateral Lung Transplantation.

Shunsuke Tatebe, Koichiro Sugimura, Tatsuo Aoki, Saori Yamamoto, Nobuhiro Yaoita, Hideaki Suzuki, Haruka Sato, Katsuya Kozu, Ryo Konno, Kimio Satoh, Koji Fukuda, Osamu Adachi, Ryoko Saito, Norifumi Nakanishi, Hiroko Morisaki, Kotaro Oyama, Yoshikatsu Saiki, Yoshinori Okada, Hiroaki Shimokawa

Internal medicine (Tokyo, Japan)　56　(23)　3193-3197　2017年12月1日

DOI： 10.2169/internalmedicine.8686-16 　

詳細を見る詳細を閉じる

Severe pulmonary arterial hypertension (PAH) rarely develops in children with an atrial septal defect (ASD), even those with a large defect. We herein report the case of a 27-year-old man with a moderate-sized secundum ASD and right ventricular failure due to severe PAH, which developed in his early teens. He was diagnosed as having a genetic mutation of the bone morphogenetic protein receptor-2 (BMPR2) gene and was successfully treated with bilateral lung transplantation with ASD path closure. In patients with congenital heart disease, a genetic analysis may provide information about the lifetime risk of developing PAH.
Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. 国際誌

Tatsuo Aoki, Koichiro Sugimura, Shunsuke Tatebe, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Hideaki Suzuki, Haruka Sato, Katsuya Kozu, Ryo Konno, Satoshi Miyata, Kotaro Nochioka, Kimio Satoh, Hiroaki Shimokawa

European heart journal　38　(42)　3152-3159　2017年11月7日

DOI： 10.1093/eurheartj/ehx530 　

詳細を見る詳細を閉じる

Aims: Although balloon pulmonary angioplasty (BPA) improves haemodynamics and short-term prognosis in patients with inoperable chronic thrombo-embolic pulmonary hypertension (CTEPH), the long-term effects of BPA, and procedure-related complications remain to be fully elucidated. Methods and results: From July 2009 to October 2016, we performed a total of 424 BPA sessions in 84 consecutive patients with inoperable CTEPH. We used 3D reconstructed computed tomography to determine target lesions of pulmonary arteries and optical computed tomography to select balloon size, if needed. In 77 patients (92%) who completed the BPA treatment [65 ± 14 (SD) years-old, male/female 14/63], haemodynamics and exercise capacity were examined at 6 months after last BPA and in the chronic phase [>12 months after first BPA, 31 (20, 41) months]. The BPA treatment significantly improved mean pulmonary arterial pressure (38 ± 10 to 25 ± 6 mmHg), pulmonary vascular resistance (7.3 ± 3.2 to 3.8 ± 1.0 Wood units), and 6-minute walk distance (380 ± 138 to 486 ± 112 m) (all P < 0.01), and the improvements persisted throughout the follow-up period (43 ± 27 months) (N = 53). In the 424 sessions, haemoptysis was noted in 60 sessions (14%), and non-invasive positive pressure ventilation (NPPV) was used to treat haemoptysis and/or hypoxemia in 33 sessions (8%). Furthermore, 5-year survival was 98.4% (only one patient died of colon cancer) with no peri-procedural death. Conclusion: These results indicate that BPA improves haemodynamics and exercise capacity in inoperable CTEPH patients with acceptable complication rate and that the beneficial haemodynamic effects of BPA persist for years with resultant good long-term prognosis.
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of a Multicenter Registry. 国際誌

Aiko Ogawa, Toru Satoh, Tetsuya Fukuda, Koichiro Sugimura, Yoshihiro Fukumoto, Noriaki Emoto, Norikazu Yamada, Atsushi Yao, Motomi Ando, Hitoshi Ogino, Nobuhiro Tanabe, Ichizo Tsujino, Masayuki Hanaoka, Kenji Minatoya, Hiroshi Ito, Hiromi Matsubara

Circulation. Cardiovascular quality and outcomes　10　(11)　2017年11月

DOI： 10.1161/CIRCOUTCOMES.117.004029 　

詳細を見る詳細を閉じる

BACKGROUND: Balloon pulmonary angioplasty (BPA) is an alternative therapy for patients with chronic thromboembolic pulmonary hypertension who are ineligible for pulmonary endarterectomy-the standard therapy. Currently, most reported results of BPA are from relatively small cohorts treated at single centers. The present study evaluated the safety and efficacy of BPA for chronic thromboembolic pulmonary hypertension based on a multicenter registry. METHODS AND RESULTS: A total of 308 patients (62 men and 246 women; mean age, 61 years) underwent 1408 procedures at 7 institutions in Japan. Data were retrospectively reviewed to evaluate clinical outcome and complications. Hemodynamics were significantly improved in 249 patients in whom BPA was terminated, most often because of improvement in mean pulmonary arterial pressure or symptomatic improvement after 1154 procedures. In 196 patients who underwent follow-up right heart catheterization, improvement of hemodynamic parameters was maintained. Mean pulmonary arterial pressure decreased from 43.2±11.0 to 24.3±6.4 mm Hg after final BPA and 22.5±5.4 mm Hg at follow-up, with significant reduction of concomitant use of pulmonary hypertension-targeted therapy and oxygen supplementation. Complications occurred in 511 (36.3%), including pulmonary injury (17.8%), hemoptysis (14.0%), and pulmonary artery perforation (2.9%). Twelve patients (3.9%) died during follow-up, including 8 patients who died within 30 days after BPA. The leading causes of death were right heart failure, multiorgan failure, and sepsis. Overall survival was 96.8% (95% confidence interval, 93.7%-98.4%) at 1 and 2 years and 94.5% (95% confidence interval, 89.3%-97.3%) at 3 years, respectively, after the initial BPA procedure for all 308 patients. CONCLUSIONS: This multicenter registry suggested improved hemodynamic results after BPA. Complication rates were high, but overall survival was comparable with pulmonary endarterectomy. BPA may be an important therapeutic option in patients with chronic thromboembolic pulmonary hypertension.
慢性血栓塞栓性肺高血圧症に対するバルーン肺動脈形成術の包括的評価長期予後と合併症

青木竜男, 杉村宏一郎, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 神津克也, 紺野亮, 後岡広太朗, 佐藤公雄, 下川宏明

脈管学　57　(Suppl.)　S128-S128　2017年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
バルーン肺動脈形成術後の慢性血栓塞栓性肺高血圧症における運動負荷右心カテーテル

青木竜男, 杉村宏一郎, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 神津克也, 紺野亮, 後岡広太朗, 佐藤公雄, 下川宏明

脈管学　57　(Suppl.)　S228-S228　2017年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
Prognostic Impacts of Plasma Levels of Cyclophilin A in Patients With Coronary Artery Disease. 国際誌

Tomohiro Ohtsuki, Kimio Satoh, Junichi Omura, Nobuhiro Kikuchi, Taijyu Satoh, Ryo Kurosawa, Masamichi Nogi, Shinichiro Sunamura, Nobuhiro Yaoita, Tatsuo Aoki, Shunsuke Tatebe, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

Arteriosclerosis, thrombosis, and vascular biology　37　(4)　685-693　2017年4月

DOI： 10.1161/ATVBAHA.116.308986 　

詳細を見る詳細を閉じる

OBJECTIVE: Cyclophilin A (CyPA) is secreted from vascular smooth muscle cells, inflammatory cells, and activated platelets in response to oxidative stress. We have recently demonstrated that plasma CyPA level is a novel biomarker for diagnosing coronary artery disease. However, it remains to be elucidated whether plasma CyPA levels also have a prognostic impact in such patients. APPROACH AND RESULTS: In 511 consecutive patients undergoing diagnostic coronary angiography, we measured the plasma levels of CyPA, high-sensitivity C-reactive protein (hsCRP), and brain natriuretic peptide and evaluated their prognostic impacts during the follow-up (42 months, interquartile range: 25-55 months). Higher CyPA levels (≥12 ng/mL) were significantly associated with all-cause death, rehospitalization, and coronary revascularization. Higher hsCRP levels (≥1 mg/L) were also significantly correlated with the primary end point and all-cause death, but not with rehospitalization or coronary revascularization. Similarly, higher brain natriuretic peptide levels (≥100 pg/mL) were significantly associated with all-cause death and rehospitalization, but not with coronary revascularization. Importantly, the combination of CyPA (≥12 ng/mL) and hsCRP (≥1 mg/L) was more significantly associated with all-cause death (hazard ratio, 21.2; 95% confidence interval, 4.9-92.3,; P<0.001) than CyPA (≥12 ng/mL) or hsCRP (≥1 mg/L) alone. CONCLUSIONS: The results indicate that plasma CyPA levels can be used to predict all-cause death, rehospitalization, and coronary revascularization in patients with coronary artery disease and that when combined with other biomarkers (hsCRP and brain natriuretic peptide levels), the CyPA levels have further enhanced prognostic impacts in those patients.
心臓移植成績向上のための取り組み植込型心室補助人工心臓を留置された心臓移植レシピエント候補における肺高血圧症(Pulmonary Hypertension in Potential Heart Transplant Recipients with Implantable Ventricular Assist Device)

青木竜男, 杉村宏一郎, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 神津克也, 佐藤公雄, 秋山正年, 川本俊輔, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　81回　SY19-2　2017年3月
出版者・発行元： (一社)日本循環器学会
Anderson-Fabry病の患者における心臓病変に対する新たな診断戦略(Novel Diagnostic Strategy for Cardiac Involvement in Patients with Anderson-Fabry Disease)

山本沙織, 杉村宏一郎, 鈴木秀明, 建部俊介, 青木竜男, 矢尾板信裕, 佐藤遥, 神津克也, 大田英揮, 高浪健太郎, 高瀬圭, 佐藤公雄, 下川宏明

日本循環器学会学術集会抄録集　81回　OJ-053　2017年3月
出版者・発行元： (一社)日本循環器学会
全サプタイプに関する肺高血圧症患者の長期予後単一施設における経験(Long-term Prognosis of Patients with Pulmonary Hypertension for All Subtypes: A Single Center Experience)

神津克也, 杉村宏一郎, 青木竜男, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 後岡広太郎, 佐藤公雄, 宮田敏, 下川宏明

日本循環器学会学術集会抄録集　81回　LBCSP1-3　2017年3月
出版者・発行元： (一社)日本循環器学会
バルーン肺動脈形成術は手術不能な慢性血栓塞栓性肺高血圧症患者の両心室機能を改善する(Balloon Pulmonary Angioplasty Improves Biventricular Functions in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension)

佐藤遥, 大田英揮, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 神津克也, 佐藤公雄, 下川宏明

日本循環器学会学術集会抄録集　81回　PJ-284　2017年3月
出版者・発行元： (一社)日本循環器学会
ADAMTS8は肺高血圧における肺血管リモデリングと右心不全を増悪させる

大村淳一, 佐藤公雄, 菊地順裕, 佐藤大樹, 黒澤亮, 沼野和彦, 神津克也, 青木竜男, 建部俊介, 杉村宏一郎, 下川宏明

血管　40　(1)　51-51　2017年1月
出版者・発行元：日本心脈管作動物質学会
ISSN：0911-4637
Focal Reduction in Cardiac 123I-Metaiodobenzylguanidine Uptake in Patients With Anderson-Fabry Disease.

Saori Yamamoto, Hideaki Suzuki, Koichiro Sugimura, Shunsuke Tatebe, Tatsuo Aoki, Masanobu Miura, Nobuhiro Yaoita, Haruka Sato, Katuya Kozu, Hideki Ota, Kentaro Takanami, Kei Takase, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(12)　2550-2551　2016年11月25日

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: It remains to be elucidated whether cardiac sympathetic nervous activity is impaired in patients with Anderson-Fabry disease (AFD).Methods and Results:We performed 123I-meta-iodobenzylguanidine (MIBG) scintigraphy and gadolinium-enhanced cardiovascular magnetic resonance (CMR) in 5 AFD patients. MIBG uptake in the inferolateral wall, where wall thinning and delayed enhancement were noted on CMR, was significantly lower compared with the anteroseptal wall. The localized reduction in MIBG uptake was also noted in 2 patients with no obvious abnormal findings on CMR. CONCLUSIONS: Cardiac sympathetic nervous activity is impaired in AFD before development of structural myocardial abnormalities. (Circ J 2016; 80: 2550-2551).
Multiple sclerosis lesion in the medulla oblongata in a patient with takotsubo cardiomyopathy. 国際誌

Katsuya Kozu, Hideaki Suzuki, Shuhei Nishiyama, Nobuhiro Yaoita, Saori Yamamoto, Shunsuke Tatebe, Masanobu Miura, Tatsuo Aoki, Kiyotaka Hao, Yasuharu Matsumoto, Koichiro Sugimura, Masashi Aoki, Hiroaki Shimokawa

International journal of cardiology　222　980-981　2016年11月1日

DOI： 10.1016/j.ijcard.2016.08.128 　
バルーン肺動脈形成術が安全に施行できたハイリスク中枢型慢性血栓塞栓性肺高血圧症の一例

神津克也, 青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 下川宏明

脈管学　56　(Suppl.)　S235-S235　2016年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
慢性血栓塞栓性肺高血圧症に対するBPAの合併症と予後の検討

青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 佐藤遥, 神津克也, 佐藤公雄, 下川宏明

脈管学　56　(Suppl.)　S147-S147　2016年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
Effects of Balloon Pulmonary Angioplasty on Oxygenation in Patients With Chronic Thromboembolic Pulmonary Hypertension - Importance of Intrapulmonary Shunt.

Tatsuo Aoki, Koichiro Sugimura, Kotaro Nochioka, Masanobu Miura, Shunsuke Tatebe, Saori Yamamoto, Nobuhiro Yaoita, Hideaki Suzuki, Haruka Sato, Katsuya Kozu, Satoshi Miyata, Kimio Satoh, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(10)　2227-34　2016年9月23日

DOI： 10.1253/circj.CJ-16-0254 　

詳細を見る詳細を閉じる

BACKGROUND: Although balloon pulmonary angioplasty (BPA) improves the hemodynamics and prognosis of patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), the mechanisms of improvement in oxygenation remain to be elucidated. METHODS AND RESULTS: From August 2013 to May 2015, we performed a total of 113 BPA procedures in 24 patients with inoperable CTEPH (mean 4.7 procedures per patient). Median age was 70 [60, 74] years and 18 were female (75%). We examined hemodynamics, respiratory functions, and intrapulmonary shunt before and after the BPA procedure. Mean pulmonary arterial pressure (37 [28, 45] to 23[19, 27] mmHg, P<0.01), pulmonary vascular resistance (517 [389, 696] to 268 [239, 345] dyne/s/cm(5)) and 6-min walk distance (390 [286, 484] to 490 [411, 617] m, P<0.01) were significantly improved after BPA therapy. Furthermore, arterial oxygen partial pressure (PaO2, 54.8 [50.0, 60.8] to 65.2 [60.6, 73.2] %, P<0.01) and intrapulmonary shunt (23.4±6.0% to 19.3±5.0%, P<0.01) were also significantly ameliorated. In the multivariate analysis, decrease in intrapulmonary shunt after BPA was significantly correlated with improvement of both PaO2(r(2)=0.26, P<0.01) and SaO2(r(2)=0.49, P<0.01) after BPA. CONCLUSIONS: These results indicated that BPA improved not only pulmonary hemodynamics but also oxygenation with a resultant decrease in intrapulmonary shunt. (Circ J 2016; 80: 2227-2234).
Dual-energy CT to estimate clinical severity of chronic thromboembolic pulmonary hypertension: Comparison with invasive right heart catheterization. 国際誌

Hidenobu Takagi, Hideki Ota, Koichiro Sugimura, Katharina Otani, Junya Tominaga, Tatsuo Aoki, Shunsuke Tatebe, Masanobu Miura, Saori Yamamoto, Haruka Sato, Nobuhiro Yaoita, Hideaki Suzuki, Hiroaki Shimokawa, Kei Takase

European journal of radiology　85　(9)　1574-80　2016年9月

DOI： 10.1016/j.ejrad.2016.06.010 　

詳細を見る詳細を閉じる

PURPOSE: To evaluate whether the extent of perfusion defects assessed by examining lung perfused blood volume (PBV) images is a stronger estimator of the clinical severity of chronic thromboembolic pulmonary hypertension (CTEPH) compared with other computed tomography (CT) findings and noninvasive parameters. MATERIALS AND METHODS: We analyzed 46 consecutive patients (10 men, 36 women) with CTEPH who underwent both dual-energy CT and right-heart catheter (RHC) examinations. Lung PBV images were acquired using a second-generation dual-source CT scanner. Two radiologists independently scored the extent of perfusion defects in each lung segment employing the following criteria: 0, no defect, 1, defect in <50% of a segment, 2, defect in ≥50% of a segment. Each lung PBV score was defined as the sum of the scores of 18 segments. In addition, all of the following were recorded: 6-min walk distance (6MWD), brain natriuretic peptide (BNP) level, and RHC hemodynamic parameters including pulmonary artery pressure (PAP), right ventricular pressure (RVP), cardiac output (CO), the cardiac index (CI), and pulmonary vascular resistance (PVR). Bootstrapped weighted kappa values with 95% confidence intervals (CIs) were calculated to evaluate the level of interobserver agreement. Correlations between lung PBV scores and other parameters were evaluated by calculating Spearman's rho correlation coefficients. Multivariable linear regression analyses (using a stepwise method) were employed to identify useful estimators of mean PAP and PVR among CT, BNP, and 6MWD parameters. A p value<0.05 was considered to reflect statistical significance. RESULTS: Interobserver agreement in terms of the scoring of perfusion defects was excellent (κ=0.88, 95% CIs: 0.85, 0.91). The lung PBV score was significantly correlated with the PAP (mean, rho=0.48; systolic, rho=0.47; diastolic, rho=0.39), PVR (rho=0.47), and RVP (rho=0.48) (all p values<0.01). Multivariable linear regression analyses showed that only the lung PBV score was significantly associated with both the mean PAP (coefficient, 0.84, p<0.01) and the PVR (coefficient, 28.83, p<0.01). CONCLUSION: The lung PBV score is a useful and noninvasive estimator of clinical CTEPH severity, especially in comparison with the mean PAP and PVR, which currently serve as the gold standards for the management of CTEPH .
High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis.

Fumiko Tomiyama, Ryu Watanabe, Tomonori Ishii, Yukiko Kamogawa, Yoko Fujita, Yuko Shirota, Koichiro Sugimura, Hiroshi Fujii, Hideo Harigae

The Tohoku journal of experimental medicine　239　(4)　297-305　2016年8月

DOI： 10.1620/tjem.239.297 　

詳細を見る詳細を閉じる

Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by extensive fibrosis and autoantibodies. Its clinical manifestations are diverse and include Raynaud's phenomenon, gastrointestinal dysmotility, interstitial lung disease (ILD), pulmonary hypertension, and renal crisis. Among these, ILD is the primary cause of SSc-related death. It has been considered that acute exacerbation of ILD (AE-ILD) is not common in patients with SSc; however, little is known about the prevalence of AE-ILD in Japanese patients with SSc. In this study, we aimed to clarify the prevalence, clinical characteristics, and prognosis of patients with SSc who developed AE-ILD and to identify predictive factors for AE-ILD in our Japanese cohorts. Clinical data of patients who visited our department from 1990 to 2014 and fulfilled the 2013 classification criteria for SSc were retrospectively reviewed. A total of 139 patients were enrolled. The mean age of onset was 49.1 years, and 113 (81.3%) patients were female; 116 (83.5%) had limited cutaneous involvement, and the overall 10-year survival rate was 92.0%. Among 66 (47.5%) patients with ILD, 13 (9.4%) developed AE-ILD. Patients with AE-ILD had a significantly higher incidence of overlap with polymyositis (PM) or dermatomyositis (DM) and lower prevalence of anticentromere antibodies with higher mortality rate compared with those without AE-ILD. Multivariate Cox regression analysis identified that an overlap with PM or DM was the most significant predictive factor for AE-ILD. Our study results suggest that Japanese patients with SSc, particularly patients overlapped with PM or DM, have a high risk of AE-ILD.
Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension. 国際誌

Nobuhiro Yaoita, Kimio Satoh, Taijyu Satoh, Koichiro Sugimura, Shunsuke Tatebe, Saori Yamamoto, Tatsuo Aoki, Masanobu Miura, Satoshi Miyata, Takeshi Kawamura, Hisanori Horiuchi, Yoshihiro Fukumoto, Hiroaki Shimokawa

Arteriosclerosis, thrombosis, and vascular biology　36　(6)　1293-301　2016年6月

DOI： 10.1161/ATVBAHA.115.306845 　

詳細を見る詳細を閉じる

OBJECTIVE: The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) remains to be elucidated. Thrombin-activatable fibrinolysis inhibitor (TAFI) inhibits fibrinolysis. It remains to be elucidated whether TAFI is directly involved in the pathogenesis of CTEPH. We examined potential involvement of TAFI in the pathogenesis of CTEPH in humans. APPROACH AND RESULTS: We enrolled 68 consecutive patients undergoing right heart catheterization in our hospital, including those with CTEPH (n=27), those with pulmonary arterial hypertension (n=22), and controls (non-pulmonary hypertension, n=19). Whole blood clot lysis assay showed that the extent of clot remaining after 4 hours was significantly higher in CTEPH compared with pulmonary arterial hypertension or controls (41.9 versus 26.5 and 24.6%, both P<0.01). Moreover, plasma levels of TAFI were significantly higher in CTEPH than in pulmonary arterial hypertension or controls (19.4±4.2 versus 16.1±4.5 or 16.3±3.3 μg/mL, both P<0.05), which remained unchanged even after hemodynamic improvement by percutaneous transluminal pulmonary angioplasty. Furthermore, the extent of clot remaining after 4 hours was significantly improved with CPI-2KR (an inhibitor of activated TAFI) or prostaglandin E1 (an inhibitor of activation of platelets). Importantly, plasma levels of TAFI were significantly correlated with the extent of clot remaining after 4 hours. In addition, the extent of clot remaining after 4 hours was improved with an activated TAFI inhibitor. CONCLUSIONS: These results indicate that plasma levels of TAFI are elevated in patients with CTEPH and are correlated with resistance to clot lysis in those patients.
Balloon Pulmonary Angioplasty Improves Biventricular Functions and Pulmonary Flow in Chronic Thromboembolic Pulmonary Hypertension.

Haruka Sato, Hideki Ota, Koichiro Sugimura, Tatsuo Aoki, Shunsuke Tatebe, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Hideaki Suzuki, Kimio Satoh, Kei Takase, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(6)　1470-7　2016年5月25日

DOI： 10.1253/circj.CJ-15-1187 　

詳細を見る詳細を閉じる

BACKGROUND: It remains to be determined whether balloon pulmonary angioplasty (BPA) improves biventricular cardiac functions and pulmonary flow in patients with chronic thromboembolic pulmonary hypertension (CTEPH). METHODS AND RESULTS: We enrolled 30 consecutive patients with inoperable CTEPH who underwent BPA, and carried out serial cardiac magnetic resonance imaging (CMR; M/F, 9/21; median age, 65.2 years). No patient died during the treatment or follow-up period. BPA significantly improved WHO functional class (III/IV, 83.0 to 4.0%), 6-min walking distance (330.2±168.7 to 467.3±114.4 m), mean pulmonary artery pressure (40.8±10.7 to 23.2±4.94 mmHg), pulmonary vascular resistance (9.26±4.19 to 3.35±1.40 WU) and cardiac index (2.19±0.64 to 2.50±0.57 L·min·m(2); all P<0.01). CMR also showed improvement of right ventricular (RV) ejection fraction (EF; 41.3±12.4 to 50.7±8.64%), left ventricular (LV) end-diastolic volume index (72.1±14.0 to 81.6±18.6 ml/m(2)) and LV stroke volume index (41.0±9.25 to 47.8±12.3 ml/m(2); all P<0.01). There was a significant correlation between change in RVEF and LVEF (Pearson's r=0.45, P=0.01). Average velocity in the main pulmonary artery was also significantly improved (7.50±2.43 to 9.79±2.92 cm/s, P<0.01). CONCLUSIONS: BPA improves biventricular functions and pulmonary flow in patients with inoperable CTEPH. (Circ J 2016; 80: 1470-1477).
Prognostic Impact of Loop Diuretics in Patients With Chronic Heart Failure - Effects of Addition of Renin-Angiotensin-Aldosterone System Inhibitors and β-Blockers.

Masanobu Miura, Koichiro Sugimura, Yasuhiko Sakata, Satoshi Miyata, Soichiro Tadaki, Takeshi Yamauchi, Takeo Onose, Kanako Tsuji, Ruri Abe, Takuya Oikawa, Shintaro Kasahara, Kotaro Nochioka, Jun Takahashi, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(6)　1396-403　2016年5月25日

DOI： 10.1253/circj.CJ-16-0216 　

詳細を見る詳細を閉じる

BACKGROUND: It remains to be elucidated whether addition of renin-angiotensin-aldosterone system (RAAS) inhibitors and/or β-blockers to loop diuretics has a beneficial prognostic impact on chronic heart failure (CHF) patients. METHODS AND RESULTS: From the Chronic Heart failure Analysis and Registry in the Tohoku district 2 (CHART-2) Study (n=10,219), we enrolled 4,134 consecutive patients with symptomatic stage C/D CHF (mean age, 69.3 years, 67.7% male). We constructed Cox models for composite of death, myocardial infarction, stroke and HF admission. On multivariate inverse probability of treatment weighted (IPTW) Cox modeling, loop diuretics use was associated with worse prognosis with hazard ratio (HR) 1.28 (P<0001). Furthermore, on IPTW multivariate Cox modeling for multiple treatments, both low-dose (<40 mg/day) and high-dose (≥40 mg/day) loop diuretics were associated with worse prognosis with HR 1.32 and 1.56, respectively (both P<0.001). Triple blockade with RAS inhibitor(s), mineral corticoid (aldosterone) receptor antagonist(s) (MRA), and β-blocker(s) was significantly associated with better prognosis in those on low-dose but not on high-dose loop diuretics. CONCLUSIONS: Chronic use of loop diuretics is significantly associated with worse prognosis in CHF patients in a dose-dependent manner, whereas the triple combination of RAAS inhibitor(s), MRA, and β-blocker(s) is associated with better prognosis when combined with low-dose loop diuretics. (Circ J 2016; 80: 1396-1403).
CTEPHにおける経皮的肺動脈拡張術の呼吸機能への効果

青木竜男, 杉村宏一郎, 三浦正暢, 建部俊介, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 佐藤公雄, 下川宏明

呼吸と循環　64　(5)　S32-S32　2016年5月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
心臓MRIを用いた経皮的肺動脈形成術の効果検討

佐藤遥, 大田英揮, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤公雄, 下川宏明

呼吸と循環　64　(5)　S35-S35　2016年5月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
End-Tidal CO2 Tension Is Predictive of Effective Nocturnal Oxygen Therapy in Patients with Chronic Heart Failure and Central Sleep Apnea.

Koichiro Sugimura, Tsuyoshi Shinozaki, Shigefumi Fukui, Hiromasa Ogawa, Hiroaki Shimokawa

The Tohoku journal of experimental medicine　239　(1)　39-45　2016年5月

DOI： 10.1620/tjem.239.39 　

詳細を見る詳細を閉じる

Central sleep apnea (CSA) is characterized by recurring cycles of crescendo-decrescendo ventilation during sleep, and enhances sympathetic nerve activity. Thus CSA has a prognostic impact in patients with chronic heart failure (CHF). Although nocturnal oxygen (O2) therapy decreases frequency of CSA and improves functional exercise capacity, it is also known that some non-responders to the therapy exist. We thus aimed to identify predictors of responders to nocturnal O2 therapy in CHF patients with CSA. In 12 CHF patients with CSA hospitalized at our department, sleep study was performed at 2 consecutive nights. Patients nasally inhaled O2 at either the first or second night in a randomized manner. To predict the percentage reduction in apnea-hypopnea index (%ΔAHI) in response to the nocturnal O2 therapy, we performed multiple regression analysis with a stepwise method with variables including age, brain-natriuretic peptide, circulation time, baseline AHI, hypercapnic ventilatory response and end-tidal carbon dioxide tension (PETCO2). Nocturnal O2 therapy significantly decreased AHI (from 32 ± 13 /h to 12 ± 10 /h, P < 0.0001). Among the possible predictors, PETCO2 was the only variable that is predictive of % changes in AHI. Receiver operating characteristics analysis determined 4.25% as the optimal cutoff PETCO2 level to identify responder to nocturnal O2 therapy (> 50% reduction of AHI), with 88.9% of sensitivity and 66.7% of specificity. In conclusion, PETCO2 is useful to predict the efficacy of O2 therapy in CHF patients with CSA, providing important information to the current nocturnal O2 therapy.
Chronic thromboembolic pulmonary hypertension and schizophrenia. 国際誌

Hideaki Suzuki, Koichiro Sugimura, Shunsuke Tatebe, Tatsuo Aoki, Hiroaki Shimokawa

International journal of cardiology　207　363-4　2016年3月15日

DOI： 10.1016/j.ijcard.2016.01.010 　
イマチニブ投与により長期生存が得られた肺静脈閉塞性疾患の一例査読有り

三浦正暢, 杉村宏一郎, 青木竜男, 建部俊介, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 佐藤公雄, 下川宏明

呼吸と循環　64　(5)　S48-S48　2016年
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
Effect of Respiratory Therapy on the Prognosis of Chronic Heart Failure Patients Complicated With Sleep-Disordered Breathing - A Pilot Efficacy Trial.

Hiroyuki Satake, Koichiro Sugimura, Yoshihiro Fukumoto, Koji Fukuda, Makoto Nakano, Masateru Kondo, Shigefumi Fukui, Hiromasa Ogawa, Tsuyoshi Shinozaki, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(1)　130-8　2016年

DOI： 10.1253/circj.CJ-15-0702 　

詳細を見る詳細を閉じる

BACKGROUND: Sleep-disordered breathing (SDB) has been reported to influence mortality and occurrence of ventricular tachyarrhythmia in patients with chronic heart failure (CHF). It remains to be elucidated, however, whether respiratory therapy (RT) can affect the occurrence of fatal ventricular tachyarrhythmia in CHF patients with SDB. METHODS AND RESULTS: We prospectively examined whether the severity of SDB was associated with fatal cardiac events in CHF patients and, if so, whether RT for SDB improved prognosis. We enrolled 95 patients with stable CHF, in whom SDB was examined on overnight polygraphy. The severity of SDB was quantified using the apnea-hypopnea index (AHI). All patients with AHI ≥10 (n=42) at initial evaluation were recommended to have RT, such as home oxygen therapy and continuous positive airway pressure, and 24 agreed to this. During the follow-up period of 29±17 months, 8 ventricular tachyarrhythmias occurred and 14 of the 95 patients died. On multivariate proportional hazard analysis AHI ≥5 was a risk factor for fatal arrhythmic events (P=0.026). Although RT significantly reduced AHI, it did not significantly reduce the event rates, but 4 patients with AHI <5 on RT had no fatal arrhythmic events or death. CONCLUSIONS: SDB is an independent prognostic factor and thus an important therapeutic target in CHF patients.
Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension.

Shunsuke Tatebe, Koichiro Sugimura, Tatsuo Aoki, Masanobu Miura, Kotaro Nochioka, Nobuhiro Yaoita, Hideaki Suzuki, Haruka Sato, Saori Yamamoto, Kimio Satoh, Yoshihiro Fukumoto, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(4)　980-8　2016年

DOI： 10.1253/circj.CJ-15-1212 　

詳細を見る詳細を閉じる

BACKGROUND: Pulmonary arterial hypertension with systemic dysfunctions, including metabolic disorders and renal dysfunction, has a poor prognosis. However, it remains to be elucidated whether chronic thromboembolic pulmonary hypertension (CTEPH) is also associated with systemic dysfunctions, and if so, whether balloon pulmonary angioplasty (BPA) improves them. METHODS AND RESULTS: Fifty-five consecutive patients who underwent BPA from March 2012 to December 2014 for systemic dysfunctions, including glycemic control, lipid profiles, renal and vascular function, and nutritional status were examined. The analyses were performed before and after BPA (mean, 3.5 sessions/patient) and changes in hemodynamic parameters were compared. The average follow-up period was 474±245 days. Baseline prevalence of hypertension, diabetes mellitus, dyslipidemia and advanced chronic kidney disease was 58, 7, 33 and 36%, respectively. BPA caused marked hemodynamic improvements in the CTEPH patients. Importantly, BPA also significantly improved dysglycemia (fasting blood sugar, hemoglobin A1c and homeostatic assessment model of insulin resistance), renal (creatinine and estimated glomerular filtration rate) and vascular (cardio-ankle vascular index) functions and nutritional status (albumin, cholesterols, and body mass index). Importantly, there were positive correlations between the degrees of the hemodynamic improvements and those of other improvements. CONCLUSIONS: These results indicate that BPA may exert multiple beneficial effects in CTEPH patients, not only in terms of hemodynamics but also in other systemic functions, with positive correlations among them.
Ischemic Lesion Formation in Solitary Tract Nuclei During Central Sleep Apnea With Heart Failure - Reply.

Koichiro Sugimura, Hiroyuki Satake, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(4)　1049-1049　2016年

DOI： 10.1253/circj.CJ-16-0091 　
Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension - Insights From the IBUKI and AIR Studies.

Tsutomu Saji, Masafumi Myoishi, Koichiro Sugimura, Nobuhiro Tahara, Yutaka Takeda, Keiichi Fukuda, Horst Olschewski, Yoshimi Matsuda, Sylvia Nikkho, Toru Satoh

Circulation journal : official journal of the Japanese Circulation Society　80　(4)　835-42　2016年

DOI： 10.1253/circj.CJ-16-0097 　

詳細を見る詳細を閉じる

BACKGROUND: Inhaled iloprost is approved for pulmonary arterial hypertension (PAH) in many countries. IBUKI was a phase III, non-randomized, open-label study of the efficacy and safety of inhaled iloprost in Japanese patients with PAH. METHODS AND RESULTS: Adults with PAH who were treatment-naïve or administered endothelin receptor antagonists (ERAs) and/or phosphodiesterase type 5 inhibitors (PDE5-Is) and in NYHA/WHO functional class (FC) III/IV had inhaled iloprost (2.5 µg, increased to 5.0 µg if tolerated) 6-9 times daily for 12 weeks. Eligible patients entered a 40-week extension phase. Endpoints included change from baseline to week 12 in pulmonary vascular resistance (PVR; primary endpoint), other efficacy parameters, and safety. Data were compared with new subgroup analyses of treatment-naïve Western PAH patients from the global phase III AIR study. 27 patients received iloprost: 89% were treated with an ERA and/or PDE5-I; 70% with both. At week 12, PVR improved from baseline by -124 dyn·sec·cm(-5)(95% CI, -177 to -72) and 6-min walking distance increased by 36.0 m (95% CI, 14.9 to 57.1). NYHA/WHO FC improved in 62%; none worsened. Common drug-related adverse events were headache (37%) and cough (15%); 1 patient experienced hypotension; none reported syncope or hemoptysis. There were no deaths and no unexpected long-term safety findings. AIR PAH subgroup analyses showed similar results. CONCLUSIONS: Inhaled iloprost appeared effective and safe in Japanese PAH patients, including ERA- and PDE5-I-treated patients, consistent with findings of the AIR PAH subpopulation and previous iloprost studies.
Pulmonary Arterial Hypertension Associated with Congenital Portosystemic Shunts Treated with Transcatheter Embolization and Pulmonary Vasodilators.

Haruka Sato, Masanobu Miura, Nobuhiro Yaoita, Saori Yamamoto, Shunsuke Tatebe, Tatsuo Aoki, Kimio Satoh, Hideki Ota, Kei Takase, Koichiro Sugimura, Hiroaki Shimokawa

Internal medicine (Tokyo, Japan)　55　(17)　2429-32　2016年

DOI： 10.2169/internalmedicine.55.6557 　

詳細を見る詳細を閉じる

Cardiopulmonary abnormalities are often present in patients with liver diseases. We herein report a case of congenital portosystemic shunts complicated by hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PoPH). A 57-year-old woman complained of dyspnea and was subsequently diagnosed with HPS and PoPH caused by congenital portosystemic shunts. Although shunt closure by transcatheter embolization was successfully performed, her dyspnea worsened and pulmonary artery pressure and pulmonary vascular resistance elevated. Conventional vasodilator therapy was started, resulting in an improvement of pulmonary hypertension (PH). In some patients with congenital portosystemic shunts, shunt closure could exacerbate PH, and vasodilator therapy may be effective.
4D Flow MRIを用いた慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術前後の評価

大田英揮, 杉村宏一郎, 佐藤遥, 青木竜男, 建部俊介, 三浦正暢, 矢尾板信裕, 下川宏明, 高瀬圭

日独医報　60　(2)　239-239　2015年11月
出版者・発行元：バイエル薬品(株)
ISSN：0912-0351
慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術の効果画像診断を用いた評価

青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 佐藤公雄, 大田英揮, 下川宏明

脈管学　55　(Suppl.)　S159-S159　2015年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
慢性血栓塞栓性肺高血圧患者における経皮的肺動脈拡張術の酸素化能への効果

青木竜男, 杉村宏一郎, 三浦正暢, 建部俊介, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 佐藤公雄, 下川宏明

脈管学　55　(Suppl.)　S243-S243　2015年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
経皮的肺動脈拡張術は慢性血栓塞栓性肺高血圧患者において血行動態に加えて酸素化も改善する

青木竜男, 杉村宏一郎, 三浦正暢, 建部俊介, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　63回　623-623　2015年9月
出版者・発行元： (一社)日本心臓病学会
慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術の効果検討

佐藤遥, 大田英揮, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　63回　625-625　2015年9月
出版者・発行元： (一社)日本心臓病学会
Diastolic pulmonary gradientを用いたpost-capillary PH患者の予後予測

建部俊介, 杉村宏一郎, 青木竜男, 三浦正暢, 矢尾板信裕, 鈴木秀明, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　63回　1282-1282　2015年9月
出版者・発行元： (一社)日本心臓病学会
CTEPH 慢性血栓塞栓性肺高血圧症に対するPTPAの右室機能に関する検討

三浦正暢, 杉村宏一郎, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

呼吸と循環　63　(8)　S32-S32　2015年8月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
後毛細管性肺高血圧症に対する一酸化窒素肺血管反応試験の意義

杉村宏一郎, 建部俊介, 後岡広太郎, 青木竜男, 山本沙織, 三浦正暢, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

呼吸と循環　63　(8)　S39-S40　2015年8月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
OCTでリバースリモデリングを認めた肺動脈性肺高血圧症の一例

戴哲皓, 杉村宏一郎, 建部俊介, 後岡広太郎, 青木竜男, 山本沙織, 三浦正暢, 矢尾板信裕, 佐藤公雄, 下川宏明

呼吸と循環　63　(8)　S48-S49　2015年8月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
門脈-大循環シャントに伴う肺高血圧症の2症例

佐藤遥, 三浦正暢, 矢尾板信裕, 山本沙織, 建部俊介, 青木竜男, 後岡広太郎, 佐藤公雄, 杉村宏一郎, 下川宏明

呼吸と循環　63　(8)　S63-S63　2015年8月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
Four-dimensional flow magnetic resonance imaging visualizes drastic change in vortex flow in the main pulmonary artery after percutaneous transluminal pulmonary angioplasty in a patient with chronic thromboembolic pulmonary hypertension. 国際誌

Hideki Ota, Koichiro Sugimura, Masanobu Miura, Hiroaki Shimokawa

European heart journal　36　(25)　1630-1630　2015年7月1日

DOI： 10.1093/eurheartj/ehv054 　
Cardiomyocyte steatosis and defective washout of iodine-123-β-methyl iodophenyl-pentadecanoic acid in genetic deficiency of adipose triglyceride lipase. 国際誌

Ken-ichi Hirano, Yoshihiko Ikeda, Koichiro Sugimura, Yasuhiko Sakata

European heart journal　36　(9)　580-580　2015年3月1日

DOI： 10.1093/eurheartj/ehu417 　
Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension. 国際誌

Nobuhiro Yaoita, Ryutaro Shirakawa, Yoshihiro Fukumoto, Koichiro Sugimura, Satoshi Miyata, Yutaka Miura, Kotaro Nochioka, Masanobu Miura, Shunsuke Tatebe, Tatsuo Aoki, Saori Yamamoto, Kimio Satoh, Tomohiro Kimura, Hiroaki Shimokawa, Hisanori Horiuchi

Arteriosclerosis, thrombosis, and vascular biology　34　(11)　2486-94　2014年11月

DOI： 10.1161/ATVBAHA.114.304404 　

詳細を見る詳細を閉じる

OBJECTIVE: Chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease that is distinct from pulmonary arterial hypertension (PAH). Although CTEPH is characterized by obstruction of major pulmonary artery because of chronic thrombus, it remains unclear whether CTEPH is associated with prothrombotic condition. APPROACH AND RESULTS: In addition to conventional markers, GTP-bound levels of Rap1, RhoA, RalA, Rac1, and Ras in platelets, which are implicated for platelet activation, were measured in patients without pulmonary hypertension (non-PH, n=15), patients with PAH (n=19), and patients with CTEPH (n=25). Furthermore, the responsiveness to ex vivo thrombin stimulation was also evaluated. The ratios of the P-selectin positive platelets in the non-PH patients, patients with PAH, and patients with CTEPH were 1.40% (median and interquartile range, 0.83-1.82), 2.40% (1.80-3.39), and 2.63% (1.90-8.22), respectively (non-PH versus CTEPH, P<0.01). The activated GPIIb/IIIa-positive platelets were 6.01% (1.34-7.87), 11.39% (5.69-20.86), and 9.74% (7.83-24.01), respectively (non-PH versus CTEPH, P=0.01). GTP-bound RhoA was 1.79% (0.94-2.83), 4.03% (2.01-5.14), and 2.01% (1.22-2.48), respectively (non-PH versus PAH, P=0.04), and GTP-bound RalA was 1.58% (1.08-2.11), 3.02% (2.03-3.54), and 2.64% (1.42-4.28), respectively (non-PH versus PAH, P=0.023; non-PH versus CTEPH, P=0.048). In contrast, Rac1, Rap1, or Ras was not activated in any groups. The platelets of patients with CTEPH exhibited hyperresponsiveness to ex vivo thrombin stimulation compared with those of non-PH patients when evaluated for the surface markers. Either D-dimer or fibrin degradation product level was not increased in patients with CTEPH. CONCLUSIONS: These results provide the first direct evidence that platelets of patients with CTEPH are highly activated and exhibit hyperresponsiveness to thrombin stimulation.
肺高血圧症を合併したサルコイドーシスの臨床像

建部俊介, 杉村宏一郎, 瀬川将人, 後岡広太郎, 青木竜男, 三浦正暢, 山本沙織, 佐藤遥, 佐藤公雄, 福田浩二, 下川宏明

日本サルコイドーシス/肉芽腫性疾患学会雑誌　34　(サプリメント号)　58-58　2014年10月
出版者・発行元：日本サルコイドーシス
ISSN：1883-1273
慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術と右室機能に関する検討

砂村慎一郎, 三浦正暢, 杉村宏一郎, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

脈管学　54　(Suppl.)　S171-S171　2014年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
Basigin mediates pulmonary hypertension by promoting inflammation and vascular smooth muscle cell proliferation. 国際誌

Kimio Satoh, Taijyu Satoh, Nobuhiro Kikuchi, Junichi Omura, Ryo Kurosawa, Kota Suzuki, Koichiro Sugimura, Tatsuo Aoki, Kotaro Nochioka, Shunsuke Tatebe, Saori Miyamichi-Yamamoto, Masanobu Miura, Toru Shimizu, Shohei Ikeda, Nobuhiro Yaoita, Yoshihiro Fukumoto, Tatsuro Minami, Satoshi Miyata, Kazufumi Nakamura, Hiroshi Ito, Kenji Kadomatsu, Hiroaki Shimokawa

Circulation research　115　(8)　738-50　2014年9月26日

DOI： 10.1161/CIRCRESAHA.115.304563 　

詳細を見る詳細を閉じる

RATIONALE: Cyclophilin A (CyPA) is secreted from vascular smooth muscle cells (VSMCs) by oxidative stress and promotes VSMC proliferation. However, the role of extracellular CyPA and its receptor Basigin (Bsg, encoded by Bsg) in the pathogenesis of pulmonary hypertension (PH) remains to be elucidated. OBJECTIVE: To determine the role of CyPA/Bsg signaling in the development of PH. METHODS AND RESULTS: In the pulmonary arteries of patients with PH, immunostaining revealed strong expression of CyPA and Bsg. The pulmonary arteries of CyPA(±) and Bsg(±) mice exposed to normoxia did not differ in morphology compared with their littermate controls. In contrast, CyPA(±) and Bsg(±) mice exposed to hypoxia for 4 weeks revealed significantly reduced right ventricular systolic pressure, pulmonary artery remodeling, and right ventricular hypertrophy compared with their littermate controls. These features were unaltered by bone marrow reconstitution. To further evaluate the role of vascular Bsg, we harvested pulmonary VSMCs from Bsg(+/+) and Bsg(±) mice. Proliferation was significantly reduced in Bsg(±) compared with Bsg(+/+) VSMCs. Mechanistic studies demonstrated that Bsg(±) VSMCs revealed reduced extracellular signal-regulated kinase 1/2 activation and less secretion of cytokines/chemokines and growth factors (eg, platelet-derived growth factor-BB). Finally, in the clinical study, plasma CyPA levels in patients with PH were increased in accordance with the severity of pulmonary vascular resistance. Furthermore, event-free curve revealed that high plasma CyPA levels predicted poor outcome in patients with PH. CONCLUSIONS: These results indicate the crucial role of extracellular CyPA and vascular Bsg in the pathogenesis of PH.
肺高血圧診療の進歩後毛細管性肺高血圧症に対する肺血管拡張薬の治療の可能

杉村宏一郎, 建部俊介, 後岡広太郎, 青木竜男, 山本沙織, 三浦正暢, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　62回　SS-4　2014年9月
出版者・発行元： (一社)日本心臓病学会
後毛細管性肺高血圧症における一酸化窒素吸入肺血管反応試験による検討

杉村宏一郎, 建部俊介, 後岡広太郎, 山本沙織, 三浦正暢, 青木竜男, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　62回　O-037　2014年9月
出版者・発行元： (一社)日本心臓病学会
慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術の右室機能に及ぼす効果に関する検討

三浦正暢, 杉村宏一郎, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　62回　O-333　2014年9月
出版者・発行元： (一社)日本心臓病学会
OCT imaging for the management of pulmonary hypertension. 国際誌

Zhehao Dai, Yoshihiro Fukumoto, Shunsuke Tatebe, Koichiro Sugimura, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Saori Miyamichi-Yamamoto, Nobuhiro Yaoita, Kimio Satoh, Hiroaki Shimokawa

JACC. Cardiovascular imaging　7　(8)　843-5　2014年8月

DOI： 10.1016/j.jcmg.2014.01.020 　
Enhanced [18F]fluorodeoxyglucose accumulation in the right ventricular free wall predicts long-term prognosis of patients with pulmonary hypertension: a preliminary observational study. 国際誌

Shunsuke Tatebe, Yoshihiro Fukumoto, Minako Oikawa-Wakayama, Koichiro Sugimura, Kimio Satoh, Yutaka Miura, Tatsuo Aoki, Kotaro Nochioka, Masanobu Miura, Saori Yamamoto, Manabu Tashiro, Yutaka Kagaya, Hiroaki Shimokawa

European heart journal. Cardiovascular Imaging　15　(6)　666-72　2014年6月

DOI： 10.1093/ehjci/jet276 　

詳細を見る詳細を閉じる

AIMS: We have previously demonstrated that [(18)F]fluorodeoxyglucose (FDG) accumulation is increased in the right ventricular (RV) free wall of patients with pulmonary hypertension (PH), and that this accumulation is ameliorated after the treatment with epoprostenol associated with improvement of haemodynamic overload. The aim of this study was to examine whether enhanced RV FDG accumulation by gated positron emission tomography (PET) has a prognostic impact in patients with PH. METHODS AND RESULTS: We examined the prognostic impact of the RV standardized uptake value (SUV) of FDG-PET corrected for the partial volume effect (cRV-SUV) in 27 patients with PH who underwent gated FDG-PET from March 2001 to June 2004. During the follow-up period of 69 ± 49 (mean ± SD) months, among the 27 patients, 15 showed clinical worsening (CW) and 11 died. FDG-PET examination showed that cRV-SUV was significantly higher in the CW group compared with the non-CW group (10.1 vs. 7.6, P = 0.02). Univariate Cox hazard analysis showed that cRV-SUV was significantly correlated with the time to CW (hazard ratio 1.25, 95% confidence interval 1.04-1.51, P = 0.02), which remained significant even after adjustment of World Health Organization functional class. Kaplan-Meier analysis showed that the patients with cRV-SUV ≥8.3 had poor prognosis compared with those with cRV-SUV <8.3 (log-rank P = 0.005 for time to CW and P = 0.07 for mortality). CONCLUSION: These results indicate that enhanced FDG accumulation in the RV free wall may be a novel prognostic factor in patients with PH.
Visualization of complete regression of pulmonary arterial remodeling on optical coherence tomography in a patient with pulmonary arterial hypertension.

Zhehao Dai, Koichiro Sugimura, Yoshihiro Fukumoto, Shunsuke Tatebe, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Saori Miyamichi-Yamamoto, Nobuhiro Yaoita, Kimio Satoh, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　78　(11)　2771-3　2014年

eISSN：1347-4820
肺高血圧症治療のトピックス慢性血栓塞栓性肺高血圧症における経皮的肺動脈形成術前後の肺血行動態および光干渉断層法による肺動脈病変の評価

福本義弘, 杉村宏一郎, 三浦裕, 後岡広太郎, 三浦正暢, 建部俊介, 青木竜男, 山本沙織, 佐藤公雄, 下川宏明

日本心臓病学会誌　8　(Suppl.I)　178-178　2013年9月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
Vascular Imaging 肺動脈リモデリングは肺高血圧発症前から出現する OCTを用いた検討

戴哲皓, 福本義弘, 建部俊介, 杉村宏一郎, 三浦裕, 後岡広太郎, 青木竜男, 山本沙織, 矢尾板信裕, 下川宏明

日本心臓病学会誌　8　(Suppl.I)　192-192　2013年9月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
Three-dimensional-optical coherence tomography imaging of chronic thromboembolic pulmonary hypertension. 国際誌

Koichiro Sugimura, Yoshihiro Fukumoto, Yutaka Miura, Kotaro Nochioka, Masanobu Miura, Shunsuke Tatebe, Tatsuo Aoki, Kimio Satoh, Saori Yamamoto, Nobuhiro Yaoita, Hiroaki Shimokawa

European heart journal　34　(28)　2121-2121　2013年7月

DOI： 10.1093/eurheartj/eht203 　
Plasma cyclophilin A is a novel biomarker for coronary artery disease.

Kimio Satoh, Yoshihiro Fukumoto, Koichiro Sugimura, Yutaka Miura, Tatsuo Aoki, Kotaro Nochioka, Shunsuke Tatebe, Saori Miyamichi-Yamamoto, Toru Shimizu, Shizuka Osaki, Yusuke Takagi, Ryuji Tsuburaya, Yoshitaka Ito, Yasuharu Matsumoto, Masaharu Nakayama, Morihiko Takeda, Jun Takahashi, Kenta Ito, Satoshi Yasuda, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　77　(2)　447-55　2013年

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: Oxidative stress induces secretion of cyclophilin A (CyPA) from vascular smooth muscle cells and it plays a crucial role in the pathogenesis of atherosclerosis in mice. Therefore, we tested our hypothesis that plasma CyPA levels are increased in patients with coronary artery diseases (CAD). METHODS AND RESULTS: In 320 consecutive patients undergoing coronary angiography, we examined the relationship between plasma CyPA levels and the severity of CAD. We measured plasma CyPA by an immunoassay based on the sandwich technique. Plasma CyPA levels were significantly higher in patients with significant coronary stenosis compared to those without it (P<0.001). A positive correlation was noted between plasma CyPA levels and significant coronary stenosis. The average number of stenotic coronary arteries and the need for coronary intervention were significantly increased in the quartiles of higher CyPA levels (both P<0.001). Indeed, the plasma CyPA level significantly correlated with the presence of CAD (adjusted odds ratio for CAD, 6.20; 95% confidence interval, 3.14-12.27; P<0.001). Interestingly, plasma levels of CyPA increased according to the number of atherosclerotic risk factors, all of which induce oxidative stress. Furthermore, plasma levels of CyPA significantly reduced after medical treatment of risk factors. Finally, CyPA was strongly expressed in coronary atherosclerotic plaque in patients with myocardial infarction. CONCLUSIONS: Plasma CyPA level is a novel biomarker for oxidative stress and CAD in humans.
Optical coherence tomography is superior to intravascular ultrasound for diagnosis of distal-type chronic thromboembolic pulmonary hypertension.

Shunsuke Tatebe, Yoshihiro Fukumoto, Koichiro Sugimura, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Kimio Satoh, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　77　(4)　1081-3　2013年

eISSN：1347-4820
末梢型慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術前後における光干渉断層法による肺動脈病変の評価

杉村宏一郎, 福本義弘, 佐藤公雄, 三浦裕, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 下川宏明

日本心臓病学会誌　7　(Suppl.I)　314-314　2012年8月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.

Koichiro Sugimura, Yoshihiro Fukumoto, Kimio Satoh, Kotaro Nochioka, Yutaka Miura, Tatsuo Aoki, Shunsuke Tatebe, Saori Miyamichi-Yamamoto, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　76　(2)　485-8　2012年

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: Distal-type chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease for which a new therapeutic strategy needs to be developed. We examined the effects of percutaneous transluminal pulmonary angioplasty (PTPA). METHODS AND RESULTS: We prospectively enrolled 12 patients with distal-type CTEPH. After stabilizing their condition with pulmonary vasodilators, we then performed PTPA, which markedly improved pulmonary hemodynamics and pulmonary artery structure, as confirmed by angiography and optical coherence tomography, and also significantly improved their long-term prognosis compared with 39 historical controls. CONCLUSIONS: PTPA is a promising therapeutic option for distal-type CTEPH.
Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease.

Shunsuke Tatebe, Yoshihiro Fukumoto, Koichiro Sugimura, Saori Miyamichi-Yamamoto, Tatsuo Aoki, Yutaka Miura, Kotaro Nochioka, Kimio Satoh, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　76　(5)　1235-44　2012年

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: Post-capillary pulmonary hypertension (pc-PH) is a disorder with elevated pulmonary arterial pressure and pulmonary vascular resistance (PVR) because of left heart disease (LHD), and is classified as reactive (PVR >2.5 WU) or passive (PVR ≤ 2.5 WU). However, the clinical significance of these pc-PH subtypes remains to be elucidated. METHODS AND RESULTS: We examined 676 consecutive patients with chronic heart failure (CHF) (NYHA ≥ 2), and found that 158 (23%) had pc-PH: reactive pc-PH in 58 and passive pc-PH in 100. Univariate analysis showed that 4 factors were significantly associated with reactive pc-PH and multivariate analysis showed that female sex was the only independent predictor of reactive pc-PH (odds ratio 2.12, 95% confidence interval (CI) 1.05-4.30, P=0.03). During the mean follow-up period of 2.6 years, 125 CHF patients (18%) died, including 22 with reactive pc-PH and 24 with passive pc-PH (P<0.001). Multivariate Cox regression analysis showed that elevated PVR was independently associated with higher mortality (hazard ratio 1.18, 95%CI 1.03-1.35, P=0.02). Kaplan-Meier analysis demonstrated that the prognosis of patients with reactive pc-PH was significantly worse than for those with no PH or passive pc-PH. Reactive pc-PH was a significant prognostic factor regardless of CHF etiology (ischemic vs. non-ischemic) or reduced/preserved LV ejection fraction (HFrEF vs. HFpEF). CONCLUSIONS: Reactive pc-PH is characterized by predominant female sex and is a significant prognostic factor of LHD with PH.
Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. -Comparison between preserved and reduced ejection fraction heart failure.-.

Tatsuo Aoki, Yoshihiro Fukumoto, Koichiro Sugimura, Minako Oikawa, Kimio Satoh, Makoto Nakano, Masaharu Nakayama, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　75　(11)　2605-13　2011年

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: Although myocardial fibrosis plays an important role in the progression of heart failure (HF), its prognostic impact still remains to be clarified. METHODS AND RESULTS: A total of 172 consecutive patients with chronic HF, who underwent cardiac catheterization and endomyocardial biopsy between January 2001 and September 2008, were examined. They were divided into 2 groups: HF with preserved ejection fraction (HFPEF; left ventricular ejection fraction [LVEF] ≥ 50%, n=81); and HF with reduced LVEF (HFREF; LVEF < 50%, n=91). The collagen volume fraction (CVF) in biopsy samples was calculated and its prognostic impact examined. Mean follow-up in the HFPEF and the HFREF groups was 41 ± 33 months and 41 ± 26 months, respectively. Although CVF was similar between the 2 groups (1.83 ± 1.54% vs. 2.07 ± 2.35%), CVF was significantly correlated with LV end-diastolic pressure in the HFREF group but not in the HFPEF group. When HF stage was adjusted, the long-term prognosis was comparable between the 2 groups. When the patients were divided into 2 groups according to median CVF, however, severe fibrosis was a significant predictor for all-cause death (P=0.014) and cardiac events (P=0.02) in the HFREF, but not in the HFPEF group. CONCLUSIONS: Myocardial fibrosis evaluated on biopsy samples is a useful indicator for long-term survival, suggesting that it may be an important therapeutic target as well.
Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease.

Saori Miyamichi-Yamamoto, Yoshihiro Fukumoto, Koichiro Sugimura, Tomonori Ishii, Kimio Satoh, Yutaka Miura, Shunsuke Tatebe, Kotaro Nochioka, Tatsuo Aoki, Zhulanqiqige Do E, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　75　(11)　2668-74　2011年

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: Pulmonary arterial hypertension (PAH) remains a serious disease characterized by elevated pulmonary artery pressure (PAP) and increased pulmonary vascular resistance (PVR). Among its subtypes, PAH associated with connective tissue disease (CPAH) has the worse prognosis, because of resistance to conventional vasodilator therapy. We hypothesized that intensive immunosuppressive therapy (IIT) could improve the pulmonary hemodynamics in CPAH. METHODS AND RESULTS: In our pulmonary hypertension (PH) cohort of 182 patients, we evaluated 13 consecutive patients with CPAH who received IIT combined with cyclophosphamide and glucocorticosteroids (IIT group, mean age 45 ± 8 years, 12 females and 1 male). We compared them with 8 historical controls (control group: mean age 52 ± 18 years, 8 females) for pulmonary hemodynamics and prognosis. Both groups were treated with conventional vasodilator therapy. Although the mean PAP (mPAP) remained unchanged in the control group, IIT significantly decreased mPAP (40 ± 9 to 29 ± 11 mmHg, P < 0.01) and tended to decrease PVR (700 ± 434 to 481 ± 418 dyne·s·cm⁻⁵, P=0.07). Importantly, in 6 of the 13 patients in the IIT group, mPAP was almost normalized (< 25 mmHg) and remained stabilized for more than 1 year. Furthermore, the IIT group showed significantly better prognosis compared with the control group (P<0.01). CONCLUSIONS: These results suggest that IIT as well as conventional vasodilator therapy improves the pulmonary hemodynamics and long-term prognosis of patients with CPAH.
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.

Koichiro Sugimura, Yoshihiro Fukumoto, Jun Nawata, Huan Wang, Noriko Onoue, Tomohiro Tada, Kunio Shirato, Hiroaki Shimokawa

The Tohoku journal of experimental medicine　222　(3)　201-10　2010年11月

eISSN：1349-3329

詳細を見る詳細を閉じる

Atherosclerosis is initiated by adhesion and infiltration of inflammatory leukocytes into the intima, where non-receptor protein tyrosine kinases, such as focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2), play important roles as intracellular messengers of mechanical and biochemical signals. In the present study, we examined whether FAK and PYK2 are up-regulated by elevated blood pressure or circulating humoral factors in hypertension. We used a rat model of abdominal aortic banding that allows separate evaluation of elevated blood pressure (upper body) and circulating humoral factors (lower body). We obtained the proximal and distal aortas of the banding site, 6 hours, 3 days, and 1 and 4 weeks after the banding procedure, for evaluation of phosphorylation of FAK and PYK2 by Western blotting. Arterial pressure was significantly elevated only in the upper body throughout the experimental period. The expression of FAK and the FAK phosphorylation were significantly increased at 1 and 4 weeks only in the proximal aorta. This was also the case for the expression of total PYK2 and the PYK2 phosphorylation. In contrast, there was no significant change in FAK or PYK2 phosphorylation in the distal aorta, whereas plasma levels of angiotensin II were systemically elevated. In sham-operated rats, no change in FAK or PYK2 phoshorylation was noted in the proximal and distal aortas. These results indicate that phosphorylation of FAK and PYK2 is upregulated by elevated blood pressure but not by humoral factors in the rat aorta, demonstrating novel aspects of atherogenesis in hypertension.
Identification of new prognostic factors of pulmonary hypertension.

Yutaka Miura, Yoshihiro Fukumoto, Koichiro Sugimura, Minako Oikawa, Makoto Nakano, Shunsuke Tatebe, Saori Miyamichi, Kimio Satoh, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　74　(9)　1965-71　2010年9月

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: Pulmonary hypertension (PH) still remains a serious disease, for which the plasma level of brain natriuretic peptide (BNP) and hemodynamic variables (eg, cardiac index: CI) are established prognostic factors. The aim of the present study was to identify new additional prognostic factors of the disorder to improve the management of PH. METHODS AND RESULTS: The study cohort comprised 136 consecutive PH patients admitted to hospital from 1974 to 2008, all of whom were closely followed every 6-12 months. During the follow-up period of 53.5+/-4.5 [SEM] months, 47 patients died of cardiopulmonary causes. The patients who were initially treated with monotherapy showed improved pulmonary hemodynamics when subsequently treated with combination therapy. Multivariate analysis showed that BNP and CI were significant and independent prognostic factors in all PH patients. However, in PH patients with low CI at diagnosis, only CI improvement by PH therapy was a significant and independent prognostic factor. Indeed, the patients with low CI at diagnosis (CI <2.5) followed by subsequent normalization in response to therapy (CI > or =2.5) showed a significantly better survival compared with those without such normalization. CONCLUSIONS: CI normalization in response to treatment is an independent new prognostic factor of PH in patients with low CI at diagnosis, suggesting the importance of intensive therapy to achieve CI normalization.
Optical coherence tomography as a novel diagnostic tool for distal type chronic thromboembolic pulmonary hypertension.

Shunsuke Tatebe, Yoshihiro Fukumoto, Koichiro Sugimura, Makoto Nakano, Saori Miyamichi, Kimio Satoh, Minako Oikawa, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　74　(8)　1742-4　2010年8月

eISSN：1347-4820
Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.

Hiroshi Fujita, Yoshihiro Fukumoto, Kenya Saji, Koichiro Sugimura, Jun Demachi, Jun Nawata, Hiroaki Shimokawa

Heart and vessels　25　(2)　144-9　2010年3月

DOI： 10.1007/s00380-009-1176-8 　

詳細を見る詳細を閉じる

We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models. In the present study, we examined acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, as a more feasible option to locally deliver the drug for PAH. We examined 15 patients with PAH (13 women and 2 men, 45 +/- 4 years old), including idiopathic PAH (n = 5), PAH associated with connective tissue disease (n = 6), PAH with congenital heart disease (n = 3), and portal PAH (n = 1). In those patients, we performed right heart catheterization with a Swan-Ganz catheter in the two protocols with inhalation of nitric oxide (NO) (40 ppm, 10 min) and fasudil (30 mg, 10 min) with a sufficient interval (>30 min). Both NO and fasudil inhalation significantly reduced mean pulmonary arterial pressure (PAP) (NO: P < 0.01, fasudil: P < 0.05) and tended to decrease pulmonary vascular resistance (NO: P = 0.07, fasudil: P = 0.1), but did not affect cardiac index. The ratio of pulmonary to systemic vascular resistance was significantly reduced both in NO and fasudil inhalation (NO: P < 0.01, fasudil: P < 0.05), indicating that both NO and fasudil inhalation selectively affect lung tissues. Interestingly, there was no correlation in the vasodilator effects between NO and fasudil, and a positive correlation with serum levels of high-sensitivity C-reactive protein was noted for fasudil but not for NO. These results suggest that inhalation of fasudil is as effective as NO in patients with PAH, possibly through different mechanisms.
生体肺移植を行った肺静脈閉塞を伴う肺動脈性肺高血圧症の一例

杉村宏一郎, 福本義弘, 出町順, 縄田淳, 佐治賢哉, 福井重文, 中野誠, 下川宏明, 近藤丘

Circulation Journal　72　(Suppl.III)　1055-1055　2008年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
生体肺移植により救命できた肺静脈閉塞を伴う肺動脈性肺高血圧症の一例

杉村宏一郎, 福本義弘, 出町順, 縄田淳, 佐治賢哉, 福井重文, 中野誠, 下川宏明, 近藤丘

日本心臓病学会誌　2　(Suppl.I)　437-437　2008年8月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
Unusual pulmonary embolism: septic pulmonary embolism and amniotic fluid embolism.

Masahito Sakuma, Koichiro Sugimura, Mashio Nakamura, Tohru Takahashi, Osamu Kitamukai, Takahiro Yazu, Norikazu Yamada, Masahiro Ota, Takao Kobayashi, Takeshi Nakano, Kunio Shirato

Circulation journal : official journal of the Japanese Circulation Society　71　(5)　772-5　2007年5月

ISSN：1346-9843

詳細を見る詳細を閉じる

BACKGROUND: Septic and amniotic fluid emboli are rare sources of pulmonary embolism (PE), so the present study sought to elucidate the background of these cases. METHODS AND RESULTS: A total of 11,367 PE cases were identified from 396,982 postmortem examinations. The incidence of septic PE was 247 (2.2%) of the total. The origin of infection was found in 85.6% of the cases. Fungal embolus was detected more often than bacterial embolus. The most frequently detected fungus was aspergillus (20.8%). The primary disease associated with fungal embolus was leukemia (43.2%). The incidence of PE cases associated with pregnancy and/or delivery was 89 (0.8%) of the total PE cases. Among them, amniotic fluid embolism was found in 33 (73.3%) of 45 PE cases with vaginal delivery, and in 7 (21.2%) of 33 PE cases with cesarean delivery (p<0.0001). CONCLUSION: Fungal embolus was more frequent than bacterial embolus, and leukemia was most frequent as the primary disease in cases of fungal embolus. The main cause of PE in cesarean section cases was thrombotic embolism, and the main cause in vaginal delivery cases was amniotic fluid embolism.
Peripheral pulmonary artery aneurysms in patients with pulmonary artery hypertension.

Masahito Sakuma, Jun Demachi, Jun Suzuki, Jun Nawata, Tohru Takahashi, Koichiro Sugimura, Minako Oikawa, Kei Takase, Kenji Hoshino, Shinko Souma, Kunio Shirato

Internal medicine (Tokyo, Japan)　46　(13)　979-84　2007年

eISSN：1349-7235

詳細を見る詳細を閉じる

Pulmonary artery aneurysm (PAA), especially the peripheral type, is a rare disease. We report 2 cases of peripheral PAA with pulmonary artery hypertension. Complication associated with peripheral PAA was hemoptysis. Endovascular coil embolization was performed successfully in one patient. The other with peripheral PAA was died of massive hemoptysis. In patients with peripheral PAA, coil embolization is one therapeutic option. We summarized cases with peripheral PAA in Japan.
肺高血圧症を伴った片側肺動脈無形成症の一症例

杉村宏一郎, 及川美奈子, 出町順, 福本義弘, 縄田淳, 佐藤公雄, 佐久間聖仁, 下川宏明

Circulation Journal　70　(Suppl.III)　1180-1180　2006年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
Potential risk factors and incidence of pulmonary thromboembolism in Japan: results from an overview of mailed questionnaires and matched case-control study.

Koichiro Sugimura, Masahito Sakuma, Kunio Shirato

Circulation journal : official journal of the Japanese Circulation Society　70　(5)　542-7　2006年5月

ISSN：1346-9843

詳細を見る詳細を閉じる

BACKGROUND: The potential risk factors for pulmonary thromboembolism (PTE) have not been examined in Japan, so the aims of the present study were to assess independent risk factors for PTE, and to estimate the recent incidence of symptomatic PTE. METHODS AND RESULTS: Based on a mailed questionnaire, the potential risk factors for PTE were prospectively assessed using a matched case - control study, and the number of new patients with PTE in 2004 was calculated prospectively. In multivariate analyses, increase in body mass index (odds ratio (OR) = 2.85 by 10 kg/m2; 95% confidence interval (CI), 1.51-5.39), prolonged immobilization (OR, 8.14; 95% CI, 3.15-20.99), recent major surgery (OR, 6.78; 95% CI, 2.65-17.32), and cancer (OR, 2.72; 95% CI, 1.25-5.95) were identified as independent risk factors for PTE in Japan. The risks for atherosclerosis (diabetes mellitus, hypertension, hyperlipidemia, and smoking), and alcohol consumption did not affect the incidence of PTE. The calculated number of new patients with PTE per year was 4,108 (95% CI, 3,564-4,712) in 2004. CONCLUSION: The independent risk factors for PTE in Japan are body mass index, prolonged immobilization, recent major surgery, and cancer. The number of new patients with PTE in 2004 did not demonstrate an upward trend compared with 2000.
The upregulation of ICAM-1 and P-selectin requires high blood pressure but not circulating renin-angiotensin system in vivo. 国際誌

Huan Wang, Jun Nawata, Noriko Kakudo, Koichiro Sugimura, Jun Suzuki, Masahito Sakuma, Jun Ikeda, Kunio Shirato

Journal of hypertension　22　(7)　1323-32　2004年7月

ISSN：0263-6352

詳細を見る詳細を閉じる

OBJECTIVE: To investigate the separate contributions of blood pressure and the circulating renin-angiotensin system to the upregulation of vascular endothelial adhesion molecules in vivo. METHODS: One or 4 weeks after constriction of the abdominal aortas of Wistar rats, the expressions of intercellular adhesion molecule-1 (ICAM-1), P-selectin, nuclear factor (NF) kappa B p65 subunit and monocytes were assessed at sites proximal and distal to the site of constriction, by western blot, immunohistochemistry, or both. RESULTS: At 1 week, the mean arterial pressure was increased significantly at the cervical artery in the group with aortic constriction (160 +/- 4 mmHg, compared with 104 +/- 2 mmHg before constriction), but not at the femoral artery (111 +/- 10 mmHg, compared with 100 +/- 2 mmHg before constriction) (P < 0.05), and circulating angiotensin II was increased significantly only in the group with aortic constriction (124 +/- 28 pg/ml, compared with 14 +/- 2 pg/ml in the sham-operated group; P < 0.05). In the aorta-constricted group, the expressions of ICAM-1, P-selectin, and NF-kappa B p65 subunit were significantly upregulated (2-3.1-fold) at the aorta proximal to the constriction compared with those distal to it, which were the same as those in the sham-operated group. Immunolocalization of these molecules was observed to be on the endothelial cells. Adhesive monocytes on the endothelium were also increased significantly only proximal to the constriction in the aorta-constricted group. At 4 weeks the findings were the same, except that circulating angiotensin II was within the normal range in both the aorta-constricted and the sham-operated groups. CONCLUSIONS: Our results indicate that the high blood pressure, but not the circulating renin-angiotensin system, upregulates the expression of ICAM-1 and P-selectin, suggesting that mechanical forces may be more important than humoral factors in the upregulation of adhesion molecules in hypertension.
Reply

Yosuke Terui, Koichiro Sugimura

JACC: Asia　2026年6月

DOI： 10.1016/j.jacasi.2026.04.015 　
Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry

Taijyu Satoh, Koichiro Sugimura, Yoshihiro Fukumoto, Kohtaro Abe, Yoshihiro Dohi, Kaoru Dohi, Yu Taniguchi, Akiyoshi Hashimoto, Shigehiko Kato, Kazuto Nakamura, Noriaki Takama, Toru Hashimoto, Yusuke Yamada, Yosuke Terui, Yutaka Miura, Masaki Ishiyama, Masayuki Koyama, Fusako Sera, Yuichi Tamura, Yasushi Sakata, Masaru Hatano, Satoshi Yasuda

Journal of the American Heart Association　2026年4月7日

DOI： 10.1161/JAHA.125.045155 　
Risk Prediction Models of Cardiotoxicity in Patients With Breast Cancer: Multicenter Prospective CHECK HEART-BC Study. 国際誌

Yosuke Terui, Kotaro Nochioka, Hideki Ota, Hiroshi Tada, Haruka Sato, Satoshi Miyata, Shigeru Toyoda, Shu Inami, Akihiro Nomura, Masaya Shimojima, Yasuhiro Izumiya, Yusuke Kodama, Takeshi Kitai, Kaoru Iwabuchi, Shu Suzuki, Daisuke Kitano, Keisuke Kida, Kiyotaka Shibuya, Takuya Oikawa, Takeru Nabeta, Toshiyuki Yano, Hiroyuki Iwano, Masayoshi Oikawa, Tatsuhiro Shibata, Yutaka Miura, Yoshito Ogihara, Nobuyuki Komiyama, Hiroshi Kato, Koji Higuchi, Sakiko Miyazaki, Yugo Yamashita, Satoshi Yasuda, Koichiro Sugimura

JACC. Asia　6　(2)　229-241　2026年2月

DOI： 10.1016/j.jacasi.2025.08.018 　

詳細を見る詳細を閉じる

BACKGROUND: Early detection and treatment of cardiotoxicity are essential for reducing cardiac events. However, a reliable predictive model for cardiotoxicity in patients with breast cancer receiving chemotherapy is lacking. OBJECTIVES: In this study, we aimed to develop a risk prediction model and establish effective surveillance for cardiotoxicity in patients with breast cancer undergoing chemotherapy. METHODS: Patients with breast cancer scheduled for neoadjuvant and/or adjuvant chemotherapy were prospectively screened at 25 participating institutions between August 2017 and March 2020. Cardiotoxicity was defined as a reduction in left ventricular ejection fraction of >10% from baseline to a value <53%. RESULTS: The study included 559 chemotherapy-naïve female patients. Cardiotoxicity was observed in 46 of 559 patients (8.2%) during a median follow-up period of 366 days (Q1-Q3: 365-367 days). The CHECK HEART (Comprehensive Heart Imaging to Evaluate Cardiac Damage Linked With Chemotherapy in Breast Cancer Patients) score consisted of 6 variables: heart rate, left ventricular global longitudinal strain, left ventricular end-systolic and end-diastolic diameters, right ventricular fractional area change, and treatment with anthracycline and trastuzumab. The time-dependent area under the receiver operating characteristic curve (AUC) at 12 months based on pretreatment data showed acceptable accuracy (AUC: 0.82; 95% CI: 0.76-0.89). CONCLUSIONS: The developed multivariable risk prediction models can accurately predict cardiotoxicity and support effective surveillance in patients with breast cancer receiving chemotherapy.
Rescue Balloon Pulmonary Angioplasty Prior to Pulmonary Endarterectomy With Concomitant Mitral Valve Plasty in High-Risk Operable CTEPH

Ishida, K., Ikeda, N., Sakao, S., Sugimura, K., Yamada, R., Yuge, N., Manabe, S.

Pulmonary Circulation　16　(2)　2026年

DOI： 10.1002/pul2.70308 　

ISSN：2045-8932 2045-8940
Immunosuppressive Therapy for Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases: Insights from Japanese Registry. 国際誌

Yudai Tamura, Yuichi Tamura, Ryo Takemura, Yu Taniguchi, Ichizo Tsujino, Takumi Inami, Hiromi Matsubara, Ayako Shigeta, Masaru Hatano, Shiro Adachi, Nobuhiro Tahara, Keiichi Sakurai, Koshin Horimoto, Nobuhiro Yaoita, Kohtaro Abe, Yoshihiro Dohi, Kazuhiro Kimura, Kayoko Kubota, Noriko Kikuchi, Hidekata Yasuoka, Yuichi Baba, Toshiro Shinke, Mari Amino, Natsumi Yamaguchi, Satoshi Ikeda, Teruki Sato, Masaru Ishida, Fusako Sera, Naohiko Nakanishi, Hakuoh Konishi, Koichiro Kinugawa, Takeshi Kashimura, Kaoru Dohi, Kazufumi Nakamura, Soichiro Usui, Sumiaki Tanaka, Shuji Kubota, Nobutaka Ikeda, Masanori Yoshikawa, Keiichi Odagiri, Sadatomo Tasaka, Yasuchika Takeishi, Teruyasu Sugano, Koichiro Sugimura, Koichiro Tatsumi, Masataka Kuwana

Advances in therapy　42　(12)　6103-6117　2025年12月

DOI： 10.1007/s12325-025-03389-z 　

詳細を見る詳細を閉じる

INTRODUCTION: The combination of immunosuppressive therapy (IST) and pulmonary artery vasodilators has demonstrated potential effectiveness in treating pulmonary arterial hypertension (PAH) associated with connective tissue diseases (CTD-PAH) other than systemic sclerosis (SSc). However, large-scale studies of this topic are limited. This study aimed to evaluate the effectiveness of early IST in treating PAH in patients diagnosed with non-SSc CTD-PAH. METHODS: Clinical data for patients with non-SSc CTD-PAH were collected from the Japan Pulmonary Hypertension Registry spanning 2008-2021. Early IST was defined as the initiation or intensification of therapy within 3 months of PAH diagnosis. RESULTS: The study included 141 patients (mean age 51 ± 16.7 years; 95% female), with 57 receiving early IST, across 43 centers in Japan. The primary underlying diseases were systemic lupus erythematosus, mixed connective tissue disease, and Sjögren syndrome. At baseline, there were no significant differences in hemodynamics or PAH treatment regimens between the IST and non-IST groups. However, the IST group was notably younger, had higher plasma IgG levels, and maintained better renal function. The IST group showed significantly greater improvements in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) over 12 months (p = 0.032 and p = 0.028), along with significant reductions in all-cause (p = 0.039) and PAH-related (p = 0.020) mortalities. No significant differences in deaths due to infections or malignancies were observed between groups. CONCLUSION: Our data suggest that early initiation of IST may be associated with hemodynamic improvement; prospective confirmation in international cohorts is warranted.
Dual impact of anaemia and chronic kidney disease on postpercutaneous coronary intervention outcomes: insights from the Japanese nationwide registry. 国際誌

Ryoma Fukuoka, Kyohei Yamaji, Shun Kohsaka, Hideki Ishii, Yuichiro Mori, Yohei Numasawa, Tetsu Watanabe, Takashi Nakayama, Koichiro Sugimura, Yoshihide Fujimoto, Masaki Ieda, Akio Kawamura, Tetsuya Amano, Ken Kozuma

Open heart　12　(1)　2025年6月3日

DOI： 10.1136/openhrt-2024-003146 　

詳細を見る詳細を閉じる

BACKGROUND: Anaemia and chronic kidney disease (CKD) are both established risk factors for bleeding events after percutaneous coronary intervention (PCI). These conditions often coexist; however, previous assessments of these factors individually may have led to an underestimation of their impact on clinical outcomes. METHODS: We analysed the data of 77 482 patients who underwent PCI between 2017 and 2020 in the Japanese nationwide PCI registry. Based on preprocedural anaemia (haemoglobin: <13 g/dL in men; <12 g/dL in women) and CKD (estimated glomerular filtration rate, <60 mL/min/1.73 m²) statuses, the patients were categorised into 'neither anaemia nor CKD' (n=36 629; 47.3%), 'CKD alone' (n=17 120; 22.1%), 'anaemia alone' (n=10 136; 13.1%) and 'both anaemia and CKD' (n=13 597; 17.5%) groups. The study endpoints included bleeding (fatal or non-fatal major bleeding) and ischaemic (cardiovascular death, non-fatal acute coronary syndrome or non-fatal ischaemic stroke) events. RESULTS: The 1-year incidence of bleeding and ischaemic events was highest in the 'both anaemia and CKD' group and lowest in the 'neither anaemia nor CKD' group. After adjustment, 'anaemia alone' (HR 1.52; 95% CI 1.29 to 1.79; p<0.001) and 'both anaemia and CKD' (HR 1.39; 95% CI 1.18 to 1.63; p<0.001), but not 'CKD alone' (HR 1.00; 95% CI 0.85 to 1.17; p=0.97), were significantly associated with high risks of bleeding events compared with 'neither anaemia nor CKD'. All three groups had higher ischaemic risk compared with 'neither anaemia nor CKD' ('CKD alone': HR 1.29; 95% CI 1.16 to 1.45; p<0.001, 'anaemia alone': HR 1.40; 95% CI 1.22 to 1.60; p<0.001, 'both anaemia and CKD': HR 1.61; 95% CI 1.43 to 1.81; p<0.001). CONCLUSIONS: Anaemia increased bleeding risk regardless of CKD status, whereas 'CKD alone' did not. In addition, patients with anaemia and/or CKD were at a higher risk of ischaemic events. Clinicians should routinely perform initial risk assessments stratified by anaemia and CKD for patients undergoing PCI.
Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure 査読有り

Yasuhiko Sakata, Kotaro Nochioka, Satoshi Yasuda, Koichi Ishida, Takashi Shiroto, Jun Takahashi, Shintaro Kasahara, Ruri Abe, Shinsuke Yamanaka, Takahide Fujihashi, Hideka Hayashi, Shintaro Kato, Katsunori Horii, Kanako Teramoto, Tsutomu Tomita, Satoshi Miyata, Koichiro Sugimura, Iwao Waga, Masao Nagasaki, Hiroaki Shimokawa

European Journal of Heart Failure　2025年4月15日

DOI： 10.1002/ejhf.3654 　

ISSN：1388-9842 1879-0844

詳細を見る詳細を閉じる

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>The clinical guidelines categorize heart failure (HF) based on left ventricular ejection fraction (LVEF). However, the current LVEF cutoffs, 40% and 50%, may not fully address the underlying characteristics and cardiovascular risk of HF, particularly for HF with higher LVEF. This study aimed to characterize HF with supranormal ejection fraction (HFsnEF) using different LVEF cutoffs (35%, 55%, and 70% for men, and 40%, 60%, and 75% for women).</jats:p></jats:sec><jats:sec><jats:title>Methods and results</jats:title><jats:p>This study divided 442 patients from the CHART‐Omics study into four groups: HF with reduced ejection fraction (HFrEF) (<jats:italic>n</jats:italic> = 55, 65.5 years), HF with mildly reduced ejection fraction (HFmrEF) (<jats:italic>n</jats:italic> = 125, 69.3 years), HF with normal ejection fraction (HFnEF) (<jats:italic>n</jats:italic> = 215, 69.0 years) and HFsnEF (<jats:italic>n</jats:italic> = 47, 67.1 years). When clinical backgrounds were adjusted and HFnEF served as the reference, HFsnEF carried an increased hazard ratio (HR) for the composite of cardiovascular death and HF hospitalization of 2.71 (95% confidence interval [CI] 1.10–6.66, <jats:italic>p</jats:italic> = 0.030), while HFrEF had a HR of 3.14 (95% CI 1.36–7.23, <jats:italic>p</jats:italic> = 0.007). HFsnEF was characterized by an increase in relative left ventricular wall thickness and a decrease in left ventricular dimensions, whereas increased left ventricular mass and dimensions characterized HFrEF. Quantitative analysis of 4670 plasma proteins showed essential differences between HFsnEF and HFrEF, for example, ‘protein synthesis’ versus ‘cell morphology’, ‘cellular assembly and organization’ and ‘nucleic acid metabolism’ for underlying pathophysiology, and ‘energy production’ versus ‘connective tissue disorders’ and ‘cell‐to‐cell signalling and interaction’ for prognostication.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Heart failure with supranormal ejection fraction, an unnoticed but emerging entity in HF, carries a similarly increased cardiovascular risk as HFrEF but has unique structural and plasma proteomic characteristics.</jats:p></jats:sec>
Hypopituitarism Induced by Continuous Infusion of PGI2 Analogues: A Case Series and the Role of ACTH Screening and Hydrocortisone Treatment

Taijyu Satoh, Yuichi Tamura, Noriaki Takama, Hiromi Matsubara, Nobuhiro Tanabe, Takumi Inami, Takahiro Hiraide, Kohtaro Abe, Yoshihiro Dohi, Yoshito Ogihara, Takeshi Ogo, Shiro Adachi, Kazuhiko Nakazato, Ichizo Tsujino, Hideki Ota, Kohei Komaru, Haruka Sato, Yuta Tezuka, Yoshikiyo Ono, Rika Suda, Kazuya Hosokawa, Sarasa Isobe, Takatoyo Kiko, Yuki Koga, Junichi Nakamura, Koichiro Sugimura, Masaru Hatano, Yoshihiro Fukumoto, Satoshi Yasuda

Pulmonary Circulation　15　(2)　2025年4月
出版者・発行元： Wiley
DOI： 10.1002/pul2.70116 　

ISSN：2045-8940

eISSN：2045-8940

詳細を見る詳細を閉じる

ABSTRACT Hypopituitarism has been reported in patients receiving continuous infusions of prostaglandin I2 (PGI2) analogues for pulmonary hypertension (PH). However, these patients' clinical characteristics, treatment, and prognoses remain unclear. This retrospective multicentre study included 22 patients who developed hypopituitarism while on continuous PGI2 analogue infusion between 1999 and 2021. All patients were female, and idiopathic pulmonary arterial hypertension was the most common underlying condition (63.6%). Their mean age was 38.8 ± 7.9 years. Epoprostenol was the predominant PGI2 analogue used (90.9%). At the time of hypopituitarism onset, the median PGI2 dose was 67.2 ng/kg/min (31.8–88.7 ng/kg/min), and the median treatment duration was 889.0 days (450.5–1941.5 days), suggesting that hypopituitarism occurred independent of its dose or treatment duration. Diagnoses were based on decreased adrenocorticotropic hormone levels. The hypopituitarism classification revealed isolated pituitary dysfunction in 54.5% of the cases, partial dysfunction in 18.1%, and complete dysfunction in 27.2%. Most cases could be managed without requiring specific therapies. After hypopituitarism onset, 63.6% of the patients continued to receive the same PGI2 analogue. Hydrocortisone therapy was administered to 81.8% of the patients, leading to clinical stabilisation. No deaths were reported. In conclusions, hypopituitarism may occur during continuous PGI2 analogue infusion for PH, irrespective of its dose or treatment duration. Initiating hydrocortisone therapy may be important for stabilising the clinical course.
Long-term survival and durable recovery of heart failure in patients with triglyceride deposit cardiomyovasculopathy treated with tricaprin

Ken-ichi Hirano, Satomi Okamura, Koichiro Sugimura, Hideyuki Miyauchi, Yusuke Nakano, Kotaro Nochioka, Chikako Hashimoto, Yoshitaka Iwanaga, Kenichi Nakajima, Satoshi Yamaguchi, Yoko Yasui, Shinsaku Shimamoto, Makito Hirano, Mana Okune, Yuki Nishimura, Hisashi Shimoyama, Yasuyuki Nagasawa, Tetsuya Amano, Shimpei Kuniyoshi, Shu-Ping Hui, Nobuhiro Zaima, Yoshihiko Ikeda, Tomomi Yamada, Shinichiro Fujimoto, Yasuhiko Sakata, Kunihisa Kobayashi

Nature Cardiovascular Research　2025年2月13日
出版者・発行元： Springer Science and Business Media LLC
DOI： 10.1038/s44161-025-00611-7 　

eISSN：2731-0590
Triglyceride Deposit Cardiomyovasculopathy Manifesting Coronary Artery Disease

Ken-ichi Hirano, Yusuke Nakano, Hideyuki Miyauchi, Yoshihiko Ikeda, Masahiro Higashi, Tatsuya Mori, Takayuki Nakano, Shinichiro Fujimoto, Tomomi Yamada, Koichiro Sugimura, Kunihisa Kobayashi, Tetsuya Amano

Journal of Coronary Artery Disease　30　(3)　85-91　2024年9月25日
出版者・発行元： The Japanese Coronary Association
DOI： 10.7793/jcad.30.005 　

eISSN：2434-2173
A Surgical Case of Partially Unroofed Coronary Sinus Atrial Septal Defect in an Elderly Patient Diagnosed by Preoperative Contrast-Enhanced Computed Tomography.

Norihisa Yuge, Susumu Manabe, Daiki Hirayama, Ryuki Yamada, Mariko Hori, Tomohiro Saito, Nobuhiro Mochizuki, Koichiro Sugimura, Hiroaki Shimokawa

International heart journal　65　(1)　155-158　2024年

DOI： 10.1536/ihj.23-401 　

詳細を見る詳細を閉じる

Unroofed coronary sinus syndrome is a rare congenital cardiac anomaly, involving some anatomical variations. Approximately 60% of patients with unroofed coronary sinus syndrome have a concomitant atrial septal defect, which is termed unroofed coronary sinus atrial septal defect (CSASD). The precise detection of these abnormalities has been usually difficult with conventional echocardiography, mostly due to its small and complex structures. Herein, we report a case with unroofed coronary sinus atrial septal defect, in which preoperative contrast-enhanced computed tomography (CT) was useful in the operative decision making. We successfully repaired the defective roof of the coronary sinus with a bovine patch, while eliminating the inter-atrial shunt. The patient's postoperative course was uneventful with no residual shunt.
Adult-onset idiopathic peripheral pulmonary artery stenosis

Yudai Tamura, Yuichi Tamura, Ayako Shigeta, Kazuya Hosokawa, Yu Taniguchi, Takumi Inami, Shiro Adachi, Ichizo Tsujino, Naohiko Nakanishi, Kimi Sato, Jiro Sakamoto, Nobuhiro Tanabe, Noriaki Takama, Kazuto Nakamura, Kayoko Kubota, Naohiro Komura, Shigehiko Kato, Jun Yamashita, Makoto Takei, Shuji Joho, Shunsuke Ishii, Ryo Takemura, Koichiro Sugimura, Koichiro Tatsumi

European Respiratory Journal　2300763-2300763　2023年12月7日
出版者・発行元： European Respiratory Society (ERS)
DOI： 10.1183/13993003.00763-2023 　

ISSN：0903-1936

eISSN：1399-3003

詳細を見る詳細を閉じる

Background Peripheral pulmonary artery stenosis (PPS) refers to the stenosis of the pulmonary artery from the trunk to the peripheral arteries. Although pediatric PPS is well described, the clinical characteristics of adult-onset idiopathic PPS have not been established. Objectives We characterized the disease profile of adult-onset PPS. Methods We collected data in Japanese centers. This cohort included patients underwent pulmonary angiography (PAG) and excluded patients with chronic thromboembolic pulmonary hypertension or Takayasu arteritis. Patient backgrounds, right heart catheterization findings, imaging findings, and treatment profiles were collected. Results Forty-four patients (median age: 39 years [Q1–Q3:29–57]; 29 females [65.9%]) with PPS were enrolled from 20 centers. In PAG, stenosis of segmental and peripheral pulmonary arteries was observed in 41 (93.2%) and 36 patients (81.8%), respectively. Thirty-five patients (79.5%) received medications approved for pulmonary arterial hypertension (PAH-drugs) and 22 patients (50.0%) received combination therapy. Twenty-five patients (56.8%) underwent transcatheter pulmonary angioplasty. Right heart catheterization data showed improvements in both the mean pulmonary artery pressure (44versus40 mmHg; p<0.001) and pulmonary vascular resistance (760versus514 dyn·s·cm⁻⁵; p<0.001) from baseline to the final follow-up. The 3-, 5-, and 10-year survival rates of patients with PPS were 97.5% (95% confidence interval [CI]:83.5–99.6), 89.0% [95% CI:68.9–96.4), and 67.0% (95% CI:41.4–83.3), respectively. Conclusions In this study, the patients with adult-onset idiopathic PPS presented with segmental and peripheral pulmonary artery stenosis. Although patients had severe pulmonary hypertension at baseline, they showed a favorable treatment response to the PAH-drugs combined with transcatheter pulmonary angioplasty.
Inhaled nitric oxide testing in predicting prognosis in pulmonary hypertension due to left-sided heart diseases. 国際誌

Taijyu Satoh, Nobuhiro Yaoita, Kotaro Nochioka, Shunsuke Tatebe, Hideka Hayashi, Saori Yamamoto, Haruka Sato, Hiroyuki Takahama, Hideaki Suzuki, Yosuke Terui, Kaito Yamada, Yusuke Yamada, Takumi Inoue, Tatsuo Aoki, Kimio Satoh, Koichiro Sugimura, Satoshi Miyata, Satoshi Yasuda

ESC heart failure　2023年9月29日

DOI： 10.1002/ehf2.14515 　

詳細を見る詳細を閉じる

AIMS: The pathophysiology of pulmonary hypertension (PH) due to left-sided heart disease (Group 2 PH) is distinct from that of other groups of PH, yet there are still no approved therapies that selectively target pulmonary circulation. The increase in pulmonary capillary pressure due to left-sided heart disease is a trigger event for physical and biological alterations of the pulmonary circulation, including the nitric oxide (NO)-soluble guanylate cyclase-cyclic guanosine monophosphate axis. This study investigated inhaled NO vasoreactivity tests for patients with Group 2 PH and hypothesized that these changes may have a prognostic impact. METHODS AND RESULTS: This was a single-centre, retrospective study with a median follow-up of 365 days. From January 2011 to December 2015, we studied 69 patients with Group 2 PH [age, 61.5 ± 13.0 (standard deviation) years; male:female, 49:20; left ventricular ejection fraction, 50.1 ± 20.4%; mean pulmonary arterial pressure, ≥25 mmHg; and pulmonary arterial wedge pressure (PAWP), >15 mmHg]. No adverse events were observed after NO inhalation. Thirty-four patients with Group 2 PH showed increased PAWP (ΔPAWP: 3.26 ± 2.22 mmHg), while the remaining 35 patients did not (ΔPAWP: -2.11 ± 2.29 mmHg). Multivariate analysis revealed that increased PAWP was the only significant predictor of all-cause death or hospitalization for heart failure (HF) after 1 year (hazard ratio 4.35; 95% confidence interval, 1.27-14.83; P = 0.019). The acute response of PAWP to NO differed between HF with preserved and reduced ejection fractions. CONCLUSIONS: Patients with Group 2 PH were tolerant of the inhaled NO test. NO-induced PAWP is a novel prognostic indicator.
Clinical and Sociodemographic Factors Associated With Health-Related Quality of Life in Patients With Adult Congenital Heart Disease - A Nationwide Cross-Sectional Multicenter Study.

Shunsuke Tatebe, Satoshi Yasuda, Ryo Konno, Yasuhiko Sakata, Koichiro Sugimura, Kimio Satoh, Takashi Shiroto, Satoshi Miyata, Osamu Adachi, Masato Kimura, Yoshiko Mizuno, Junko Enomoto, Shigeru Tateno, Hiromichi Nakajima, Kotaro Oyama, Yoshikatsu Saiki, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　2023年9月5日

DOI： 10.1253/circj.CJ-23-0383 　

詳細を見る詳細を閉じる

BACKGROUND: Little is known about clinical or sociodemographic factors that influence health-related quality of life (HRQoL) in patients with adult congenital heart disease (ACHD).Methods and Results: We conducted a nationwide prospective cross-sectional multicenter study at 4 large ACHD centers in Japan. From November 2016 to June 2018, we enrolled 1,223 ACHD patients; 1,025 patients had an HRQoL score. Patients completed a questionnaire survey, including sociodemographic characteristics, and the 36-Item Short-Form Health Survey (SF-36). To determine factors associated with HRQoL, correlations between 2 SF-36 summary scores (i.e., physical component score [PCS] and mental component score [MCS]) and other clinical or sociodemographic variables were examined using linear regression analysis. In multivariable analysis, poorer PCS was significantly associated with 11 variables, including older age, higher New York Heart Association class, previous cerebral infarction, being unemployed, and limited participation in physical education classes and sports clubs. Poorer MCS was associated with congenital heart disease of great complexity, being part of a non-sports club, current smoking, and social drinking. Student status and a higher number of family members were positively correlated with MCS. CONCLUSIONS: This study demonstrates that HRQoL in ACHD patients is associated with various clinical and sociodemographic factors. Further studies are needed to clarify whether some of these factors could be targets for future intervention programs to improve HRQoL outcomes.
Clinical Management and Outcomes of Patients With Portopulmonary Hypertension Enrolled in the Japanese Multicenter Registry. 査読有り

Yudai Tamura, Yuichi Tamura, Yu Taniguchi, Ichizo Tsujino, Takumi Inami, Hiromi Matsubara, Ayako Shigeta, Yoichi Sugiyama, Shiro Adachi, Kohtaro Abe, Yuichi Baba, Masaru Hatano, Satoshi Ikeda, Kenya Kusunose, Koichiro Sugimura, Soichiro Usui, Yasuchika Takeishi, Kaoru Dohi, Saki Hasegawa-Tamba, Koshin Horimoto, Noriko Kikuchi, Hiraku Kumamaru, Koichiro Tatsumi

Circulation reports　4　(11)　542-549　2022年11月10日

DOI： 10.1253/circrep.CR-22-0098 　

詳細を見る詳細を閉じる

Background: Portopulmonary hypertension (PoPH) is one of the major underlying causes of pulmonary arterial hypertension (PAH). However, PoPH, especially treatment strategies, has been poorly studied. Therefore, this study evaluated current treatments for PoPH, their efficacy, and clinical outcomes of patients with PoPH. Methods and Results: Clinical data were collected for patients with PoPH who were enrolled in the Japan Pulmonary Hypertension Registry between 2008 and 2021. Hemodynamic changes, functional class, and clinical outcomes were compared between patients with PoPH treated with monotherapy and those treated with combination therapies. Clinical data were analyzed for 62 patients with PoPH, including 25 treatment-naïve patients, from 21 centers in Japan. In more than half the patients, PAH-specific therapy improved the New York Heart Association functional class by at least one class. The 3- and 5-year survival rates of these patients were 88.5% (95% confidence interval [CI] 76.0-94.7) and 80.2% (95% CI 64.8-89.3), respectively. Forty-one (66.1%) patients received combination therapy. Compared with patients who had received monotherapy, the mean pulmonary arterial pressure, pulmonary vascular resistance, and cardiac index were significantly improved in patients who had undergone combination therapies. Conclusions: Combination therapy was commonly used in patients with PoPH with a favorable prognosis. Combination therapies resulted in significant hemodynamic improvement without an increased risk of side effects.
Onco-Cardiologyのマネージメントを知り尽くす乳がん治療による心臓合併症の疫学と発症リスク前向き多施設共同研究(CHECK HEART-BC Study)

杉村宏一郎, 照井洋輔, 後岡広太郎, 豊田茂, 下島正也, 泉家康宏, 児玉雄介, 北井豪, 岩渕薫, 鈴木秀, 北野大輔, 木田圭亮, 多田寛, 大田英揮, 安田聡, 佐藤希美

日本心臓病学会学術集会抄録　70回　S23-1　2022年9月
出版者・発行元： (一社)日本心臓病学会
高齢者における循環器疾患に対する応用薬理慢性心不全患者における脳由来成長因子(BDNF)と脳灰白質量との関連慢性心不全における脳の構造・機能に関する縦断研究(B-HeFT2)

鈴木秀明, 松本泰治, 大田英揮, 杉村宏一郎, 後岡広太郎, 高橋潤, 宮田敏, 古川勝敏, 福本義弘, 瀧靖之, 下川宏明, 安田聡

応用薬理　102　(5-6)　123-123　2022年8月
出版者・発行元：応用薬理研究会
ISSN：0300-8533
冠微小循環障害の成因に関する多施設共同研究

杉村宏一郎, 武田守彦, 柴信行, 河村朗夫, 下川宏明

国際医療福祉大学学会誌　27　(抄録号)　213-213　2022年8月
出版者・発行元：国際医療福祉大学学会
ISSN：2186-3652
Association between RNF213 c.14576G>A Variant (rs112735431) and Peripheral Pulmonary Artery Stenosis in Moyamoya Disease. 国際誌

Dan Ozaki, Hidenori Endo, Ryosuke Tashiro, Koichiro Sugimura, Shunsuke Tatebe, Satoshi Yasuda, Yasutake Tomata, Toshiki Endo, Keita Tominaga, Kuniyasu Niizuma, Miki Fujimura, Teiji Tominaga

Cerebrovascular diseases (Basel, Switzerland)　51　(3)　282-287　2022年

DOI： 10.1159/000519717 　

詳細を見る詳細を閉じる

BACKGROUND: Moyamoya disease (MMD) and peripheral pulmonary artery stenosis (PPAS) are relatively rare and demonstrate steno-occlusive vascular lesions in different organs. Genetic studies identified RNF213 polymorphism c.14576G>A (rs112735431) as a susceptibility variant for East Asian MMD. RNF213 polymorphism c.14576G>A is further associated with various vascular lesions of other organs. In this study, we aimed to clarify the incidence and clinical manifestations of PPAS in MMD patients and analyze the correlation between RNF213 genotype and PPAS. METHODS: This retrospective case-control study investigated the association between RNF213 polymorphism and PPAS in 306 MMD/quasi-MMD patients, reviewing the medical charts and imaging records of consecutive patients with MMD admitted from January 2015 to December 2020. RESULTS: PPAS was observed in 3 MMD/quasi-MMD patients (0.98%, 3/306). RNF213 polymorphism c.14576G>A was determined for all 306 MMD/quasi-MMD patients. The incidence of PPAS in RNF213-wildtype, RNF213-heterozygote, and RNF213-homozygote MMD/quasi-MMD patients was 0% (0/101), 0.5% (1/200), and 40% (2/5), respectively. The association between PPAS and homozygote polymorphism of RNF213 c.14576G>A was statistically significant in MMD/quasi-MMD patients (p = 0.0018). In all cases, pulmonary artery hypertension due to PPAS was evident during their childhood and young adolescent stages. Surgical indications for MMD were discouraged in 1 case due to her severe cardiopulmonary dysfunction. CONCLUSIONS: The homozygote variant of RNF213 polymorphism c.14576G>A can be a potential predisposing factor for PPAS in MMD/quasi-MMD patients. Despite the relatively rare entity, PPAS should be noted to determine surgical indications for MMD/quasi-MMD patients.
Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias. 国際誌

Piero Gentile, Marco Merlo, Giovanni Peretto, Enrico Ammirati, Simone Sala, Paolo Della Bella, Giovanni Donato Aquaro, Massimo Imazio, Luciano Potena, Jeness Campodonico, Alberto Foà, Anne Raafs, Mark Hazebroek, Michela Brambatti, Andreja Cerne Cercek, Gaetano Nucifora, Sanskriti Shrivastava, Florent Huang, Matthieu Schmidt, Daniele Muser, Caroline M Van de Heyning, Emeline Van Craenenbroeck, Tatsuo Aoki, Koichiro Sugimura, Hiroaki Shimokawa, Antonio Cannatà, Jessica Artico, Aldostefano Porcari, Marzia Colopi, Andrea Perkan, Rossana Bussani, Giulia Barbati, Andrea Garascia, Manlio Cipriani, Piergiuseppe Agostoni, Naveen Pereira, Stephane Heymans, Eric D Adler, Paolo Guido Camici, Maria Frigerio, Gianfranco Sinagra

European journal of heart failure　2021年7月1日

DOI： 10.1002/ejhf.2288 　

詳細を見る詳細を閉じる

AIMS: The outcomes of patients presenting with acute myocarditis and life-threatening ventricular arrhythmias (LT-VA) are unclear. The aim of this study was to assess the incidence and predictors of recurrent major arrhythmic events (MAEs) after hospital discharge in this patient population. METHODS AND RESULTS: We retrospectively analysed 156 patients (median age 44 years; 77% male) discharged with a diagnosis of acute myocarditis and LT-VA from 16 hospitals worldwide. Diagnosis of myocarditis was based on histology or the combination of increased markers of cardiac injury and cardiac magnetic resonance (CMR) Lake Louise criteria. MAEs were defined as the relapse, after discharge, of sudden cardiac death or successfully defibrillated ventricular fibrillation, or sustained ventricular tachycardia (sVT) requiring implantable cardioverter-defibrillator therapy or synchronized external cardioversion. Median follow-up was 23 months [first to third quartile (Q1-Q3) 7-60]. Fifty-eight (37.2%) patients experienced MAEs after discharge, at a median of 8 months (Q1-Q3 2.5-24.0 months; 60.3% of MAEs within the first year). At multivariable Cox analysis, variables independently associated with MAEs were presentation with sVT [hazard ratio (HR) 2.90, 95% confidence interval (CI) 1.38-6.11]; late gadolinium enhancement involving ≥2 myocardial segments (HR 4.51, 95% CI 2.39-8.53), and absence of positive short-tau inversion recovery (STIR) (HR 2.59, 95% CI 1.40-4.79) at first CMR. CONCLUSIONS: Among patients discharged with a diagnosis of myocarditis and LT-VA, 37.2% had recurrences of MAEs during follow-up. Initial CMR pattern and sVT at presentation stratify the risk of arrhythmia recurrence.
Prognostic impacts of serum uric acid levels in patients with chronic heart failure: insights from the CHART-2 study. 国際誌

Takahide Fujihashi, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Ruri Abe, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Shinsuke Yamanaka, Hideka Hayashi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

ESC heart failure　8　(2)　1027-1038　2021年4月

DOI： 10.1002/ehf2.12765 　

詳細を見る詳細を閉じる

AIMS: Prognostic impacts of serum uric acid (UA) levels in patients with chronic heart failure (CHF) remain inconclusive, especially for the whole range of serum UA levels. METHODS AND RESULTS: In the Chronic Heart Failure Registry and Analysis in the Tohoku District-2 (CHART-2) study, we enrolled 4652 consecutive patients with CHF and classified them into four groups based on baseline serum UA levels by the Classification and Regression Tree: G1 (<3.8 mg/dL, N = 313), G2 (3.8-7.1 mg/dL, N = 3070), G3 (7.2-9.2 mg/dL, N = 1018), and G4 (>9.2 mg/dL, N = 251). Mean age was 71 ± 12, 69 ± 12, 68 ± 13, and 69 ± 15 years in G1, G2, G3, and G4, respectively (P < 0.001). During the median follow-up of 6.3 years, in G1, G2, G3, and G4, 111 (35%), 905 (29%), 370 (36%), and 139 (55%) patients died and 79 (25%), 729 (24%), 300 (29%), and 115 (46%) experienced heart failure hospitalization, respectively (both P < 0.001). G1 was characterized by a significantly high prevalence of women as compared with G2, G3, and G4 (59%, 32%, 24%, and 23%, respectively). Serum creatinine levels (0.8 ± 0.4, 0.9 ± 0.4, 1.2 ± 0.6, and 1.4 ± 0.8 mg/dL, respectively), prevalence of atrial fibrillation (34%, 39%, 45%, and 50%, respectively), and diuretics use (36%, 45%, 67%, and 89%, respectively) increased from G1, G2, G3 to G4 (all P < 0.001), while left ventricular ejection fraction decreased from G1, G2, G3 to G4 (59 ± 15, 58 ± 15, 54 ± 15, and 52 ± 17%, respectively, P < 0.001). Multivariable Cox proportional hazards models showed that, as compared with G2, both G1 and G4 had increased incidence of all-cause death [adjusted hazard ratio (aHR) 1.34, 95% confidence interval (CI) 1.08-1.67, P = 0.009; aHR 1.28, 95% CI 1.02-1.61, P = 0.037, respectively] and heart failure admission (aHR 1.39, 95% CI 1.09-1.78, P = 0.008 and aHR 1.35, 95% CI, 1.06-1.71, P = 0.014, respectively). This U-shaped relationship was evident in the elderly patients. Furthermore, abnormal transitions to either higher or lower levels of serum UA from G2 were associated with increased mortality (aHR 1.29, 95% CI 1.06-1.57, P = 0.012; aHR 1.57, 95% CI 1.12-2.20, P = 0.009). CONCLUSIONS: These results demonstrate that serum UA levels have the U-shaped prognostic effects and abnormal transitions to either higher or lower levels are associated with poor prognosis in the elderly patients with CHF.
Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction. 国際誌

Shinsuke Yamanaka, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Takahide Fujihashi, Hideka Hayashi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

European journal of heart failure　22　(12)　2258-2268　2020年12月

DOI： 10.1002/ejhf.1945 　

詳細を見る詳細を閉じる

AIMS: We aimed to examine temporal changes in left ventricular (LV) structures and their prognostic impacts in patients with heart failure (HF) and preserved ejection fraction (HFpEF). METHODS AND RESULTS: In the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) study (n = 10 219), we divided 2698 consecutive HFpEF patients (68.9 ± 12.2 years, 32.1% female) into three groups by LV hypertrophy (LVH) and enlargement (LVE) at baseline: (-)LVH/(-)LVE (n = 989), (+)LVH/(-)LVE (n = 1448), and (+)LVH/(+)LVE (n = 261). We examined temporal changes in LV structures and their prognostic impacts during a median 8.7-year follow-up. From (-)LVH/(-)LVE, (+)LVH/(-)LVE to (+)LVH/(+)LVE at baseline, the incidence of the primary outcome, a composite of cardiovascular death or HF admission, significantly increased. Among 1808 patients who underwent echocardiography at both baseline and 1 year, we noted substantial group transitions from baseline to 1 year; the transition rates from (-)LVH/(-)LVE to (+)LVH/(-)LVE, from (+)LVH/(-)LVE to (-)LVH/(-)LVE, from (+)LVH/(-)LVE to (+)LVH/(+)LVE, and from (+)LVH/(+)LVE to (+)LVH/(-)LVE were 27% (182/671), 22% (213/967), 6% (59/967), and 26% (44/170), respectively. In the univariable Cox proportional hazard model, patients who transitioned from (+)LVH/(-)LVE to (+)LVH/(+)LVE or remained in (+)LVH/(+)LVE had the worst subsequent prognosis [hazard ratio (HR) 4.65, 95% confidence interval (CI) 3.09-6.99, P < 0.001; HR 4.01, 95% CI 2.85-5.65, P < 0.001, respectively], as compared with those who remained in (-)LVH/(-)LVE. These results were unchanged after adjustment for the covariates including baseline LV ejection fraction (LVEF) and 1-year LVEF change. CONCLUSION: In HFpEF patients, LV structures dynamically change over time with significant prognostic impacts, where patients who develop LVE with LVH have the worst prognosis.
未修復状態での単心房単心室症の1成人症例

勝田祐子, 建部俊介, 後岡広太郎, 遠藤洋一, 佐々木絵里奈, 杉村宏一郎, 福井重文, 山本沙織, 下川宏明

超音波医学　47　(Suppl.)　S218-S218　2020年11月
出版者・発行元： (公社)日本超音波医学会
ISSN：1346-1176

eISSN：1881-9311
補助循環下での化学療法で救命し得た胃癌による顕微鏡的微小肺動脈腫瘍塞栓の一例

福井重文, 照井洋輔, 杉村宏一郎, 建部俊介, 山本沙織, 鈴木秀明, 矢尾板信裕, 菊地順裕, 佐藤遥, 紺野亮, 下川宏明

脈管学　60　(Suppl.)　S131-S131　2020年10月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
乳癌患者における化学療法による心毒性が原因の局所左室変形に関する経時的変化(Longitudinal Change of Regional Left Ventricular Deformation by Chemotherapy-induced Cardiotoxicity in Patients with Breast Cancer)

藤原淳子, 後岡広太郎, 杉村宏一郎, 照井洋輔, 佐藤遥, 多田寛, 大田英揮, 船水康陽, 三木俊, 西條芳文, 高瀬圭, 石田孝宜, 下川宏明

日本循環器学会学術集会抄録集　84回　OJ12-6　2020年7月
出版者・発行元： (一社)日本循環器学会
ステージBとステージC/D心不全における心臓突然死の発生率と予測因子 CHART-2 Studyからの洞察(Incidence and Predictors of Sudden Cardiac Death in Stage B vs. Stage C/D Heart Failure: Insights from the CHART-2 Study)

林秀華, 坂田泰彦, 後岡広太郎, 青柳肇, 山中信介, 藤橋敬英, 白戸崇, 杉村宏一郎, 高橋潤, 宮田敏, 下川宏明

日本循環器学会学術集会抄録集　84回　PJ31-6　2020年7月
出版者・発行元： (一社)日本循環器学会
ステージBとステージC/D心不全における心臓突然死の発生率と予測因子 CHART-2 Studyからの洞察(Incidence and Predictors of Sudden Cardiac Death in Stage B vs. Stage C/D Heart Failure: Insights from the CHART-2 Study)

林秀華, 坂田泰彦, 後岡広太郎, 青柳肇, 山中信介, 藤橋敬英, 白戸崇, 杉村宏一郎, 高橋潤, 宮田敏, 下川宏明

日本循環器学会学術集会抄録集　84回　PJ31-6　2020年7月
出版者・発行元： (一社)日本循環器学会
Impacts of hippocampal blood flow on changes in left ventricular wall thickness in patients with chronic heart failure. 国際誌

Hideaki Suzuki, Yasuharu Matsumoto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Yoshihiro Fukumoto, Yasuyuki Taki, Hiroaki Shimokawa

International journal of cardiology　310　103-107　2020年7月1日

DOI： 10.1016/j.ijcard.2020.01.019 　

詳細を見る詳細を閉じる

BACKGROUND: Although depressive symptoms increased mortality and hospitalization in chronic heart failure (CHF) patients, the underlying mechanism remains unclear. The aim of this study was to investigate whether an alteration in hippocampal perfusion, which is the neural substrate of depressive symptoms, is associated with changes in cardiac structures and/or functions in CHF patients. METHODS: We used baseline data of 70 CHF patients (66.8 ± 8.9 yrs, 32.5% women), including cerebral blood flow (CBF) in the hippocampus, geriatric depression scale (GDS) scores and echocardiographic parameters, in the Brain Assessment and Investigation in Heart Failure Trial (B-HeFT) (UMIN000008584). Echocardiography was repeated at 3.1 ± 0.5 years after the baseline evaluation. We first tested voxel-wise regression model with hippocampal CBF as dependent variable and each of echocardiographic parameter change as independent variable, adjusted for age and sex. Structural equation modeling was used to test a mediation effect of cognitive test scores on associations between hippocampal perfusion and changes in cardiac structures and/or functions. RESULTS: Baseline anterior hippocampal CBF was negatively correlated with changes in left ventricular posterior wall thickness (PWT) (P < 0.05 with family-wise error corrections). An existence of depressive symptoms was positively correlated with the baseline anterior CBF and negatively with the PWT changes (P < 0.05, both). There were both direct effects of the baseline anterior hippocampal CBF on PWT thinning and effects mediated through the depressive symptoms (P < 0.05, both). CONCLUSIONS: This study provides the first evidence that the alteration in hippocampal perfusion may lead to changes in cardiac structures via increase in depressive symptoms in CHF patients.
Risk of de-novo heart failure and competing risk in asymptomatic patients with structural heart diseases. 国際誌

Tsuyoshi Takada, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Ruri Abe, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Takahide Fujihashi, Shinsuke Yamanaka, Kota Suzuki, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

International journal of cardiology　307　87-93　2020年5月15日

DOI： 10.1016/j.ijcard.2020.02.015 　

詳細を見る詳細を閉じる

AIMS: Asymptomatic patients with structural heart diseases are classified as a population at high risk for heart failure (HF) in Stage B. However, limited data are available regarding incidence and related factors of de-novo HF (DNHF) considering competing risk in this population. METHODS AND RESULTS: In 3362 Stage B patients (mean age 68 yrs, male 76%) from the CHART-2 Study (N = 10,219), we examined incidence of death and DNHF, defined as the first episode of either HF hospitalization or HF death, and factors related to DNHF. RESULTS: During the median 6.0-year follow-up, 627 deaths (31/1000 person-years) and 293 DNHF (15/1000 person-years) occurred. Among the 627 deaths, 212 (34%) and 325 (52%) were specified as cardiovascular and non-cardiovascular deaths, respectively. During the follow-up of 271 DNHF hospitalizations, we observed 124 deaths, including 65 (52%) cardiovascular and 47 (40%) non-cardiovascular deaths. The competing risk model showed that age, diabetes mellitus, stroke, atrial fibrillation, diastolic blood pressure, hemoglobin levels, estimated glomerular filtration ratio and left ventricular ejection fraction was significantly associated with DNHF. Bayesian structural equation modeling showed that many of these cardiac and non-cardiac variables contribute to DNHF by affecting each other, while diabetes mellitus was independently associated with DNHF. CONCLUSIONS: Stage B patients had a high incidence of DNHF as well as that of death due to both cardiovascular and non-cardiovascular causes. Thus, management of Stage B patients should include multidisciplinary approaches considering both cardiac and non-cardiac factors, in order to prevent DNHF as well as non-HF death as a competing risk. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT00418041.
Temporal changes in left ventricular ejection fraction and their prognostic impacts in patients with Stage B heart failure. 国際誌

Hajime Aoyanagi, Kotaro Nochioka, Yasuhiko Sakata, Masanobu Miura, Takashi Shiroto, Ruri Abe, Shintaro Kasahara, Masayuki Sato, Takahide Fujihashi, Shinsuke Yamanaka, Hideka Hayashi, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

International journal of cardiology　306　123-132　2020年5月1日

DOI： 10.1016/j.ijcard.2020.02.040 　

詳細を見る詳細を閉じる

BACKGROUND: We have recently demonstrated that left ventricular ejection fraction (LVEF) dynamically changes over time with prognostic impacts in Stage C/D patients, namely, those who have a current or past history of heart failure (HF). However, it is unknown whether this is also the case in asymptomatic Stage B patients, namely, those who have a risk of HF, but do not have a history of HF. METHODS: In our CHART-2 Study (N = 10,219), we enrolled 4005 Stage B patients and divided them into 3 groups by LVEF; preserved EF (pEF, LVEF ≥50%, N = 3526), mid-range EF (mrEF, LVEF 41-49%, N = 302), and reduced EF (rEF, LVEF ≤40%, N = 177). We examined the prognostic impacts of LVEF transitions among the 3 groups in comparison with 4477 patients with Stage C/D HF. RESULTS: Stage B were characterized by less severe clinical status and better prognosis compared with Stage C/D. Stage B in mrEF and rEF at baseline dynamically transitioned to other groups at 1-year, whereas those in pEF unchanged; at 1-year, mrEF transitioned to pEF/rEF by 50/16%, and rEF transitioned to pEF/mrEF by 25/31%, respectively, whereas pEF transitioned to mrEF/rEF by only 3.6/0.7%, respectively, which were consistent with findings in findings with Stage C/D. Although LVEF decrease was directly associated with all-cause mortality in both the Stage B and Stage C/D with pEF, factors related to LVEF changes were different between the 2 groups. CONCLUSIONS: In Stage B, LVEF dynamically changes with prognostic impacts as in Stage C/D, whereas different determination factors may be involved in the 2 stages. CLINICAL TRIAL REGISTRATION: Chronic Heart Failure Analysis and Registry in the Tohoku District (CHART)-2 (NCT00418041).
Clinical implication of myocardial FDG uptake pattern in oncologic PET: retrospective comparison study with stress myocardial perfusion imaging as the reference standard.

Kentaro Takanami, Mioko Saito, Yasuharu Matsumoto, Koichiro Sugimura, Kei Takase

Annals of nuclear medicine　34　(4)　233-243　2020年4月

DOI： 10.1007/s12149-020-01437-y 　

詳細を見る詳細を閉じる

OBJECTIVE: The purpose of this study was to determine the clinical implication of the myocardial FDG uptake patterns by comparing with the results of stress myocardial perfusion imaging (MPI) as the reference standard. METHODS: By reviewing the medical records, 86 pairs of stress MPI and FDG PET/CT of 84 patients who underwent stress MPI and oncologic FDG PET/CT in 1 month were included in this study. The patterns of the myocardial FDG uptake were classified into five patterns such as 'low', 'diffuse', 'basal ring', 'focal high', and 'focal defect on diffuse high'. MPI was evaluated using a 5-point scoring model ranging from 0 (normal uptake) to 4 (uptake absent) based on the 17-segment model. The summed stress score of 4 or higher was defined as 'abnormal MPI'. Factors predictive of abnormal MPI were analyzed using a log-rank multivariate test and p < 0.05 was set as significant. RESULTS: Abnormal MPI was observed in only 16 of 36 (44%) patients with 'low' pattern, 10 of 23 (43%) patients with 'diffuse high' pattern, and 1 of 9 (11%) patients with 'basal ring' pattern, but in 8 of 9 (89%) patients with 'focal high' pattern, and 8 of 9 (89%) patients with 'focal defect on diffuse high' pattern. The log-rank multivariate test revealed that 'focal high' and 'focal defect on diffuse high' pattern were correlated with an abnormal MPI. CONCLUSIONS: These results indicate that further cardiac work-up might be helpful in the patients with 'focal high' pattern or 'focal defect on diffuse high' pattern of myocardial FDG at oncologic PET. A prospective study should be needed to further support this conclusion.
Clinical characteristics and prognostic factors in elderly patients with chronic heart failure -A report from the CHART-2 study. 国際誌

Masayuki Sato, Yasuhiko Sakata, Kenjiro Sato, Kotaro Nochioka, Masanobu Miura, Ruri Abe, Takuya Oikawa, Shintaro Kasahara, Hajime Aoyanagi, Shinsuke Yamanaka, Takahide Fujihashi, Hideka Hayashi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

International journal of cardiology. Heart & vasculature　27　100497-100497　2020年4月

DOI： 10.1016/j.ijcha.2020.100497 　

詳細を見る詳細を閉じる

Background: Since most of the randomized clinical trials for heart failure (HF) were designed to exclude elderly patients, limited data are available on their clinical characteristics, prognosis, and prognostic factors. Methods: We compared clinical characteristics, prognosis, and prognostic factors among Stage C/D HF patients in our CHART-2 Study (N = 4876, mean 69 years, women 32%, 6.3-year follow-up) by age (G1, ≤64 years, N = 1521; G2, 65-74 years, N = 1510; and G3, ≥75 years, N = 1845). Results: From G1 to G3, the prevalence of women, left ventricular ejection fraction (LVEF) and plasma levels of B-type natriuretic peptide (BNP) increased (all P < 0.001). Similarly, 5-year mortality increased (9.9, 17.3 to 39.9%, P < 0.001) along with a decrease in proportion of cardiovascular death and an increase in non-cardiovascular death in both sexes. While all-cause and cardiovascular mortality was comparable between the sexes, women had significantly lower incidence of non-cardiovascular death than men in G2 and G3, which was attributable to the higher incidence of cancer death and pneumonia death in men than in women. Although NYHA functional class III-IV, chronic kidney disease, cancer, LVEF, and BNP had significant impacts on all-cause death in all groups, their impacts were less evident in G3 as compared with G1. Conclusions: The elderly HF patients, as compared with younger HF patients, were characterized by more severe clinical background, increased proportion of non-cardiovascular death and worse prognosis with different impacts of prognostic factors across the age groups.
Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. 国際誌

Tomohiro Ohtsuki, Kimio Satoh, Toru Shimizu, Shohei Ikeda, Nobuhiro Kikuchi, Taijyu Satoh, Ryo Kurosawa, Masamichi Nogi, Shinichiro Sunamura, Nobuhiro Yaoita, Junichi Omura, Tatsuo Aoki, Shunsuke Tatebe, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

Journal of the American Heart Association　8　(23)　e013716　2019年12月3日

DOI： 10.1161/JAHA.119.013716 　

詳細を見る詳細を閉じる

Background Circulating proteins are exposed to vascular endothelial layer and influence their functions. Among them, adipsin is a member of the trypsin family of peptidases and is mainly secreted from adipocytes, monocytes, and macrophages, catalyzing the rate-limiting step of the alternative complement pathway. However, its pathophysiological role in cardiovascular disease remains to be elucidated. Here, we examined whether serum adipsin levels have a prognostic impact in patients with coronary artery disease. Methods and Results In 370 consecutive patients undergoing diagnostic coronary angiography, we performed a cytokine array analysis for screening serum levels of 50 cytokines/chemokines and growth factors. Among them, classification and regression analysis identified adipsin as the best biomarker for prediction of their long-term prognosis (median 71 months; interquartile range, 55-81 months). Kaplan-Meier curve showed that higher adipsin levels (≥400 ng/mL) were significantly associated with all-cause death (hazard ratio [HR], 4.2; 95% CI, 1.7-10.6 [P<0.001]) and rehospitalization (HR, 2.4; 95% CI, 1.7-3.5 [P<0.001]). Interestingly, higher high-sensitivity C-reactive protein levels (≥1 mg/L) were significantly correlated with all-cause death (HR, 3.2; 95% CI, 1.7-5.9 [P<0.001]) and rehospitalization (HR, 1.5, 95% CI, 1.1-1.9 [P<0.01]). Importantly, the combination of adipsin (≥400 ng/mL) and high-sensitivity C-reactive protein (≥1 mg/L) was more significantly associated with all-cause death (HR, 21.0; 95% CI, 2.9-154.1 [P<0.001]). Finally, the receiver operating characteristic curve demonstrated that serum adipsin levels predict the death caused by acute myocardial infarction in patients with coronary artery disease (C-statistic, 0.847). Conclusions These results indicate that adipsin is a novel biomarker that predicts all-cause death and rehospitalization in patients with coronary artery disease, demonstrating the novel aspects of the alternative complementary system in the pathogenesis of coronary artery disease.
Association between temporal changes in C-reactive protein levels and prognosis in patients with previous myocardial infarction - A report from the CHART-2 Study. 国際誌

Takuya Oikawa, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Ruri Abe, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Chiharu Saga, Yasuko Ikeno, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

International journal of cardiology　293　17-24　2019年10月15日

DOI： 10.1016/j.ijcard.2019.07.022 　

詳細を見る詳細を閉じる

BACKGROUND: Several studies have reported that C-reactive protein (CRP), an inflammatory biomarker, predicts cardiovascular events independently of low-density lipoprotein cholesterol levels. However, no study examined whether temporal changes in CRP levels are associated with clinical events in patients with previous myocardial infarction (MI). METHODS AND RESULTS: We examined 2184 consecutive patients with previous MI and CRP data at baseline in the Chronic Heart Failure Registry and Analysis in the Tohoku district-2 (CHART-2) Study. During the median 6.4 years follow-up, 592 all-cause, 245 cardiovascular, and 273 non-cardiovascular deaths occurred. Patients with CRP ≥ 2.0 mg/L at baseline had significantly increased incidence of all-cause (hazard ratio (HR) 1.68, P < 0.001) and non-cardiovascular death (HR 1.86, P < 0.001), compared with those with CRP < 2.0 mg/L. Temporal changes in CRP levels were associated with prognosis; among patients with CRP ≥ 2.0 mg/L at baseline, those with CRP ≥ 2.0 mg/L at 1-year had significantly increased incidence of all-cause (HR 2.12, P < 0.001), cardiovascular (HR 2.31, P < 0.001), and non-cardiovascular death (HR 2.29, P < 0.001). Among patients with CRP < 2.0 mg/L at baseline, those with CRP ≥ 2.0 mg/L at 1-year had significantly increased incidence of all-cause (HR 1.76, P < 0.001) and cardiovascular death (HR 2.10, P = 0.001). These results remained significant after adjusted with the inverse probability of treatment weighted models using propensity sore. Furthermore, as compared with patients with CRP < 2.0 mg/L at both baseline and 1-year, those with CRP ≥ 2.0 mg/L at both baseline and 1-year had increased incidence of all-cause, cardiovascular, and non-cardiovascular death. CONCLUSIONS: These results provide the evidence that temporal increases in CRP levels are associated with increased clinical events in patients with previous MI.
Successful Management of Acute Congestive Heart Failure by Emergent Caesarean Section Followed by Adrenalectomy in a Pregnant Woman with Cushing's Syndrome-induced Cardiomyopathy.

Miku Sakota, Shunsuke Tatebe, Koichiro Sugimura, Tatsuo Aoki, Saori Yamamoto, Haruka Sato, Nobuhiro Kikuchi, Ryo Konno, Yosuke Terui, Kimio Satoh, Yuta Tezuka, Ryo Morimoto, Masatoshi Saito, Shimpei Kuniyoshi, Hiroaki Shimokawa

Internal medicine (Tokyo, Japan)　58　(19)　2819-2824　2019年10月1日

DOI： 10.2169/internalmedicine.2427-18 　

詳細を見る詳細を閉じる

Congestive heart failure (CHF) is rare during pregnancy. We herein report a 35-year-old woman who developed CHF with severe left ventricular dysfunction at 35 weeks' gestation. She underwent emergency Caesarean section followed by intensive-care treatment for CHF. The diagnosis of Cushing's syndrome (CS) caused by adrenal adenoma was confirmed by endocrinological examinations and histology after adrenalectomy. She was discharged on heart failure medications and glucocorticoid replacement therapy. Both the symptoms and cardiac function had recovered after 12 months of follow-up. This case highlights the importance of considering CS-induced cardiomyopathy as a cause of CHF in pregnant women.
CardioOncologyの現状と未来当院データと本邦における多施設共同研究への発展

杉村宏一郎, 大田英揮, 多田寛, 照井洋輔, 佐藤遥, 後岡広太郎, 石田孝宣, 高瀬圭, 下川宏明

日本心臓病学会学術集会抄録　67回　SS-3　2019年9月
出版者・発行元： (一社)日本心臓病学会
脳卒中診療におけるカテーテルインターベンションの新たな役割卵円孔開存症に対するデバイス閉鎖術におけるBrain-Heart Team 循環器内科の立場から

福井重文, 建部俊介, 紺野亮, 照井洋輔, 佐藤遥, 山本沙織, 佐藤公雄, 杉村宏一郎, 下川宏明

日本心血管インターベンション治療学会抄録集　28回　[S39-4]　2019年9月
出版者・発行元： (一社)日本心血管インターベンション治療学会
Increased risk of cancer death in patients with chronic heart failure with a special reference to inflammation-A report from the CHART-2 Study. 国際誌

Takuya Oikawa, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Ruri Abe, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

International journal of cardiology　290　106-112　2019年9月1日

DOI： 10.1016/j.ijcard.2019.04.078 　

詳細を見る詳細を閉じる

BACKGROUND: Although several factors, including heart failure (HF) and inflammation, are known to increase the incidence of cancer, it remains unknown whether HF may increase cancer mortality, especially with a reference to inflammation. METHODS AND RESULTS: We examined 8843 consecutive cardiovascular patients without a prior history of cancer in our CHART-2 Study (mean 68 yrs., female 30.9%). As compared with patients without HF (Stage A/B, N = 4622), those with HF (Stage C/D, N = 4221) were characterized by higher prevalence of diabetes, previous myocardial infarction, atrial fibrillation, and stroke. During the median 6.5-year follow-up (52,675 person-years), 282 cancer deaths occurred. HF patients had significantly higher cancer mortality than those without HF in both the overall (3.7 vs, 2.8%, hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.12-1.79, P = 0.004) and the propensity score-matched cohorts (HR 1.46, 95%CI 1.10-1.93, P = 0.008), which was confirmed in the competing risk models. The multivariable Cox proportional hazard model in the matched cohort showed that HF was associated with increased cancer mortality in patients with C-reactive protein (CRP) ≥ 2.0 mg/L (HR 1.87, 95%CI 1.18-2.96, P = 0.008) at baseline, but not in those with CRP < 2.0 mg/L (HR 0.89, 95%CI 0.54-1.45, P = 0.64) (P for interaction = 0.03). Furthermore, temporal changes in CRP levels were associated with cancer death in the overall cohort; HF patients with CRP ≥ 2.0 mg/L at both baseline and 1-year had significantly increased cancer death, while those with CRP ≥ 2.0 mg/L at baseline and < 2.0 mg/L at 1-year not. CONCLUSIONS: These results provide the first evidence that HF is associated with increased cancer death, especially when associated with prolonged inflammation.
The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. 国際誌

Shintaro Kasahara, Yasuhiko Sakata, Kotaro Nochioka, Wan Ting Tay, Brian Lee Claggett, Ruri Abe, Takuya Oikawa, Masayuki Sato, Hajime Aoyanagi, Masanobu Miura, Takashi Shiroto, Jun Takahashi, Koichiro Sugimura, Tiew-Hwa Katherine Teng, Satoshi Miyata, Hiroaki Shimokawa

International journal of cardiology　284　42-49　2019年6月1日

DOI： 10.1016/j.ijcard.2018.10.076 　

詳細を見る詳細を閉じる

BACKGROUND: Few simple risk models, without echocardiography have been developed for patients with heart failure (HF) and preserved left ventricular ejection fraction (LVEF) (HFpEF). METHODS: To develop a risk score to predict all-cause death for HFpEF patients, we examined 1277 HF patients with LVEF ≥50% and BNP ≥100 pg/ml in the CHART-2 Study, a large-scale prospective cohort study for HF in Japan. We selected the optimal subset of covariates for the score with Cox proportional hazard models and random survival forests (RSF). RESULTS: During the median 5.7-year follow-up, 576 deaths occurred. Cox models and RSF analyses consistently indicated age ≥75 years, albumin <3.7 g/dl, anemia, BMI <22 kg/m2, BNP ≥300 pg/ml (or NT-proBNP ≥1400 pg/ml), and BUN ≥25 mg/dl, as the important 6 prognostic variables. Incorporating these 6 variables, we developed a scoring system (3A3B score, with 2 points given to age ≥75 years and 1 point to the others based on the hazard ratios. The discrimination ability of the risk score was excellent (c-index 0.708). Regarding model goodness-of-fit, the overall gradient in 5-year risk was well captured by the score. The predictive accuracy of the 3A3B score was confirmed in the external validation cohorts from the TOPCAT trial (N = 835, c-index 0.652) and the ASIAN-HF registry (N = 170, c-index 0.741). CONCLUSIONS: We developed a simple risk score to predict long-term prognosis of HFpEF patients. The 3A3B score, comprising 6 commonly available parameters in daily practice, has potential utility in the risk stratification and management of HFpEF patients.
Gender differences in prognostic relevance of self-care behaviors on mortality and hospitalization in patients with heart failure - A report from the CHART-2 Study. 国際誌

Ruri Abe, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Takuya Oikawa, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

Journal of cardiology　73　(5)　370-378　2019年5月

DOI： 10.1016/j.jjcc.2018.11.006 　

詳細を見る詳細を閉じる

BACKGROUND: Self-care behaviors (ScB) are associated with symptoms and outcomes in patients with heart failure (HF). However, little is known about gender differences in the prognostic relevance of ScB in HF patients. METHODS: We examined gender differences in ScB of HF patients regarding its prognostic associations with mortality and HF hospitalization with a reference to ScB dimensions. The European Heart Failure Self-Care Behavior Scale (EHFScBS) was used to evaluate ScB in 2233 patients with Stage C/D HF in the CHART-2 Study. RESULTS: Male patients (n=1583) were younger (71 vs. 73 yrs) and had lower ScB (median 33 vs. 31) (all p<0.001) than females (n=650). During the median follow-up of 2.57 years, patients with high ScB (score 12-32, n=1090), as compared with low ScB patients (score 33-60, n=1143), had significantly increased all-cause mortality in males [adjusted hazard ratio (aHR) 1.44, p=0.02] but not in females (aHR 0.80, p=0.40) (p for interaction 0.02), while ScB was not significantly associated with incidence of HF hospitalization in both genders. Among the 3 dimensions in EHFScBS, complying with regimen was associated with decreased mortality in females, but not in males (p for interaction 0.003), while asking for help was related with increased incidence of HF hospitalization in males (aHR 1.34, p=0.072) but not in females (aHR 0.98, p=0.931) (p for interaction 0.048). CONCLUSIONS: There were gender differences in the prognostic relevance of self-care with mortality and incidence of HF hospitalization, suggesting that self-care should be implemented considering gender differences to improve prognosis.
Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases. 国際誌

Shintaro Kasahara, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Ruri Abe, Masayuki Sato, Hajime Aoyanagi, Takahide Fujihashi, Shinsuke Yamanaka, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

International journal of cardiology　280　184-189　2019年4月1日

DOI： 10.1016/j.ijcard.2018.12.069 　

詳細を見る詳細を閉じる

BACKGROUND: Although B-type natriuretic peptide (BNP) and N-terminal prohormone B-type natriuretic peptide (NT-proBNP) are released in equimolar proportions, their values differ depending on clinical conditions. A useful conversion formula between BNP and NT-proBNP remains to be developed for the clinical use. AIM: To develop a conversion formula from BNP to NT-proBNP. METHODS: In the derivation cohort, 923 patients with chronic heart failure, in whom both BNP and NT-proBNP values were available, were enrolled from our SUPPORT (Supplemental Benefit of ARB in Hypertensive Patients with Stable Heart Failure using Olmesartan) trial. The validation cohort included 1154 consecutive patients with or at risk of cardiovascular diseases, in whom both BNP and NT-proBNP values were measured simultaneously at Tohoku University Hospital. We regressed log10 NT-proBNP onto log10 BNP and factors influencing BNP and NT-proBNP values. RESULTS: We adopted the model with the smallest Akaike information criterion consisting of log10 BNP, age, sex, BMI, creatinine clearance (CCr), hemoglobin, and atrial fibrillation (AF). As compared with the previously reported conversion formulas, the present conversion formula utilized non-linear transformation by spline function, and exhibited the strongest correlation between actual and calculated values of NT-proBNP (r = 0.928). The root mean squared error (RMSE) of the present conversion formula was smallest compared with the previously reported conversion formulas, indicating that this formula most effectively converts BNP values to NT-proBNP values. CONCLUSIONS: We have developed a useful conversion formula from BNP to NT-proBNP values, using age, sex, BMI, CCr, hemoglobin, and AF, which could be widely used in daily clinical practice.
左室駆出率の保たれた心不全患者に対する簡便で有用なリスクスコアとしての3A3Bスコア(3A3B Score as a Simple and Useful Risk Score for Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction)

笠原信太郎, 坂田泰彦, 後岡広太郎, Tay Wan Ting, Claggett Brian Lee, 阿部瑠璃, 佐藤雅之, 青柳肇, 藤橋敬英, 山中信介, 三浦正暢, 白戸崇, 高橋潤, 杉村宏一郎, Teng Tiew-Hwa Katherine, 宮田敏, 下川宏明

日本循環器学会学術集会抄録集　83回　OJ03-6　2019年3月
出版者・発行元： (一社)日本循環器学会
心不全リスクのある患者における左室駆出率の推移の影響 CHART-2研究からの報告(Impact of Transition of Left Ventricular Ejection Fraction in Patients at Risk of Heart Failure: Report from the CHART-2 Study)

青柳肇, 坂田泰彦, 後岡広太郎, 三浦正暢, 笠原信太郎, 佐藤雅之, 藤橋敬英, 山中信介, 白戸崇, 杉村宏一郎, 高橋潤, 宮田敏, 下川宏明

日本循環器学会学術集会抄録集　83回　PJ073-5　2019年3月
出版者・発行元： (一社)日本循環器学会
CTEPHにおける重症度と姿勢変化に伴うPET CO2の変化と特徴

秋月三奈, 柿花隆昭, 上月正博, 杉村宏一郎, 青木竜男, 下川宏明

日本呼吸ケア・リハビリテーション学会誌　27　(3)　433-433　2018年11月
出版者・発行元： (一社)日本呼吸ケア・リハビリテーション学会
ISSN：1881-7319

eISSN：2189-4760
悪性腫瘍合併肺塞栓症の治療 FMCの有用性に関する検討

青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 山本沙織, 佐藤遥, 紺野亮, 照井洋輔, 後岡広太郎, 佐藤公雄, 下川宏明

脈管学　58　(Suppl.)　S159-S160　2018年9月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
運動負荷右心カテーテルによるBPAの効果判定

青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 山本沙織, 佐藤遥, 紺野亮, 照井洋輔, 後岡広太郎, 佐藤公雄, 下川宏明

脈管学　58　(Suppl.)　S168-S168　2018年9月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
Structural brain abnormalities and cardiac dysfunction in patients with chronic heart failure. 国際誌

Hideaki Suzuki, Yasuharu Matsumoto, Hideki Ota, Koichiro Sugimura, Jun Takahashi, Kenta Ito, Satoshi Miyata, Yoshihiro Fukumoto, Yasuyuki Taki, Hiroaki Shimokawa

European journal of heart failure　20　(5)　936-938　2018年5月

DOI： 10.1002/ejhf.1104 　
慢性心不全患者における可溶型basiginが予後に与える影響患者1147例を対象とするプロスペクティブ大規模臨床試験(Prognostic Impacts of Soluble Form of Basigin in Patients with Chronic Heart Failure: Prospective Large Clinical Trial with 1,147 Patients)

佐藤公雄, 大槻知広, 宮田敏, 三浦正暢, 後岡広太郎, 砂村慎一郎, 鈴木康太, 野木正道, 黒澤亮, 大村淳一, 菊地順裕, 佐藤大樹, 青木竜男, 建部俊介, 杉村宏一郎, 坂田泰彦, 下川宏明

日本循環器学会学術集会抄録集　82回　PL8-3　2018年3月
出版者・発行元： (一社)日本循環器学会
慢性血栓塞栓性肺高血圧症の新規病因蛋白TAFIの発見とその機能的意義

矢尾板信裕, 佐藤大樹, 佐藤公雄, 杉村宏一郎, 大村淳一, 福本義弘, 下川宏明

血管　40　(2)　79-86　2017年6月
出版者・発行元：日本心脈管作動物質学会
ISSN：0911-4637

詳細を見る詳細を閉じる

慢性血栓塞栓性肺高血圧症(CTEPH)患者の血栓が線溶系に抵抗性を示し、その線溶抵抗性にThrombin Activatable Fibrinolysis Inhibitor(TAFI)が関与しているか否かを検討した。右心カテーテル検査を行ったCTEPH患者27例、非肺高血圧症患者22例、肺動脈性肺高血圧症患者19例を対象とした。その結果、肺動脈性肺高血圧症患者や非肺高血圧症患者に比べて、CTEPH患者では血栓が線溶系に抵抗性を示すこと、血漿中TAFI抗原量が多く、経皮的肺動脈形成術により肺循環が改善した後も高値であったこと、血小板は活性化しやすく、血小板から放出されるTAFIの抗原量が多いこと、tPAに対する抵抗性はTAFIa阻害薬だけでなくPGE1でも改善することが示された。また、全身TAFI過剰発現マウスでは肺動脈内血栓の線溶が抑制されることがわかった。今回、CTEPH患者の血栓では全線溶能の低下を認め、TAFIがCTEPH患者の線溶系への抵抗性に関与していることが示された。
Reduced brain-derived neurotrophic factor is associated with cognitive dysfunction in patients with chronic heart failure.

Hideaki Suzuki, Yasuharu Matsumoto, Hideki Ota, Koichiro Sugimura, Jun Takahashi, Kenta Ito, Satoshi Miyata, Hiroyuki Arai, Yasuyuki Taki, Katsutoshi Furukawa, Yoshihiro Fukumoto, Hiroaki Shimokawa

Geriatrics & gerontology international　17　(5)　852-854　2017年5月

DOI： 10.1111/ggi.12959 　
Fabry病の同一遺伝子変化(R301Q)における表現型の違いについての報告

長澤将, 山本沙織, 後岡広太郎, 杉村宏一郎, 下川宏明

日本腎臓学会誌　59　(3)　257-257　2017年4月
出版者・発行元： (一社)日本腎臓学会
ISSN：0385-2385

eISSN：1884-0728
心臓リハビリテーションにおける心理、認知機能への対応心不全患者の日常生活における問題点とリハビリ介入のありかたについて

齊藤夕貴, 羽尾清貴, 長谷部雄飛, 青木竜男, 杉村宏一郎, 梶川アユミ, 明珍千恵, 黒澤桂子, 秋月三奈, 柿花隆昭, 下川宏明

日本循環器学会学術集会抄録集　81回　CS1-3　2017年3月
出版者・発行元： (一社)日本循環器学会
Rho-Kinase as a Therapeutic Target for Pulmonary Hypertension

Satoh, K., Sugimura, K., Shimokawa, H.

Diagnosis and Treatment of Pulmonary Hypertension from Bench to Bedside　2017年

DOI： 10.1007/978-981-287-840-3_5 　
慢性血栓塞栓性肺高血圧症における新規病因蛋白TAFIの機能解析

佐藤大樹, 佐藤公雄, 矢尾板信裕, 菊地順裕, 大村淳一, 黒澤亮, Al-Mamun Elias, Hai Siddique Mohammad Abdul, 杉村宏一郎, 下川宏明

血管　40　(1)　51-51　2017年1月
出版者・発行元：日本心脈管作動物質学会
ISSN：0911-4637
新規肺高血圧症治療薬セラストラマイシンの発見

黒澤亮, 佐藤公雄, 菊地順裕, 大村淳一, 佐藤大樹, 野木正道, 砂村慎一郎, 沼野和彦, Hai Siddique Mohammad Abdul, 鈴木康太, Al-Mamun Md. Elias, 建部俊介, 青木竜男, 杉村宏一郎, 下川宏明

血管　40　(1)　38-38　2017年1月
出版者・発行元：日本心脈管作動物質学会
ISSN：0911-4637
心臓移植後におけるtacrolimus徐放性製剤の使用経験

河津聡, 秋山正年, 細山勝寛, 正木直樹, 高原真吾, 坂爪公, 神田桂輔, 鈴木智之, 片平晋太郎, 吉岡一朗, 藤原英記, 安達理, 熊谷紀一郎, 川本俊輔, 三浦正暢, 青木竜男, 杉村宏一郎, 下川宏明, 秋場美紀, 齋木佳克

移植　51　(4-5)　383-390　2016年10月
出版者・発行元： (一社)日本移植学会
ISSN：0578-7947

eISSN：2188-0034

詳細を見る詳細を閉じる

カルシニューリン阻害薬として従来型経口タクロリムス製剤による免疫抑制療法を行っている心臓移植後患者10例(平均36歳)を対象とした。徐放性製剤への切り替え前(B)、徐放性製剤切り替え直後(C)、切り替え1ヵ月後(1M)、3ヵ月後(3M)、6ヵ月後(6M)でのタクロリムスの血中濃度、内服量の変化について比較検討した。全ての測定点においてタクロリムス血中濃度に有意な変化を認めなかった。Cと1M、6Mに有意な投与量の増加を認めた。切り替え6ヵ月後には、切り替え前より投与量が増加している症例は8例(80%)であった。ASTは切り替え時期によっても有意差は認めなかったが、γ-GTPは遠隔期切り替え群6MでCと比較し有意差を認めた。Bと1Mの比較において血清クレアチニン値は有意に上昇、eGFRは有意に低下した。脂質とHbA1cは、各測定時点において有意差は認めなかった。切り替えにより追加治療が必要な拒絶反応の出現は認めなかった。
LDL-Cに依存しない全く新しい新規病因蛋白とバイオマーカーの臨床応用

佐藤公雄, 野木正道, 工藤俊, 大槻知広, 杉村宏一郎, 建部俊介, 青木竜男, 矢尾板信裕, 大村淳一, 菊地順裕, 佐藤大樹, 黒澤亮, 砂村慎一郎, 神津克也, 下川宏明

日本心臓病学会学術集会抄録　64回　SS1-5　2016年9月
出版者・発行元： (一社)日本心臓病学会
日本から発信する肺高血圧診療肺高血圧症の全く新しい病因蛋白に着目した早期診断と治療薬開発の可能性

佐藤公雄, 杉村宏一郎, 建部俊介, 青木竜男, 矢尾板信裕, 大村淳一, 菊地順裕, 佐藤大樹, 黒澤亮, 野木正道, 砂村慎一郎, 神津克也, 下川宏明

日本心臓病学会学術集会抄録　64回　S15-4　2016年9月
出版者・発行元： (一社)日本心臓病学会
肺高血圧症の最新の薬物治療と今後の治療薬開発

佐藤公雄, 矢尾板信裕, 大村淳一, 菊地順裕, 佐藤大樹, 黒澤亮, 山本沙織, 青木竜男, 建部俊介, 杉村宏一郎, 下川宏明

日本心臓病学会学術集会抄録　64回　SP3-1　2016年9月
出版者・発行元： (一社)日本心臓病学会
Bartonella quintana感染に伴う感染性心内膜炎の一例

矢尾板信裕, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 鈴木秀明, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　64回　P-243　2016年9月
出版者・発行元： (一社)日本心臓病学会
Hippocampal Blood Flow Abnormality Associated With Depressive Symptoms and Cognitive Impairment in Patients With Chronic Heart Failure.

Hideaki Suzuki, Yasuharu Matsumoto, Hideki Ota, Koichiro Sugimura, Jun Takahashi, Kenta Ito, Satoshi Miyata, Katsutoshi Furukawa, Hiroyuki Arai, Yoshihiro Fukumoto, Yasuyuki Taki, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(8)　1773-80　2016年7月25日

DOI： 10.1253/circj.CJ-16-0367 　

詳細を見る詳細を閉じる

BACKGROUND: Depressive symptoms and memory impairment are prevalent in patients with chronic heart failure (CHF). Although the mechanisms remain to be elucidated, the hippocampus (an important brain area for emotion and memory) may be a possible neural substrate for these symptoms. METHODS AND RESULTS: We prospectively enrolled 40 Stage C patients, who had past or current CHF symptoms, and as controls 40 Stage B patients, who had structural heart disease but had never had CHF symptoms, in Brain Assessment and Investigation in Heart Failure Trial (B-HeFT) (UMIN000008584). As the primary index, we measured cerebral blood flow (CBF) in the 4 anterior-posterior segments of the hippocampus, using brain MRI analysis. Depressive symptoms, immediate memory (IM) and delayed memory (DM) were assessed using Geriatric Depression Scale (GDS), and Wechsler Memory Scale-revised (WMS-R), respectively. Hippocampus CBF in the most posterior segment was significantly lower in Stage C than in Stage B group (P=0.029 adjusted for Holm's method). Multiple regression analysis identified significant association between hippocampus CBF and GDS or DM score in Stage C group (all P<0.05). GDS score was significantly higher, and IM and DM scores were lower in Stage C patients with hippocampus CBF below the median than those with hippocampus CBF above the median (all P<0.05). CONCLUSIONS: Hippocampus abnormalities are associated with depressive symptoms and cognitive impairment in CHF patients. (Circ J 2016; 80: 1773-1780).
Overview of the 80(th) Annual Scientific Meeting of the Japanese Circulation Society - The Past, Present and Future of Cardiovascular Medicine in Japan - - The 5(th) Anniversary of the Great East Japan Earthquake.

Jun Takahashi, Kimio Satoh, Koji Fukuda, Koichiro Sugimura, Yasuharu Matsumoto, Makoto Nakano, Ryuji Tsuburaya, Tatsuo Aoki, Kiyotaka Hao, Kensuke Nishimiya, Kenta Ito, Yasuhiko Sakata, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(8)　1689-94　2016年7月25日

DOI： 10.1253/circj.CJ-16-0644 　

詳細を見る詳細を閉じる

The 80(th)Annual Scientific Meeting of the Japanese Circulation Society was held in Sendai, Japan, on March 18-20, 2016, which coincided with the 5(th)anniversary of the Great East Japan Earthquake that hit the Tohoku area on March 11, 2011. Thus, the main themes for this meeting were "The Past, Present and Future of Cardiovascular Medicine in Japan" and "The 5(th)Anniversary of the Great East Japan Earthquake". Despite the provincial location, approximately 15,000 people attended during the 3-day meeting, and there were in-depth discussions in each of the various sessions on these themes. Especially, to our great pleasure, the Japanese Royals, Emperor Akihito and Empress Michiko, kindly visited the panel exhibition of the Great East Japan Earthquake and spoke words of appreciation to us. The meeting successfully completed and we sincerely appreciate the great cooperation and support from all affiliates. (Circ J 2016; 80: 1689-1694).
Protective Roles of Endothelial AMP-Activated Protein Kinase Against Hypoxia-Induced Pulmonary Hypertension in Mice. 国際誌

Junichi Omura, Kimio Satoh, Nobuhiro Kikuchi, Taijyu Satoh, Ryo Kurosawa, Masamichi Nogi, Tomohiro Otsuki, Katsuya Kozu, Kazuhiko Numano, Kota Suzuki, Shinichiro Sunamura, Shunsuke Tatebe, Tatsuo Aoki, Koichiro Sugimura, Satoshi Miyata, Yasushi Hoshikawa, Yoshinori Okada, Hiroaki Shimokawa

Circulation research　119　(2)　197-209　2016年7月8日

DOI： 10.1161/CIRCRESAHA.115.308178 　

詳細を見る詳細を閉じる

RATIONALE: Endothelial AMP-activated protein kinase (AMPK) plays an important role for vascular homeostasis, and its role is impaired by vascular inflammation. However, the role of endothelial AMPK in the pathogenesis of pulmonary arterial hypertension (PAH) remains to be elucidated. OBJECTIVE: To determine the role of endothelial AMPK in the development of PAH. METHODS AND RESULTS: Immunostaining showed that endothelial AMPK is downregulated in the pulmonary arteries of patients with PAH and hypoxia mouse model of pulmonary hypertension (PH). To elucidate the role of endothelial AMPK in PH, we used endothelial-specific AMPK-knockout mice (eAMPK(-/-)), which were exposed to hypoxia. Under normoxic condition, eAMPK(-/-) mice showed the normal morphology of pulmonary arteries compared with littermate controls (eAMPK(flox/flox)). In contrast, development of hypoxia-induced PH was accelerated in eAMPK(-/-) mice compared with controls. Furthermore, the exacerbation of PH in eAMPK(-/-) mice was accompanied by reduced endothelial function, upregulation of growth factors, and increased proliferation of pulmonary artery smooth muscle cells. Importantly, conditioned medium from endothelial cells promoted pulmonary artery smooth muscle cell proliferation, which was further enhanced by the treatment with AMPK inhibitor. Serum levels of inflammatory cytokines, including tumor necrosis factor-α and interferon-γ were significantly increased in patients with PAH compared with healthy controls. Consistently, endothelial AMPK and cell proliferation were significantly reduced by the treatment with serum from patients with PAH compared with controls. Importantly, long-term treatment with metformin, an AMPK activator, significantly attenuated hypoxia-induced PH in mice. CONCLUSIONS: These results indicate that endothelial AMPK is a novel therapeutic target for the treatment of PAH.
経皮的肺動脈形成術治療が施行された慢性血栓塞栓性肺高血圧患者における心エコーによる右室機能評価法の検討

藤原淳子, 船水康陽, 三木俊, 建部俊介, 青木竜男, 大田英揮, 杉村宏一郎, 坂田泰彦, 西條芳文, 下川宏明

超音波医学　43　(4)　603-603　2016年7月
出版者・発行元： (公社)日本超音波医学会
ISSN：1346-1176

eISSN：1881-9311
外科的血栓摘除術を施行した肺塞栓の1例

青木竜男, 杉村宏一郎, 増田信也, 秋山正年, 川本俊輔, 齋木佳克, 下川宏明

超音波医学　43　(4)　603-603　2016年7月
出版者・発行元： (公社)日本超音波医学会
ISSN：1346-1176

eISSN：1881-9311
心臓移植後に液性拒絶反応を呈した1例

青木竜男, 杉村宏一郎, 河津聡, 秋山正年, 川本俊輔, 齋木佳克, 下川宏明

超音波医学　43　(4)　602-602　2016年7月
出版者・発行元： (公社)日本超音波医学会
ISSN：1346-1176

eISSN：1881-9311
中性脂肪蓄積症ミオパチー/中性脂肪蓄積心筋血管症に対するリハビリテーションによりQOLの向上を認めた症例査読有り

高橋珠緒, 阿部将之, 森信芳, 伊藤修, 杉村宏一郎, 上月正博

The Japanese Journal of Rehabilitation Medicine　53　(6)　495-502　2016年6月
出版者・発行元： (公社)日本リハビリテーション医学会
ISSN：1881-3526

eISSN：1881-8560

詳細を見る詳細を閉じる

中性脂肪蓄積症ミオパチー(NLSDM)は、骨格筋に中性脂肪が蓄積することで、四肢に進行性の筋力低下や筋萎縮をきたす。中性脂肪蓄積心筋血管症(TGCV)は、心筋細胞や冠動脈血管平滑筋に中性脂肪が蓄積することで、重度の心不全、不整脈、虚血性心疾患などを呈する。今回、NLSDM/TGCV患者にリハビリテーションを施行した本邦初の症例を経験したので、文献的考察を加えて報告した。症例は62歳男性で、ミオパチーに伴う筋力・持久力低下の治療および慢性心不全のコントロールを目的として当科に入院となった。心不全の加療と、中鎖脂肪食による食事療法に併行して、心肺運動負荷試験をもとにした有酸素運動の指導や、エネルギー不全に配慮した筋力強化訓練を実施した。さらに、心不全症状の増悪予防を目的とした患者教育を行い、良好な結果が得られた。
心臓移植後早期に拒絶反応を呈した1症例

遠藤洋一, 青木竜男, 藤原淳子, 船水康陽, 三木俊, 西條芳文, 杉村宏一郎, 秋山正年, 川本俊輔, 齋木佳克, 下川宏明

超音波検査技術　41　(Suppl.)　S151-S151　2016年6月
出版者・発行元： (一社)日本超音波検査学会
DOI： 10.11272/jssabst.41.0_S151_2 　

ISSN：1881-4506

eISSN：1881-4514
Respiratory Therapy in Chronic Heart Failure Patients Complicated With Sleep-Disordered Breathing: Potential Study Bias - Reply.

Koichiro Sugimura, Hiroyuki Satake, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　80　(6)　1487-1487　2016年5月25日

DOI： 10.1253/circj.CJ-16-0292 　
CTEPHにおける新規病因蛋白TAFIの基礎的・臨床的機能解析

佐藤大樹, 佐藤公雄, 矢尾板信裕, 菊地順裕, 大村淳一, 黒澤亮, 杉村宏一郎, 中村一文, 伊藤浩, 下川宏明

呼吸と循環　64　(5)　S19-S20　2016年5月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
肺動脈血管内皮AMPKは肺高血圧症の進行を抑制する

大村淳一, 佐藤公雄, 菊地順裕, 佐藤大樹, 黒澤亮, 神津克也, 沼野和彦, 青木竜男, 建部俊介, 杉村宏一郎, 下川宏明

呼吸と循環　64　(5)　S23-S23　2016年5月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
PH患者の血漿中サイクロフィリンAと炎症性サイトカインの相関

沼野和彦, 佐藤公雄, 大槻知広, 菊地順裕, 大村淳一, 佐藤大樹, 黒澤亮, 青木竜男, 建部俊介, 杉村宏一郎, 下川宏明

呼吸と循環　64　(5)　S23-S23　2016年5月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
Eisenmenger Syndromeに肺移植と心内修復術を施行した一例

伊藤記彦, 青木竜男, 船水康陽, 藤原淳子, 三木俊, 西條芳文, 建部俊介, 杉村宏一郎, 岡田克典, 下川宏明

超音波医学　43　(Suppl.)　S585-S585　2016年4月
出版者・発行元： (公社)日本超音波医学会
ISSN：1346-1176

eISSN：1881-9311
Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. 国際誌

Kota Suzuki, Kimio Satoh, Shohei Ikeda, Shinichiro Sunamura, Tomohiro Otsuki, Taijyu Satoh, Nobuhiro Kikuchi, Junichi Omura, Ryo Kurosawa, Masamichi Nogi, Kazuhiko Numano, Koichiro Sugimura, Tatsuo Aoki, Shunsuke Tatebe, Satoshi Miyata, Rupak Mukherjee, Francis G Spinale, Kenji Kadomatsu, Hiroaki Shimokawa

Arteriosclerosis, thrombosis, and vascular biology　36　(4)　636-46　2016年4月

DOI： 10.1161/ATVBAHA.115.306686 　

詳細を見る詳細を閉じる

OBJECTIVE: Basigin (Bsg) is a transmembrane glycoprotein that activates matrix metalloproteinases and promotes inflammation. However, the role of Bsg in the pathogenesis of cardiac hypertrophy and failure remains to be elucidated. We examined the role of Bsg in cardiac hypertrophy and failure in mice and humans. APPROACH AND RESULTS: We performed transverse aortic constriction in Bsg(+/-) and in wild-type mice. Bsg(+/-) mice showed significantly less heart and lung weight and cardiac interstitial fibrosis compared with littermate controls after transverse aortic constriction. Both matrix metalloproteinase activities and oxidative stress in loaded left ventricle were significantly less in Bsg(+/-) mice compared with controls. Echocardiography showed that Bsg(+/-) mice showed less hypertrophy, less left ventricular dilatation, and preserved left ventricular fractional shortening compared with littermate controls after transverse aortic constriction. Consistently, Bsg(+/-) mice showed a significantly improved long-term survival after transverse aortic constriction compared with Bsg(+/+) mice, regardless of the source of bone marrow (Bsg(+/+) or Bsg(+/-)). Conversely, cardiac-specific Bsg-overexpressing mice showed significantly poor survival compared with littermate controls. Next, we isolated cardiac fibroblasts and examined their responses to angiotensin II or mechanical stretch. Both stimuli significantly increased Bsg expression, cytokines/chemokines secretion, and extracellular signal-regulated kinase/Akt/JNK activities in Bsg(+/+) cardiac fibroblasts, all of which were significantly less in Bsg(+/-) cardiac fibroblasts. Consistently, extracellular and intracellular Bsg significantly promoted cardiac fibroblast proliferation. Finally, serum levels of Bsg were significantly elevated in patients with heart failure and predicted poor prognosis. CONCLUSIONS: These results indicate the crucial roles of intracellular and extracellular Bsg in the pathogenesis of cardiac hypertrophy, fibrosis, and failure in mice and humans.
肺高血圧の基礎から臨床まで

佐藤公雄, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 矢尾板信裕, 鈴木秀明, 山本沙織, 菊地順裕, 大村淳一, 佐藤大樹, 黒澤亮, 神津克也, 下川宏明

日本小児肺循環研究会プログラム・抄録集　22回　37-37　2016年2月
出版者・発行元：日本小児肺循環研究会
震災と心血管病東日本大震災に関する検討から

青木竜男, 杉村宏一郎, 中野誠, 羽尾清貴, 二瓶太郎, 小野瀬剛生, 高橋潤, 福田浩二, 坂田泰彦, 下川宏明

Japanese Journal of Disaster Medicine　20　(3)　444-444　2016年2月
出版者・発行元： (一社)日本災害医学会
ISSN：2189-4035
化合物スクリーニングによる新規肺高血圧症治療薬の開発査読有り

黒澤亮, 佐藤公雄, 菊地順裕, 大村淳一, 佐藤大樹, 野木正道, 沼野和彦, SIDDIQUE Mohammad, AL-MAMUN Elias, 杉村宏一郎, 下川宏明

呼吸と循環　64　(5)　S24-S24　2016年
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
統合失調症に伴う抗リン脂質抗体症候群で発症した肺塞栓症の一例査読有り

鈴木秀明, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 佐藤公雄, 久志本成樹, 下川宏明

呼吸と循環　64　(5)　S51-S51　2016年
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
慢性血栓塞栓性肺高血圧症の病因におけるTAFIの関与査読有り

矢尾板信裕, 佐藤公雄, 佐藤大樹, 杉村宏一郎, 青木竜男, 三浦正暢, 建部俊介, 福本義弘, 下川宏明

呼吸と循環　64　(5)　S29-S30　2016年
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
血漿中サイクロフィリンAはPTPA治療の有効性を反映する査読有り

佐藤公雄, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 矢尾板信裕, 鈴木秀明, 山本沙織, 神津克也, 大槻知広, 下川宏明

呼吸と循環　64　(5)　S32-S32　2016年
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
肺動脈血管内皮AMPKは肺高血圧症の進行を抑制する

大村淳一, 佐藤公雄, 菊地順裕, 佐藤大樹, 黒澤亮, 神津克也, 青木竜男, 建部俊介, 杉村宏一郎, 下川宏明

血管　39　(1)　45-45　2016年1月
出版者・発行元：日本心脈管作動物質学会
ISSN：0911-4637
高齢者成人先天性心疾患患者の心血管病リスクと予後査読有り

建部俊介, 杉村宏一郎, 青木竜男, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 佐藤公雄, 坂田泰彦, 下川宏明

日本成人先天性心疾患学会雑誌(Web)　5　(1)　112-112　2016年
出版者・発行元：日本成人先天性心疾患学会
Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. 国際誌

Masaaki Yoshida, Ryu Watanabe, Tomonori Ishii, Tomoaki Machiyama, Kanae Akita, Yoko Fujita, Yuko Shirota, Koichiro Sugimura, Hiroshi Fujii, Hiroaki Shimokawa, Hideo Harigae

International journal of rheumatic diseases　19　(1)　87-94　2016年1月

DOI： 10.1111/1756-185X.12777 　

詳細を見る詳細を閉じる

AIM: Although Takayasu arteritis (TAK) and giant cell arteritis (GCA) have been considered as distinct disease entities, similarities of these diseases have been recently reported. However, little data is available regarding this issue in Japanese patients with TAK and GCA. In addition, the classification criteria for TAK established in 1990 by the American College of Rheumatology (ACR) have been criticized due to the age restriction for disease onset (≤ 40 years). Thus, we aimed to compare the clinical characteristics of Japanese patients with TAK and those with GCA and to clarify whether clinical differences existed between patients with early-onset (≤ 40 years) and late-onset (> 40 years) TAK. METHODS: We enrolled 86 patients with TAK and nine with GCA who visited our department from 1990 to 2014. The diagnoses of TAK and GCA were based on the criteria of the Japanese Circulation Society and the ACR, respectively. RESULTS: Mean ages at onset for TAK and GCA were 36.4 and 71.0 years, respectively. Patients with TAK had significantly higher incidences of aortic regurgitation and carotid and subclavian arterial involvement, lower frequencies of polymyalgia rheumatica, and better prognoses than those with GCA. In contrast, the clinical characteristics, distribution of arterial lesions, treatments administered, and prognoses of patients with early- and late-onset TAK were comparable. CONCLUSIONS: These results suggested that TAK and GCA differed substantially, and that the age restriction (≤ 40 years) may not be necessary for the diagnosis of TAK.
二管球CTによる肺灌流画像を用いた慢性血栓塞栓性肺高血圧症の重症度評価

高木英誠, 大田英揮, 佐藤遙, 三浦正暢, 青木竜男, 建部俊介, 杉村宏一郎, 冨永循哉, 下川宏明, 高瀬圭

日独医報　60　(2)　238-238　2015年11月
出版者・発行元：バイエル薬品(株)
ISSN：0912-0351
動脈ガス脳塞栓症に合併したたこつぼ心筋症の1例ヨード造影剤アレルギー症例における心臓MRIの有用性

大邉寛幸, 鈴木秀明, 大田英揮, 青木竜男, 杉村宏一郎, 松本泰治, 久志本成樹, 下川宏明

日本心臓病学会学術集会抄録　63回　292-292　2015年9月
出版者・発行元： (一社)日本心臓病学会
慢性血栓塞栓性肺高血圧症の病因におけるTAFIの役割とその機能的意義

矢尾板信裕, 佐藤公雄, 杉村宏一郎, 青木竜男, 三浦正暢, 建部俊介, 下川宏明

日本心臓病学会学術集会抄録　63回　785-785　2015年9月
出版者・発行元： (一社)日本心臓病学会
Burn-associated delayed dilated cardiomyopathy evaluated by cardiac PET and SPECT: Report of a case.

Reimu Fukui, Hideaki Suzuki, Noriko Miyagawa, Tomoyuki Endo, Tomohiro Kaneta, Koichiro Sugimura, Yasuharu Matsumoto, Shoki Takahashi, Yutaka Kagaya, Shigeki Kushimoto, Hiroaki Shimokawa

Journal of cardiology cases　10　(5)　180-183　2014年11月

DOI： 10.1016/j.jccase.2014.07.005 　

詳細を見る詳細を閉じる

Dilated cardiomyopathy is a delayed-onset and rarely reported cardiac complication of burn injury although the mechanism remains unclear. We thus report a case of dilated cardiomyopathy following severe burn injury, in which technetium 99m sestamibi single-photon emission computed tomography (SPECT), iodine-123 beta-methyl-iodophenylpentadecanoic acid SPECT and 18F-fluorodeoxyglucose positron emission tomography (PET) were performed to evaluate the pathophysiologic condition in combination with cardiac catheterization and myocardial biopsy. The cardiac PET and SPECT images showed reduced myocardial blood flow, decreased fatty acid metabolism, and increased glucose utilization in the left ventricular lateral wall in spite of normal coronary angiography, no significant cardiac fibrosis, and inflammatory cell infiltration, which suggests that myocardial ischemia due to microcirculatory disturbance in hypermetabolic state associated with burn injury might be a causative mechanism of dilated cardiomyopathy in this case. A beta blocker, bisoprolol, was successfully introduced in this patient in combination with oral inotropic agents, pimobendan and digitalis after the prolonged use of intravenous dobutamine infusion, which might have been beneficial for this patient with burn-associated dilated cardiomyopathy not only to reduce regional myocardial ischemia but also to attenuate hypermetabolic state after severe burn injury. <Learning objective: Dilated cardiomyopathy complicated with burn injury has been reported to cause a sudden attack of dyspnea and death. This case report suggests that burn-associated dilated cardiomyopathy may be caused by relative myocardial ischemia due to microvascular disturbance in hypermetabolic state associated with burn injuries and can be treated effectively with beta blockers with or without oral inotropic agents.>.
肺高血圧を診る 4D flow MRI(3D phase contrast MRI)における肺動脈内vortex flowと肺高血圧症との関連

大田英揮, 杉村宏一郎, 後岡広太郎, 建部俊介, 山本沙織, 三浦正暢, 下川宏明

日本心臓病学会学術集会抄録　62回　VW4-4　2014年9月
出版者・発行元： (一社)日本心臓病学会
電子カルテ時代のクリニカルパス電子カルテ導入移行期における問題点

圓谷隆治, 中山雅晴, 太田有佳, 後岡広太郎, 中野誠, 杉村宏一郎, 高橋潤, 福田浩二, 下川宏明

日本心臓病学会学術集会抄録　62回　MS1-6　2014年9月
出版者・発行元： (一社)日本心臓病学会
心臓移植登録申請適応外と判断した不可逆的肝線維症を合併したファロー四徴症心内修復術後の1例

建部俊介, 杉村宏一郎, 後岡広太郎, 青木竜男, 三浦正暢, 山本沙織, 矢尾板信裕, 佐藤遙, 下川宏明

日本心臓病学会学術集会抄録　62回　P-288　2014年9月
出版者・発行元： (一社)日本心臓病学会
A novel mutation in PNPLA2 causes neutral lipid storage disease with myopathy and triglyceride deposit cardiomyovasculopathy: a case report and literature review. 国際誌

Kimihiko Kaneko, Hiroshi Kuroda, Rumiko Izumi, Maki Tateyama, Masaaki Kato, Koichiro Sugimura, Yasuhiko Sakata, Yoshihiko Ikeda, Ken-Ichi Hirano, Masashi Aoki

Neuromuscular disorders : NMD　24　(7)　634-41　2014年7月

DOI： 10.1016/j.nmd.2014.04.001 　

詳細を見る詳細を閉じる

Mutations in PNPLA2 cause neutral lipid storage disease with myopathy (NLSDM) or triglyceride deposit cardiomyovasculopathy (TGCV). We report a 59-year-old patient with NLSDM/TGCV presenting marked asymmetric skeletal myopathy and cardiomyovasculopathy. Skeletal muscle and endomyocardial biopsies showed cytoplasmic vacuoles containing neutral lipid. Gene analysis revealed a novel homozygous mutation (c.576delC) in PNPLA2. We reviewed 37 genetically-proven NLSDM/TGCV cases; median age was 30 years; distribution of myopathy was proximal (69%) and distal predominant (16%); asymmetric myopathy (right>left) was reported in 41% of the patients. Frequently-affected muscles were posterior compartment of leg (75%), shoulder girdle to upper arm (50%), and paraspinal (33%). Skeletal muscle biopsies showed lipid accumulation in 100% and rimmed vacuoles in 22%. Frequent comorbidities were cardiomyopathy (44%), hyperlipidemia (23%), diabetes mellitus (24%), and pancreatitis (14%). PNPLA2 mutations concentrated in Exon 4-7 without apparent genotype-phenotype correlations. To know the characteristic features is essential for the early diagnosis of NLSDM/TGCV.
不可逆的な肝線維症の進行により心臓移植登録申請適応外と判断したファロー四徴症心内修復術後の1例

建部俊介, 杉村宏一郎, 後岡広太郎, 三浦正暢, 山本沙織, 安達理, 齋木佳克, 下川宏明

日本小児循環器学会雑誌　30　(Supplement)　s323-s323　2014年
出版者・発行元： (NPO)日本小児循環器学会
ISSN：0911-1794

eISSN：2187-2988
Evidence for brain activation in patients with takotsubo cardiomyopathy.

Hideaki Suzuki, Yasuharu Matsumoto, Tomohiro Kaneta, Koichiro Sugimura, Jun Takahashi, Yoshihiro Fukumoto, Shoki Takahashi, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　78　(1)　256-8　2014年

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: It remains to be elucidated whether brain activity is altered in takotsubo cardiomyopathy. METHODS AND RESULTS: We measured cerebral blood flow (CBF) in 3 consecutive patients with takotsubo cardiomyopathy using (99m)Tc ethyl cysteinate dimmer single photon-emission computed tomography (SPECT) in the acute and chronic phases. In all patients, CBF was significantly increased in the hippocampus, brainstem and basal ganglia and significantly decreased in the prefrontal cortex in the acute phase, which changes subsided in the chronic phase with full recovery of cardiac wall motion. CONCLUSIONS: These results provide the first direct evidence for brain activation in takotsubo cardiomyopathy.
Successful use of intensive immunosuppressive therapy for treating simultaneously occurring cerebral lesions and pulmonary arterial hypertension in a patient with systemic lupus erythematosus.

Ryu Watanabe, Hiroshi Fujii, Tsuyoshi Shirai, Shinichiro Saito, Akira Hatakeyama, Koichiro Sugimura, Yoshihiro Fukumoto, Tomonori Ishii, Hideo Harigae

Internal medicine (Tokyo, Japan)　53　(6)　627-31　2014年

eISSN：1349-7235

詳細を見る詳細を閉じる

A 59-year-old woman who had been diagnosed with systemic lupus erythematosus (SLE) was admitted to our hospital due to paralysis in all of her limbs. The patient presented with dysarthria, cerebellar ataxia and hypoxia. Magnetic resonance imaging (MRI) revealed vasogenic edema in the brain stem and the cerebellum. She was diagnosed with neuropsychiatric lupus syndrome (NPSLE) and pulmonary arterial hypertension (PAH), and was successfully treated using immunosuppressive therapy. To our knowledge, this is the first reported case of simultaneously developing NPSLE and PAH.
"Porcelain heart" a case of acute heart failure with massive myocardial calcification complicated with primary hyperparathyroidism.

Hidenori Takahashi, Tatsuo Aoki, Yoshihiro Fukumoto, Koichiro Sugimura, Kotaro Nochioka, Yutaka Miura, Shunsuke Tatebe, Saori Yamamoto, Kiyotaka Shibuya, Hiroaki Shimokawa

Journal of cardiology cases　8　(6)　183-186　2013年12月

DOI： 10.1016/j.jccase.2013.08.006 　

詳細を見る詳細を閉じる

A 47-year-old Japanese woman was transported to our hospital due to acute heart failure (AHF). She had been diagnosed with primary hyperparathyroidism (pHPT) and undergone parathyroidectomy 3 months previously. Chest X-ray showed marked cardiomegaly and severe pulmonary congestion, and transthoracic echocardiography indicated both left ventricular (LV) systolic and diastolic dysfunction, complicated with extensive massive myocardial calcification and no LV hypertrophy. Computed tomography also showed massive myocardial calcification in the posterior wall of the LV and the interventricular septum. After treatment with furosemide, olprinone, and carperitide under Swan-Ganz monitoring, LV ejection fraction was almost normalized. However, cardiac catheterization in the chronic phase indicated that LV diastolic dysfunction still existed, which might be affected by myocardial calcification. We followed this patient using spironolactone (25 mg/day), perindopril (8 mg/day), and bisoprolol (1.25 mg/day), with no further episode of heart failure for at least 6 months. Here, we report a rare case of AHF complicated with massive myocardial calcification possibly caused by primary hyperparathyroidism. <Learning objective: This is the first case report of acute heart failure due to left ventricular systolic and diastolic dysfunction, complicated with massive myocardial calcification, "porcelain heart", possibly caused by primary hyperparathyroidism.>.
右室FDG取込み亢進は肺高血圧患者の長期予後を予測する

建部俊介, 福本義弘, 杉村宏一郎, 若山美奈子, 後岡広太郎, 三浦正暢, 山本沙織, 加賀谷豊, 下川宏明

日本心臓病学会誌　8　(Suppl.I)　388-388　2013年9月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
光干渉断層法三次元構築像により肺動脈病変を評価し得た慢性血栓塞栓性肺高血圧症の一例

杉村宏一郎, 福本義弘, 後岡広太郎, 建部俊介, 山本沙織, 三浦正暢, 下川宏明

日本心臓病学会誌　8　(Suppl.I)　413-413　2013年9月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
ダサチニブ治療中に肺動脈性肺高血圧症を合併した急性リンパ性白血病の1例

大槻知広, 建部俊介, 福本義弘, 杉村宏一郎, 後岡広太郎, 三浦正暢, 山本沙織, 下川宏明

日本心臓病学会誌　8　(Suppl.I)　726-726　2013年9月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
右室FDG取込みの亢進は肺高血圧患者の予後不良因子である

建部俊介, 福本義弘, 杉村宏一郎, 後岡広太郎, 三浦正暢, 宮道沙織, 若山美奈子, 加賀谷豊, 下川宏明

核医学　50　(3)　S204-S204　2013年9月
出版者・発行元： (一社)日本核医学会
ISSN：0022-7854

eISSN：2189-9932
肺高血圧の治療の最前線薬物治療と侵襲治療重症慢性血栓塞栓性肺高血圧症に対する治療戦略査読有り

後岡広太郎, 杉村, 宏一郎, 福本, 義弘, 建部, 俊介, 山本, 沙織, 三浦, 正暢, 佐藤, 公雄, 下川宏明

脈管学　53　(Suppl.)　S70-S71　2013年9月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
肺動脈リモデリングは肺高血圧発症前から出現する光干渉断層法を用いた検討査読有り

矢尾板, 信裕, 戴, 哲皓, 福本, 義弘, 建部, 俊介, 杉村, 宏一郎, 後岡, 広太郎, 山本, 沙織, 三浦, 正暢, 佐藤, 公雄, 下川宏明

脈管学　53　(Suppl.)　S186-S187　2013年9月
出版者・発行元： (一社)日本脈管学会
ISSN：0387-1126

eISSN：1880-8840
当院における成人重症心不全診療の変遷と予後

後岡広太郎, 福本義弘, 杉村宏一郎, 三浦裕, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 佐藤公雄, 下川宏明, 秋山正年, 川本俊輔, 齋木佳克, 秋場美紀

呼吸と循環　61　(4)　S11-S12　2013年4月
出版者・発行元： (株)医学書院
ISSN：0452-3458

eISSN：1882-1200
慢性心不全に合併する肺高血圧症の性差と予後

建部俊介, 福本義弘, 杉村宏一郎, 三浦裕, 後岡広太郎, 青木竜男, 三浦正暢, 下川宏明

日本内科学会雑誌　102　(Suppl.)　207-207　2013年2月
出版者・発行元： (一社)日本内科学会
ISSN：0021-5384

eISSN：1883-2083
Collaborative management for PAH Eisenmenger症候群の肺血管拡張療法と肺移植適応の検討

建部俊介, 福本義弘, 杉村宏一郎, 三浦裕, 後岡広太郎, 青木竜男, 三浦正暢, 下川宏明

日本成人先天性心疾患学会雑誌　2　(1)　41-41　2013年1月
出版者・発行元：日本成人先天性心疾患学会
当院における成人重症心不全診療の変遷と予後

後岡広太郎, 福本義弘, 杉村宏一郎, 三浦裕, 青木竜男, 建部俊介, 山本沙織, 佐藤公雄, 下川宏明, 秋山正年, 川本俊輔, 齋木佳克, 秋場美紀

移植　48　(1)　68-68　2013年
出版者・発行元： (一社)日本移植学会
ISSN：0578-7947

eISSN：2188-0034
院外心停止から蘇生された機能的単心室血行動態を有するEisenmenger症候群の1例

建部俊介, 福本義弘, 杉村宏一郎, 三浦裕, 後岡広太郎, 三浦正暢, 安達理, 齋木佳克, 下川宏明

日本小児循環器学会雑誌　29　(Supplement)　s334-s334　2013年
出版者・発行元： (NPO)日本小児循環器学会
ISSN：0911-1794

eISSN：2187-2988
Rho-kinase activation in patients with heart failure.

Zhulanqiqige Do e, Yoshihiro Fukumoto, Koichiro Sugimura, Yutaka Miura, Shunsuke Tatebe, Saori Yamamoto, Tatsuo Aoki, Kotaro Nochioka, Suvd Nergui, Nobuhiro Yaoita, Kimio Satoh, Masateru Kondo, Makoto Nakano, Yuji Wakayama, Koji Fukuda, Taro Nihei, Yoku Kikuchi, Jun Takahashi, Hiroaki Shimokawa

Circulation journal : official journal of the Japanese Circulation Society　77　(10)　2542-50　2013年

eISSN：1347-4820

詳細を見る詳細を閉じる

BACKGROUND: Heart failure (HF) is a complex clinical syndrome, resulting from structural and/or functional cardiac disease. The aim of this study was to determine whether the activity of Rho-kinase, which has been identified as an important therapeutic target of cardiovascular disease, is enhanced in HF patients. METHODS AND RESULTS: Total and phosphorylated forms of myosin binding subunit (t-MBS and p-MBS), a substrate of Rho-kinase, were measured on western blotting in circulating leukocytes, and the p-MBS/t-MBS ratio was defined as an index of systemic Rho-kinase activity. First, during the time-course of acute HF (n=12), Rho-kinase activity was significantly elevated in the acute phase compared to the chronic phase (1.19 ± 0.06 vs. 0.97 ± 0.04, P<0.05). Next, Rho-kinase activity was examined in 30 controls and 130 chronic HF patients (cardiomyopathy, n=57; valvular heart disease, n=35; ischemic heart disease [IHD], n=33; and others, n=5). As compared with the controls, Rho-kinase activity was significantly elevated in the total HF group (1.14 ± 0.02 vs. 0.77 ± 0.05, P<0.0001) and in each underlying heart disease (P<0.05 each). Importantly, in the high-risk non-IHD group, Rho-kinase activity was significantly associated with plasma brain nutriuretic peptide level. Finally, p-MBS was expressed in myocardial biopsy samples (immunohistochemistry) in chronic HF patients (n=36), independent of Rho-kinase activity in leukocytes. CONCLUSIONS: Rho-kinase is activated in HF patients, suggesting that it could be a new therapeutic target of the disorder.
血漿サイクロフィリンAの冠動脈疾患診断における有用性

佐藤公雄, 福本義弘, 杉村宏一郎, 三浦裕, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 高木祐介, 圓谷隆治, 伊藤愛剛, 松本泰治, 中山雅晴, 高橋潤, 伊藤健太, 下川宏明

日本心臓病学会誌　7　(Suppl.I)　358-358　2012年8月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
A Case of Angiosarcoma Arising in Trunk of the Right Pulmonary Artery Clinically Simulating Pulmonary Thromboembolism. 国際誌

Yasuhiro Nakamura, Toru Shimizu, Yoshihiro Fukumoto, Koichiro Sugimura, Shigemi Ito, Fumiyoshi Fujishima, Mariko Oikawa, Mika Watanabe, Hiroaki Shimokawa, Hironobu Sasano

World journal of oncology　3　(3)　119-123　2012年6月

DOI： 10.4021/wjon467w 　

詳細を見る詳細を閉じる

Angiosarcoma arising in the pulmonary artery is extremely rare. We herein report a case of angiosarcoma arising in the pulmonary artery trunk of 71 year-old woman. This case was clinically diagnosed as pulmonary thromboembolism but angiosarcoma of the pulmonary artery should be considered as the differential diagnosis of unusual clinical manifestations of pulmonary thromboembolism because of the extremely poor prognosis of the lesion.
成人先天性心疾患診療体制の構築東北地方の成人先天性心疾患患者における慢性心不全の臨床的特徴(Clinical Characteristics of Chronic Heart Failure with Adult Congenital Heart Disease in Tohoku Districts)

建部俊介, 福本義弘, 杉村宏一郎, 佐藤公雄, 三浦裕, 後岡広太郎, 青木竜男, 山本沙織, 下川宏明

日本成人先天性心疾患学会雑誌　1　(1)　61-61　2012年1月
出版者・発行元：日本成人先天性心疾患学会
Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. 国際誌

Kimio Satoh, Yoshihiro Fukumoto, Makoto Nakano, Koichiro Sugimura, Jun Nawata, Jun Demachi, Akihiko Karibe, Yutaka Kagaya, Naoto Ishii, Kazuo Sugamura, Hiroaki Shimokawa

Cardiovascular research　81　(1)　226-34　2009年1月1日

DOI： 10.1093/cvr/cvn244 　

詳細を見る詳細を閉じる

AIMS: Mobilization of stem cells/progenitors is regulated by the interaction between stromal cell-derived factor-1 (SDF-1) and its ligand, CXC chemokine receptor 4 (CXCR4). Statins have been suggested to ameliorate pulmonary arterial hypertension (PAH); however, the mechanisms involved, especially their effects on progenitors, are largely unknown. Therefore, we examined whether pravastatin ameliorates hypoxia-induced PAH in mice, and if so, which type of progenitors and what mechanism(s) are involved. METHODS AND RESULTS: Chronic hypoxia (10% O(2) for 5 weeks) increased the plasma levels of SDF-1 and mobilization of CXCR4(+)/vascular endothelial growth factor receptor (VEGFR)2(+)/c-kit(+) cells from bone marrow (BM) to pulmonary artery adventitia in Balb/c mice in vivo, both of which were significantly suppressed by simultaneous oral treatment with pravastatin (2 mg/kg/day). Furthermore, in vitro experiments demonstrated that hypoxia enhances differentiation of VEGFR2(+)/c-kit(+) cells into alpha-smooth muscle actin(+) cells. Importantly, pravastatin ameliorated hypoxia-induced PAH associated with a decrease in the number of BM-derived progenitors accumulating in the pulmonary artery adventitia. The expression of intercellular adhesion molecule-1 (ICAM-1) and its ligand, CD18 (beta2-integrin), were enhanced by hypoxia and were again suppressed by pravastatin. CONCLUSIONS: These results suggest that pravastatin ameliorates hypoxia-induced PAH through suppression of SDF-1/CXCR4 and ICAM-1/CD18 pathways with a resultant reduction in the mobilization and homing of BM-derived progenitor cells.
Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension. 国際誌

Tomohiro Tada, Jun Nawata, Huan Wang, Noriko Onoue, Doe Zhulanqiqige, Kenta Ito, Koichiro Sugimura, Yoshihiro Fukumoto, Hiroaki Shimokawa

Cardiovascular research　80　(3)　346-53　2008年12月1日

DOI： 10.1093/cvr/cvn211 　

詳細を見る詳細を閉じる

AIMS: Clinical studies have suggested that pulsatile pressure is an independent risk factor for atherosclerosis. However, it is unknown whether enhanced pulsatile pressure per se directly accelerates vascular smooth muscle cell (VSMC) migration, an important process of atherosclerosis. METHODS AND RESULTS: Using our original Pressure-loading system with a Boyden chamber, we examined the direct effects of variable pressures and pulse rates on migration of rat aortic VSMCs in vitro. High pulse pressure (180/90 mmHg, pulsatile vs. 180 mmHg, static), high mean pressure (180/90 vs. 90/0 mmHg, with the same pulse pressure), wide pulse pressure (190/110 vs. 170/130 mmHg, with the same mean pressure), and high pulse rate (120 vs. 40 per min) significantly accelerated the VSMC migration (1.35, 2.38, 1.38 and 1.27-fold, respectively). The increase in intracellular calcium levels measured by fura-2/AM fluorescence was proportional to the magnitude of pressure loaded. The pressure-promoted VSMC migration was significantly inhibited by a phospholipase-C inhibitor U-73122 or a calmodulin inhibitor W-7. Inositol 1,4,5-trisphosphate receptor blockers 2-aminoethoxydiphenyl borate or xestospongin-C significantly inhibited the VSMC migration, whereas a ryanodine receptor blocker ryanodine had no effects. Furthermore, a calcium channel blocker (CCB), azelnidipine, and an angiotensin type-1 receptor blocker, olmesartan, also significantly inhibited the VSMC migration. CONCLUSION: These results provide direct evidence for the pro-atherogenic effects of enhanced pulsatile pressure and also suggest that the anti-atherogenic actions of CCBs and angiotensin type-1 receptor blockers are mediated in part by their direct inhibitory effects on VSMC migration in addition to their anti-hypertensive effects.
感冒様症状に続発した甲状腺機能亢進症を契機に増悪した肺高血圧症の一例

三浦裕, 福本義弘, 福井重文, 杉村宏一郎, 縄田淳, 下川宏明

Circulation Journal　72　(Suppl.III)　1022-1022　2008年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
糖尿病は高血圧ラットにおいてレニン-アンジオテンシン系の活性化を介して左室拡張機能障害を悪化させる

福井重文, 福本義弘, 鈴木潤, 佐治賢哉, 杉村宏一郎, 縄田淳, 加賀谷豊, 下川宏明

日本高血圧学会総会プログラム・抄録集　31回　341-341　2008年10月
出版者・発行元： (NPO)日本高血圧学会
血性心嚢液を認めたeffusive constrictive pericarditisの一例

福井重文, 福本義弘, 杉村宏一郎, 縄田淳, 佐治賢哉, 三浦裕, 加賀谷豊, 下川宏明

Circulation Journal　72　(Suppl.III)　1026-1026　2008年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
重症僧帽弁閉鎖不全症を伴った成人リウマチ熱の一例

福井重文, 福本義弘, 杉村宏一郎, 縄田淳, 佐治賢哉, 三浦裕, 中野誠, 加賀谷豊, 下川宏明

日本心臓病学会誌　2　(Suppl.I)　448-448　2008年8月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
肺高血圧に合併する甲状腺機能障害の特徴

三浦裕, 福本義弘, 中野誠, 福井重文, 杉村宏一郎, 下川宏明

日本心臓病学会誌　2　(Suppl.I)　438-438　2008年8月
出版者・発行元： (一社)日本心臓病学会
ISSN：1882-4501
Rho-kinaseの長期阻害は高血圧ラットにおける拡張不全を改善させる

福井重文, 福本義弘, 鈴木潤, 佐治賢哉, 田原俊介, 杉村宏一郎, 縄田淳, 加賀谷豊, 下川宏明

血管　31　(1)　20-20　2008年1月
出版者・発行元：日本心脈管作動物質学会
ISSN：0911-4637
糖尿病が左室拡張機能障害を悪化させるメカニズムについてダール食塩感受性高血圧ラットにおける検討

福井重文, 福本義弘, 鈴木潤, 佐治賢哉, 杉村宏一郎, 縄田淳, 加賀谷豊, 下川宏明

血管　31　(1)　38-38　2008年1月
出版者・発行元：日本心脈管作動物質学会
ISSN：0911-4637
Increased static pressure promotes migration of vascular smooth muscle cells: involvement of the Rho-kinase pathway. 国際誌

Noriko Onoue, Jun Nawata, Tomohiro Tada, Doe Zhulanqiqige, Huan Wang, Koichiro Sugimura, Yoshihiro Fukumoto, Kunio Shirato, Hiroaki Shimokawa

Journal of cardiovascular pharmacology　51　(1)　55-61　2008年1月

DOI： 10.1097/FJC.0b013e31815b9d26 　

詳細を見る詳細を閉じる

Vascular smooth muscle cell (VSMC) migration plays a pivotal role in the pathogenesis of arteriosclerosis, under influences of various mechanical factors. Thus, we examined whether static pressure promotes VSMC migration and if so, whether Rho-kinase is involved. Rat VSMCs were cultured on chambers coated on fibronectin, vitronectin, laminin, or type IV collagen, under pressure-free conditions and at 90 and 180 mm Hg. In monolayer-wounding assay, VSMC migration was significantly increased after 72 hours at 180 mm Hg on both fibronectin (11.3 +/- 3.4-fold vs. pressure-free conditions) and vitronectin (10.6 +/- 0.7-fold; both P < 0.05). In Boyden chamber assay, the VSMC migration was again significantly increased at 180 mm Hg on both fibronectin (4.0 +/- 0.5-fold) and vitronectin (5.0 +/- 0.8-fold; both P < 0.05). Neutralizing antibodies against beta1-, beta3- and beta5-integrins, all of which play an important role in cell migration, significantly inhibited the pressure-promoted VSMC migration. Static pressure also significantly increased Rho-kinase activity in VSMC, as evaluated by the extent of phosphorylation of its downstream substrate, ezrin-radixin-moesin. Fasudil, a selective Rho-kinase inhibitor, significantly suppressed the pressure-promoted VSMC migration with reduced Rho-kinase activity. These results indicate that increased static pressure promotes VSMC migration through the integrin/Rho-kinase signaling, suggesting the therapeutic importance of this mechanism for the treatment of hypertensive vascular diseases.
微小管重合と心筋細胞アポトーシスの関連性

佐治賢哉, 鈴木潤, 縄田淳, 杉村宏一郎, 福井重文, 佐久間聖仁, 白土邦男, 下川宏明

Circulation Journal　70　(Suppl.III)　1135-1135　2006年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
肺高血圧症に対するボセンタンの使用成績

縄田淳, 出町順, 福本義弘, 杉村宏一郎, 佐藤公雄, 鈴木潤, 佐久間聖仁, 下川宏明

Circulation Journal　70　(Suppl.III)　1180-1180　2006年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
近位部肺動脈瘤を伴う特発性肺動脈性肺高血圧症の3例

出町順, 縄田淳, 杉村宏一郎, 鈴木潤, 福本義弘, 佐藤公雄, 佐久間聖仁, 白土邦男, 下川宏明

Circulation Journal　70　(Suppl.III)　1180-1180　2006年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
Portopulmonary hypertension - Hemodynamics, pulmonary angiography, and configuration of the heart 査読有り

M Sakuma, S Souma, O Kitamukai, J Demachi, T Takahashi, J Suzuki, J Nawata, K Sugimura, M Oikawa, K Saji, T Tada, S Fukui, Y Kagaya, J Watanabe, K Shirato

CIRCULATION JOURNAL　69　(11)　1386-1393　2005年11月

DOI： 10.1253/circj.69.1386 　

ISSN：1346-9843
慢性心不全の予後予測因子として中枢性睡眠時無呼吸とBNPの意義

福井重文, 篠崎毅, 杉村宏一郎, 加賀谷豊, 渡辺淳, 小川浩正

Circulation Journal　69　(Suppl.III)　949-949　2005年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
原発性肺高血圧症合併した肺動脈仮性瘤にコイル塞栓術が有効であった一例

佐久間聖仁, 出町順, 鈴木潤, 縄田淳, 杉村宏一郎, 多田智洋, 福井重文, 白土邦男

Circulation Journal　69　(Suppl.III)　899-899　2005年10月
出版者・発行元： (一社)日本循環器学会
ISSN：1346-9843

eISSN：1347-4820
Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion 査読有り

K Saji, M Sakuma, J Suzuki, T Takahashi, J Demachi, J Nawata, O Kitamukai, N Onoue, K Sugimura, T Tada, S Fukui, Y Kagaya, J Watanabe, K Shirato

CIRCULATION JOURNAL　69　(3)　335-338　2005年3月

DOI： 10.1253/circj.69.335 　

ISSN：1346-9843

︎全件表示 ︎最初の5件までを表示

MISC 240

難治性呼吸器疾患・肺高血圧症に関する調査研究 Group2PH症例に対するNO負荷試験による予後と心予備能の評価

杉村宏一郎, 佐藤大樹, 矢尾板信裕, 後岡広太郎, 建部俊介, 林秀華, 山本沙織, 佐藤遥, 高濱博幸, 鈴木秀明, 照井洋輔, 山田魁人, 山田祐資, 井上巧, 青木竜男, 佐藤公雄, 宮田敏, 安田聡

難治性呼吸器疾患・肺高血圧症に関する調査研究令和5年度研究報告書(Web)　2024年
治療薬チェックシートの普及,リアルワールドデータ検証から目指す心不全診療の質向上

福岡良磨, 杉村宏一郎, 河村朗夫, 福田浩二, 武田守彦, 稲見茂信

国際医療福祉大学学会誌　29　2024年

ISSN： 2186-3652
当院におけるクリニカルシーケンスを用いた肥大型心筋症関連遺伝子の網羅的解析

加藤倫子, 相澤義泰, 杉村宏一郎, 河村朗夫, 佐藤菜穂子, 辻省次

日本心臓病学会学術集会抄録　71回　P-6　2023年9月
出版者・発行元： (一社)日本心臓病学会
心不全患者の突然死予防目的の植込型除細動器挿入の実態と至適薬物療法、予後との関係

福岡良磨, 杉村宏一郎, 相澤義泰, 河村朗夫, 真鍋晋

国際医療福祉大学学会誌　28　(抄録号)　190-190　2023年9月
出版者・発行元：国際医療福祉大学学会
ISSN： 2186-3652
サルコイドーシスに合併した肺高血圧症の一例

門間雄斗, 杉村宏一郎, 杉本一将, 館野馨, 福岡良磨, 吉澤彰宏, 相澤義泰, 中山崇, 加藤倫子, 永井敏雄, 河村朗夫

日本肺高血圧・肺循環学会学術集会抄録集　8回　100-100　2023年6月
出版者・発行元：日本肺高血圧・肺循環学会
心疾患を伴う周産期の薬物治療(Immunosuppressive Therapy during Pregnancy and Perinatal Management in Heart Transplant Recipients)

加藤倫子, 相澤義泰, 杉村宏一郎, 中山崇, 舘野馨, 河村朗夫

日本循環器学会学術集会抄録集　87回　SY23-5　2023年3月
出版者・発行元： (一社)日本循環器学会
中等度大動脈弁狭窄症を合併した左主幹部直下の左前下行枝高度石灰化病変に対し、Diamondback 360を用いて安全に治療を行った1例

福岡良磨, 荒谷玄, 中山崇, 藤本善英, 杉本一将, 相澤義泰, 舘野馨, 杉村宏一郎, 真鍋晋, 河村朗夫

日本心臓病学会学術集会抄録　70回　C-2　2022年9月
出版者・発行元： (一社)日本心臓病学会
心不全データベースを用いた予後予測とフィードバックシステムによる医療の質改善検証

福岡良磨, 相澤義泰, 河村朗夫, 杉村宏一郎, 加藤倫子

国際医療福祉大学学会誌　27　(抄録号)　184-184　2022年8月
出版者・発行元：国際医療福祉大学学会
ISSN： 2186-3652
高齢者における循環器疾患に対する応用薬理慢性心不全患者における脳由来成長因子(BDNF)と脳灰白質量との関連慢性心不全における脳の構造・機能に関する縦断研究(B-HeFT2)

鈴木秀明, 松本泰治, 大田英揮, 杉村宏一郎, 後岡広太郎, 高橋潤, 宮田敏, 古川勝敏, 福本義弘, 瀧靖之, 下川宏明, 安田聡

応用薬理　102　(5-6)　123-123　2022年8月
出版者・発行元：応用薬理研究会
ISSN： 0300-8533
左主幹部の急性心筋梗塞にPCIを行い、左室内血栓と心嚢液貯留に対処し、9ヵ月後の回旋枝再狭窄へのPCIに成功した1例

中山崇, 藤本善英, 舘野馨, 門間雄斗, 吉澤彰宏, 市来智子, 加藤倫子, 福岡良磨, 中井大貴, 相澤義泰, 杉本一将, 稲見茂信, 杉村宏一郎, 河村朗夫

日本心血管インターベンション治療学会抄録集　30回　[MO001]-[MO001]　2022年7月
出版者・発行元： (一社)日本心血管インターベンション治療学会
薬剤溶出ステント時代の経皮的冠動脈インターベンションにおける冠動脈穿孔(Coronary Perforation during Percutaneous Coronary Intervention in the Drug-Eluting Stent Era)

藤本善英, 齋藤佑一, 加藤賢, 北原秀喜, 外池範正, 芳生旭志, 田中秀造, 兵働裕介, 山本雅史, 中井大貴, 門間雄斗, 福岡良磨, 杉本一将, 吉澤彰宏, 中山崇, 相澤義泰, 稲見茂信, 加藤倫子, 舘野馨, 杉村宏一郎, 永井敏雄, 河村朗夫, 小林欣夫

日本循環器学会学術集会抄録集　86回　JO11-4　2022年3月
出版者・発行元： (一社)日本循環器学会
心臓移植後の拒絶反応診断および冠動脈病変の診断についての心臓MRIの有用性

加藤倫子, 桐生茂, 赤羽正章, 高村千智, 佐藤万基人, 伊藤みゆき, 伊藤順子, 高桑蓉子, 寺島正浩, 杉村宏一郎, 中山崇, 福岡良磨, 河村朗夫

移植　56　(総会臨時)　P2-16　2021年9月
出版者・発行元： (一社)日本移植学会
ISSN： 0578-7947

eISSN： 2188-0034
慢性血栓塞栓性肺高血圧症(CTEPH)に対するBAP技術の進歩と課題慢性血栓塞栓性患者に対するバルーン肺動脈形成術の効果

杉村宏一郎, 青木竜男, 建部俊介, 福井重文, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 紺野亮, 下川宏明

日本心血管インターベンション治療学会抄録集　29回　468-468　2021年2月
出版者・発行元： (一社)日本心血管インターベンション治療学会
心臓置換後早期の生体弁機能不全と異種免疫応答についての病理学的検討

加藤倫子, 真鍋晋, 平山大貴, 弓削徳久, 村田舞, 杉村宏一郎, 中山崇, 福岡良磨, 吉澤彰宏, 河村朗夫

日本移植学会総会(Web)　57th　2021年

ISSN： 0578-7947
Longitudinal Change of Regional Left Ventricular Deformation by Chemotherapy-induced Cardiotoxicity in Patients with Breast Cancer(和訳中)

藤原淳子, 後岡広太郎, 杉村宏一郎, 照井洋輔, 佐藤遥, 多田寛, 大田英揮, 船水康陽, 三木俊, 西條芳文, 高瀬圭, 石田孝宜, 下川宏明

日本循環器学会学術集会抄録集　84回　OJ12-6　2020年7月
出版者・発行元： (一社)日本循環器学会
成人先天性心疾患患者における心血管イベントと緊急入院の予測因子としての健康関連QoL(Health-related Quality of Life Predicts Cardiovascular Outcomes and Unplanned Hospital Admissions in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 福井重文, 鈴木秀明, 山本沙織, 佐藤遥, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本成人先天性心疾患学会雑誌　9　(1)　243-243　2020年1月
出版者・発行元：日本成人先天性心疾患学会
冠動脈疾患における新規予後予測バイオマーカーAdipsinの発見補体系を介した心筋梗塞発症予測の新たな展開

大槻知広, 佐藤公雄, 清水亨, 池田尚平, 菊地順裕, 佐藤大樹, 黒澤亮, 野木正道, 砂村慎一郎, 矢尾板信裕, 大村淳一, 杉村宏一郎, 青木竜男, 建部俊介, 高橋潤, 宮田敏, 下川宏明

血管　43　(1)　36-36　2020年1月
出版者・発行元：日本心脈管作動物質学会
ISSN： 0911-4637
Temporal Changes in Left Ventricular Ejection Fraction and Their Prognostic Impacts in Patients With Stage B Heart Failure: Insights From the Chart-2 Study

Hajime Aoyanagi, Kotaro Nochioka, Yasuhiko Sakata, Masanobu Miura, Takashi Shiroto, Ruri Abe, Shintaro Kasahara, Masayuki Sato, Takahide Fujihashi, Shinsuke Yamanaka, Hideka Hayashi, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

CIRCULATION　140　2019年11月

ISSN： 0009-7322

eISSN： 1524-4539
Health-related Quality of Life in Patients With Adult Congenital Heart Disease - A Nation-wide Cross-sectional Questionnaire Survey -

Ryo Konno, Shunsuke Tatebe, Yasuhiko Sakata, Koichiro Sugimura, Kimio Satoh, Takashi Shiroto, Satoshi Miyata, Osamu Adachi, Masato Kimura, Yoshiko Mizuno, Junko Enomoto, Shigeru Tateno, Hiromichi Nakajima, Kotaro Oyama, Yoshikatsu Saiki, Hiroaki Shimokawa

CIRCULATION　140　2019年11月

ISSN： 0009-7322

eISSN： 1524-4539
Prognostic Impacts of Dynamic Left Ventricular Structural Changes in Heart Failure Patients With Preserved Ejection Fraction -A Report From the CHART-2 Study-

Shinsuke Yamanaka, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Takahide Fujihashi, Hideka Hayashi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa

CIRCULATION　140　2019年11月

ISSN： 0009-7322

eISSN： 1524-4539
CardioOncologyの現状と未来当院データと本邦における多施設共同研究への発展

杉村宏一郎, 大田英揮, 多田寛, 照井洋輔, 佐藤遥, 後岡広太郎, 石田孝宣, 高瀬圭, 下川宏明

日本心臓病学会学術集会抄録　67回　SS-B10　2019年9月
出版者・発行元： (一社)日本心臓病学会
わが国の心不全高リスク患者(Stage B)における左室駆出率と予後との関連に関する検討 CHART-2研究からの知見

青柳肇, 坂田泰彦, 後岡広太郎, 白戸崇, 藤橋敬英, 山中信介, 林秀華, 杉村宏一郎, 高橋潤, 宮田敏, 下川宏明

日本心臓病学会学術集会抄録　67回　P-129　2019年9月
出版者・発行元： (一社)日本心臓病学会
薬物療法による副作用のマネージメント腫瘍循環器病学Cardio-Oncologyの現状と未来当院での横断的前向き研究から

多田寛, 宮下穣, 佐藤章子, 原田成美, 濱中洋平, 藤井里圭, 照井洋輔, 杉村宏一郎, 大田英輝, 石田孝宣

日本乳癌学会総会プログラム抄録集　27回　242-242　2019年7月
出版者・発行元： (一社)日本乳癌学会
【第6回肺高血圧症ワールドシンポジウム-併用療法-】

田村雄一, 白井悠一郎, 杉村宏一郎, 須田理香, 谷口悠

Pulmonary Hypertension Update　5　(1)　12-21　2019年5月
出版者・発行元： (株)メディカルレビュー社
ISSN： 2189-4434
乳癌患者における化学療法による心毒性を早期発見するための2D speckle tracking心エコーの有用性(Usefulness of 2D Speckle Tracking Echocardiography for Early Detection of Chemotherapy-induced Cardiotoxicity in Patients with Breast Cancer)

後岡広太郎, 杉村宏一郎, 藤原淳子, 照井洋輔, 佐藤遥, 多田寛, 太田英揮, 船水康陽, 三木俊, 高瀬圭, 石田孝宣, 下川宏明

日本循環器学会学術集会抄録集　83回　PJ022-1　2019年3月
出版者・発行元： (一社)日本循環器学会
将来の心不全症状増悪に関連する脳領域(Brain Areas Associated with Future Exacerbation of Heart Failure Symptoms)

鈴木秀明, 松本泰治, 杉村宏一郎, 高橋潤, 宮田敏, 福本義弘, 瀧靖之, 下川宏明

日本循環器学会学術集会抄録集　83回　OJ04-6　2019年3月
出版者・発行元： (一社)日本循環器学会
MELD-XI(Model for End-Stage Liver Disease Excluding INR) Score Predicts Cardiovascular Outcomes in Patients with Adult Congenital Heart Disease(和訳中)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 三浦正暢, 鈴木秀明, 山本沙織, 佐藤遥, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　83回　OJ29-2　2019年3月
出版者・発行元： (一社)日本循環器学会
癌患者における潜在性化学療法関連心機能障害早期検出に対する心臓MRIの有用性(Usefulness of Cardiac Magnetic Resonance Imaging for Early Detection of Subclinical Chemotherapy-related Cardiac Dysfunction in Cancer Patients)

照井洋輔, 杉村宏一郎, 大田英揮, 多田寛, 佐藤遥, 後岡広太郎, 建部俊介, 宮田敏, 坂田泰彦, 石田孝宜, 高瀬圭, 下川宏明

日本循環器学会学術集会抄録集　83回　OJ33-3　2019年3月
出版者・発行元： (一社)日本循環器学会
先天性心臓疾患を有する成人患者における健康関連QOLに影響する因子 AMED支援下の全国調査(Factors Influencing Health-related Quality of Life in Patients with Adult Congenital Heart Disease: A Nationwide Study Supported by AMED)

紺野亮, 建部俊介, 坂田泰彦, 杉村宏一郎, 佐藤公雄, 白戸崇, 宮田敏, 安達理, 木村正人, 水野芳子, 榎本淳子, 立野滋, 中島弘道, 小山耕太郎, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　83回　LBCS1-4　2019年3月
出版者・発行元： (一社)日本循環器学会
フォンタン循環成人患者のQOL AMEDの支援を受けて実施された全国研究(Quality of Life in Adult Patients with A Fontan Circulation: A Nationwide Study Supported by AMED)

建部俊介, 坂田泰彦, 杉村宏一郎, 佐藤公雄, 白戸崇, 紺野亮, 宮田敏, 安達理, 木村正人, 水野芳子, 榎本淳子, 立野滋, 中島弘道, 小山耕太郎, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　83回　PJ055-4　2019年3月
出版者・発行元： (一社)日本循環器学会
Factors Influencing Health-related Quality of Life in Patients with Adult Congenital Heart Disease: A Nationwide Study Supported by AMED(和訳中)

紺野亮, 建部俊介, 坂田泰彦, 杉村宏一郎, 佐藤公雄, 白戸崇, 宮田敏, 安達理, 木村正人, 水野芳子, 榎本淳子, 立野滋, 中島弘道, 小山耕太郎, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　83回　LBCS1-4　2019年3月
出版者・発行元： (一社)日本循環器学会
Quality of Life in Adult Patients with A Fontan Circulation: A Nationwide Study Supported by AMED(和訳中)

建部俊介, 坂田泰彦, 杉村宏一郎, 佐藤公雄, 白戸崇, 紺野亮, 宮田敏, 安達理, 木村正人, 水野芳子, 榎本淳子, 立野滋, 中島弘道, 小山耕太郎, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　83回　PJ055-4　2019年3月
出版者・発行元： (一社)日本循環器学会
慢性血栓塞栓性肺高血圧症の治療前後における肺野ヨードマップのヒストグラム解析

大田英揮, 高木英誠, 冨永循哉, 高瀬圭, 杉村宏一郎, 佐藤遙, 高木英誠

Japanese Journal of Radiology　37　(Suppl.)　3-3　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
心臓移植レシピエントへのPCSK9阻害薬の使用経験

青木竜男, 杉村宏一郎, 建部俊介, 山本沙織, 佐藤遥, 秋場美紀, 佐々木康之輔, 秋山正年, 齋木佳克, 下川宏明

日本移植学会総会プログラム抄録集　55th　(総会臨時)　313-313　2019年
出版者・発行元： (一社)日本移植学会
ISSN： 0578-7947

eISSN： 2188-0034
呼気ガス分析による肺うっ血の評価

青木竜男, 杉村宏一郎, 秋月美奈, 建部俊介, 山本沙織, 佐藤遥, 紺野亮, 照井洋輔, 佐藤公雄, 下川宏明

日本心臓病学会学術集会(Web)　67th　O-178　2019年
出版者・発行元： (一社)日本心臓病学会
成人先天性心疾患患者の予後予測におけるMELD-XI Scoreの有用性(Prognostic Utility of Model for End-Stage Liver Disease Excluding INR(MELD-XI) Score in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 三浦正暢, 鈴木秀明, 山本沙織, 佐野遥, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本成人先天性心疾患学会雑誌　8　(1)　124-124　2019年1月
出版者・発行元：日本成人先天性心疾患学会
慢性血栓塞栓性肺高血圧症に対する4D flow MRI:肺動脈拡張術前後に於る血流動態解析

大田英揮, 孫文羽, 佐藤遥, 杉村宏一郎, 高瀬圭

日本心血管画像動態学会プログラム・抄録集　29th　2019年
左心不全に合併する右心不全の問題点

杉村宏一郎, 建部俊介, 福井重文, 山本沙織, 佐藤遥, 紺野亮, 照井洋輔, 佐藤公雄, 下川宏明

日本心不全学会学術集会プログラム・抄録集　23rd　2019年
The Simple Risk Model for Heart Failure With Preserved Ejection Fraction-A Report From the CHART-2 Study

Shintaro Kasahara, Yasuhiko Sakata, Kotaro Nochioka, Ruri Abe, Masayuki Sato, Hajime Aoyanagi, Takahide Fujihashi, Shinsuke Yamanaka, Masanobu Miura, Takashi Shiroto, Jun Takahashi, Koichiro Sugimura, Satoshi Miyata, Hiroaki Shimokawa

CIRCULATION　138　2018年11月

ISSN： 0009-7322

eISSN： 1524-4539
Development of Useful Conversion Equation between B-type Natriuretic Peptide and N-terminal pro BNP Levels

Shintaro Kasahara, Yasuhiko Sakata, Kotaro Nochioka, Ruri Abe, Masayuki Sato, Hajime Aoyanagi, Masanobu Miura, Takashi Shiroto, Jun Takahashi, Koichiro Sugimura, Satoshi Miyata, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　24　(8)　S23-S23　2018年8月

DOI： 10.1016/j.cardfail.2018.07.068 　

ISSN： 1071-9164

eISSN： 1532-8414
心疾患を有する妊娠女性の臨床特性(Clinical Profiles of Pregnant Women with Heart Disease)

建部俊介, 杉村宏一郎, 齋藤昌利, 坂田泰彦, 佐藤公雄, 青木竜男, 山本沙織, 清水亨, 佐藤遥, 大槻知広, 神津克也, 紺野亮, 照井洋輔, 川野研吾, 木村正人, 安達理, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　82回　PJ002-5　2018年3月
出版者・発行元： (一社)日本循環器学会
心疾患を有する妊娠女性の臨床特性(Clinical Profiles of Pregnant Women with Heart Disease)

建部俊介, 杉村宏一郎, 齋藤昌利, 坂田泰彦, 佐藤公雄, 青木竜男, 山本沙織, 清水亨, 佐藤遥, 大槻知広, 神津克也, 紺野亮, 照井洋輔, 川野研吾, 木村正人, 安達理, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　82回　PJ002-5　2018年3月
出版者・発行元： (一社)日本循環器学会
成人先天性心疾患患者においてhepatitis C virus陽性は心機能および長期予後に悪影響を及ぼす(Hepatitis C Virus Positivity Adversely Impacts Cardiac Functions and Long-term Prognosis in Patients with Adult Congenital Heart Disease)

紺野亮, 建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 山本沙織, 清水亨, 佐藤遥, 神津克也, 照井洋輔, 安達理, 木村正人, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　82回　PJ043-4　2018年3月
出版者・発行元： (一社)日本循環器学会
突然死を来した心臓移植後の1症例

青木竜男, 杉村宏一郎, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 神津克也, 紺野亮, 佐藤公雄, 秋葉美紀, 秋山正年, 川本俊輔, 齋木佳克, 下川宏明

移植　52　(6)　577-577　2018年2月
出版者・発行元： (一社)日本移植学会
ISSN： 0578-7947

eISSN： 2188-0034
心疾患合併妊娠の臨床像の検討

建部俊介, 杉村宏一郎, 佐藤公雄, 青木竜男, 山本沙織, 清水亨, 斎藤昌利, 川野研悟, 安達理, 下川宏明

日本成人先天性心疾患学会雑誌　7　(1)　178-178　2018年1月
出版者・発行元：日本成人先天性心疾患学会
心臓移植後患者におけるde novo悪性腫瘍

齋木佳克, 秋山正年, 吉岡一朗, 高橋悟朗, 鈴木佑輔, 鈴木智之, 熊谷紀一郎, 青木竜男, 三浦正暢, 山本沙織, 杉村宏一郎, 下川宏明, 安達理

日本移植学会総会プログラム抄録集　54th　(総会臨時)　228-228　2018年
出版者・発行元： (一社)日本移植学会
ISSN： 0578-7947

eISSN： 2188-0034
循環器疾患合併の妊娠・出産管理~内科の立場から~

建部俊介, 杉村宏一郎, 青木竜男, 山本沙織, 清水亨, 佐藤遥, 紺野亮, 斎藤昌利, 川野研悟, 木村正人, 安達理, 佐藤公雄, 齋木佳克, 下川宏明

日本成人先天性心疾患学会雑誌(Web)　7　(1)　114-114　2018年
出版者・発行元：日本成人先天性心疾患学会
eISSN： 2435-287X
右総腸骨動静脈瘻に対しEVAR施行後に左心不全の悪化を認めた1例

迫田みく, 菊池順裕, 杉村宏一郎, 建部俊介, 青木竜男, 三浦正暢, 山本沙織, 鈴木秀明, 佐藤遥, 紺野亮, 照井洋輔, 後岡広太郎, 佐藤公雄, 下川宏明

日本循環器学会東北地方会(Web)　167th　2018年
Non-invasive Distinction Between Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension Using Ventilatory Gas Analysis 査読有り

Akizuki Mina, Sugimura Koichiro, Aoki Tatsuo, Kakihana Takaaki, Shimokawa Hiroaki, Kohzuki Masahiro

CIRCULATION　136　2017年11月14日

ISSN： 0009-7322
Adverse Effect of Hepatitis C Virus Positivity on Cardiac Function and Long-term Prognosis in Patients With Adult Congenital Heart Disease 査読有り

Konno Ryo, Tatebe Shunsuke, Sugimura Koichiro, Satoh Kimio, Aoki Tatsuo, Yamamoto Saori, Shimizu Toru, Sato Haruka, Kozu Katsuya, Adachi Osamu, Kimura Masato, Saiki Yoshikatsu, Shimokawa Hiroaki

CIRCULATION　136　2017年11月14日

ISSN： 0009-7322
Plasma Cyclophilin A as a Useful Biomarker for Evaluation of the Effects of Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension

Katsuya Kozu, Kimio Satoh, Toru Shimizu, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Haruka Sato, Tomohiro Ohtsuki, Ryo Konno, Satoshi Miyata, Koichiro Sugimura, Hiroaki Shimokawa

CIRCULATION　136　2017年11月

ISSN： 0009-7322

eISSN： 1524-4539
Prognostic Impacts of Plasma Levels of Cyclophilin A in Patients With Heart Failure

Tomohiro Ohtsuki, Kimio Satoh, Toru Shimizu, Shohei Ikeda, Nobuhiro Yaoita, Taijyu Satoh, Junichi Omura, Nobuhiro Kikuchi, Ryo Kurosawa, Shinichiro Sunamura, Masamichi Nogi, Koichiro Sugimura, Tatsuo Aoki, Shunsuke Tatebe, Satoshi Miyata, Hiroaki Shimokawa

CIRCULATION　136　2017年11月

ISSN： 0009-7322

eISSN： 1524-4539
抗体関連型拒絶反応を合併した心臓移植の一例

秋山正年, 河津聡, 増田信也, 神田桂輔, 秋場美紀, 青木竜男, 杉村宏一郎, 熊谷紀一郎, 安達理, 川本俊輔, 下川宏明, 齋木佳克

移植　52　(2-3)　240-240　2017年9月
出版者・発行元： (一社)日本移植学会
ISSN： 0578-7947

eISSN： 2188-0034
DVT/PEの診断と治療、予後は明確になったか? 当院における肺動脈血栓症診療の現状

杉村宏一郎, 矢尾板信裕, 建部俊介, 青木竜男, 山本沙織, 清水亨, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録　65回　S9-2　2017年9月
出版者・発行元： (一社)日本心臓病学会
心臓移植後周術期液性拒絶に投与したRituximabの遠隔期の影響

秋山正年, 秋場美紀, 河津聡, 吉岡一朗, 青木竜男, 杉村宏一郎, 川本俊輔, 下川宏明, 齋木佳克

移植　52　(総会臨時)　424-424　2017年8月
出版者・発行元： (一社)日本移植学会
ISSN： 0578-7947
心臓移植後周術期液性拒絶に投与したRituximabの遠隔期の影響

秋山正年, 秋場美紀, 河津聡, 吉岡一朗, 青木竜男, 杉村宏一郎, 川本俊輔, 下川宏明, 齋木佳克

移植　52　(総会臨時)　424-424　2017年8月
出版者・発行元： (一社)日本移植学会
ISSN： 0578-7947
留置から1年を経てIVCフィルターを抜去した1例

青木竜男, 杉村宏一郎, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 神津克也, 佐藤公雄, 下川宏明

心臓　49　(7)　751-751　2017年7月15日
出版者・発行元： (公財)日本心臓財団
DOI： 10.11281/shinzo.49.751 　

ISSN： 0586-4488

eISSN： 2186-3016
プロスペクティブ多施設共同コホート試験における成人先天性心疾患の臨床特性 CHART-2試験の第一報(Clinical Characteristics of Adult Congenital Heart Disease in a Prospective Multicenter Cohort Study: An Initial Report from the CHART-2 Study)

建部俊介, 坂田泰彦, 杉村宏一郎, 佐藤公雄, 白戸崇, 紺野亮, 安達理, 木村正人, 立野滋, 中島弘道, 小山耕太郎, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　81回　LBCS1-2　2017年3月
出版者・発行元： (一社)日本循環器学会
経カテーテル大動脈弁留置術に対する継続的なフレイルガイドのリハビリテーションは、術後回復レベルを予測し、在宅期のQOLとフレイルを改善する

竹内雅史, 松本泰治, 川本俊輔, 高橋潤, 青木竜男, 杉村宏一郎, 宮田敏, 上月正博, 荒井啓行, 齋木佳克, 下川宏明

日本循環器学会学術集会抄録集　81回　CP-236　2017年3月
出版者・発行元： (一社)日本循環器学会
ACHDの臨床像に関する多施設前向き研究 CHART-2研究からの第1報(Prospective Multicenter Cohort Study for Clinical Characteristics and Cardiovascular Events of Patients with Adult Congenital Heart Disease: An Initial Report from the CHART-2 Study)

建部俊介, 坂田泰彦, 杉村宏一郎, 佐藤公雄, 白戸崇, 紺野亮, 安達理, 木村正人, 立野滋, 中島弘道, 小山耕太郎, 齋木佳克, 下川宏明

日本成人先天性心疾患学会雑誌　6　(1)　112-112　2017年1月
出版者・発行元：日本成人先天性心疾患学会
eISSN： 2435-287X
Bridge to candidacyとして体外式VADと肺血管拡張薬療法を行った修正大血管転位症の1例

紺野亮, 建部俊介, 杉村宏一郎, 青木竜男, 山本沙織, 矢尾板信裕, 佐藤公雄, 安達理, 小山耕太郎, 齋木佳克, 下川宏明

日本循環器学会東北地方会(Web)　164th　2017年
末梢型肺動脈狭窄の一例

佐藤遥, 杉村宏一郎, 建部俊介, 青木竜男, 山本沙織, 清水亨, 神津克也, 紺野亮, 照井洋輔, 佐藤公雄, 下川宏明

日本循環器学会東北地方会(Web)　165th　2017年
生体肺移植を施行した小児期発症の肺動脈性肺高血圧症の1例

建部俊介, 杉村宏一郎, 青木竜男, 山本沙織, 清水亨, 佐藤遥, 大槻知広, 神津克也, 紺野亮, 照井洋輔, 安達理, 秋場美紀, 佐藤公雄, 岡田克典, 下川宏明

日本循環器学会東北地方会(Web)　165th　2017年
東日本大震災と心血管病

青木竜男, 中野誠, 二瓶太郎, 羽尾清貴, 小野瀬剛生, 杉村宏一郎, 高橋潤, 福田浩二, 宮田敏, 坂田泰彦, 下川宏明

日本冠疾患学会雑誌　(Suppl.)　173-173　2016年12月
出版者・発行元： (NPO)日本冠疾患学会
ISSN： 1341-7703

eISSN： 2187-1949
Non-Invasive Evaluation of the Severity of Chronic Thromboembolic Pulmonary Hypertension With Ventilatory Gas Analysis 査読有り

Mina Akizuki, Koichiro Sugimura, Tatsuo Aoki, Takaaki Kakihana, Osamu Ito, Hiroaki Shimokawa, Masahiro Kohzuki

CIRCULATION　134　2016年11月

ISSN： 0009-7322

eISSN： 1524-4539
Thrombin Activatable Fibrinolysis Inhibitor Promotes Development of Chronic Thromboembolic Pulmonary Hypertension -A Possible Novel Therapeutic Target

Taijyu Satoh, Kimio Satoh, Nobuhiro Yaoita, Nobuhiro Kikuchi, Junichi Omura, Ryo Kurosawa, Shinichiro Sunamura, Masamichi Nogi, Tomohiro Otsuki, Kazuhiko Numano, Md Elias Al-Mamun, Mohammad Abdul Hai Siddique, Shunsuke Tatebe, Tatsuo Aoki, Koichiro Sugimura, John Morser, Hiroaki Shimokawa

CIRCULATION　134　2016年11月

ISSN： 0009-7322

eISSN： 1524-4539
Safety of Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension -Detail Analyses of Procedure Related Complications

Tatsuo Aoki, Koichiro Sugimura, Masanobu Miura, Shunsuke Tatebe, Saori Yamamoto, Nobuhiro Yaoita, Hideaki Suzuki, Haruka Sato, Katsuya Kozu, Kimio Satoh, Hiroaki Shimokawa

CIRCULATION　134　2016年11月

ISSN： 0009-7322

eISSN： 1524-4539
Cardiopulmonary Best Abstract Award: A Disintegrin and Metalloproteinase With Thrombospondin Motifs 8 Downregulates AMP-activated Protein Kinase and Promotes Matrix Metalloproteinases Activation and Pulmonary Hypertension

Junichi Omura, Kimio Satoh, Nobuhiro Kikuchi, Taijyu Satoh, Ryo Kurosawa, Masamichi Nogi, Shinichiro Sunamura, Tomohiro Ohtsuki, Katsuya Kozu, Kazuhiko Numano, Koichiro Sugimura, Shunsuke Tatebe, Tatsuo Aoki, Kota Suzuki, Nobuhiro Yaoita, Hiroaki Shimokawa

CIRCULATION　134　2016年11月

ISSN： 0009-7322

eISSN： 1524-4539
心臓移植後におけるtacrolimus徐放性製剤の使用経験

河津聡, 秋山正年, 細山勝寛, 正木直樹, 高原真吾, 坂爪公, 神田桂輔, 鈴木智之, 片平晋太郎, 吉岡一朗, 藤原英記, 安達理, 熊谷紀一郎, 川本俊輔, 三浦正暢, 青木竜男, 杉村宏一郎, 下川宏明, 秋場美紀, 齋木佳克

移植(Web)　51　(4-5)　383‐390(J‐STAGE)-390　2016年10月
出版者・発行元： (一社)日本移植学会
DOI： 10.11386/jst.51.4-5_383 　

ISSN： 2188-0034

詳細を見る詳細を閉じる

カルシニューリン阻害薬として従来型経口タクロリムス製剤による免疫抑制療法を行っている心臓移植後患者10例(平均36歳)を対象とした。徐放性製剤への切り替え前(B)、徐放性製剤切り替え直後(C)、切り替え1ヵ月後(1M)、3ヵ月後(3M)、6ヵ月後(6M)でのタクロリムスの血中濃度、内服量の変化について比較検討した。全ての測定点においてタクロリムス血中濃度に有意な変化を認めなかった。Cと1M、6Mに有意な投与量の増加を認めた。切り替え6ヵ月後には、切り替え前より投与量が増加している症例は8例(80%)であった。ASTは切り替え時期によっても有意差は認めなかったが、γ-GTPは遠隔期切り替え群6MでCと比較し有意差を認めた。Bと1Mの比較において血清クレアチニン値は有意に上昇、eGFRは有意に低下した。脂質とHbA1cは、各測定時点において有意差は認めなかった。切り替えにより追加治療が必要な拒絶反応の出現は認めなかった。
抗体関連型拒絶反応を合併した心臓移植の一例

河津聡, 高原真吾, 秋山正年, 川本俊輔, 安達理, 青木竜男, 杉村宏一郎, 下川宏明, 齋木佳克

移植　51　(総会臨時)　411-411　2016年9月
出版者・発行元： (一社)日本移植学会
ISSN： 0578-7947
心臓リハビリテーションでフレイルを克服しよう経カテーテル大動脈弁留置術における心臓リハビリテーション理学療法士の立場から「フレイル」を認識し対応する重要性

竹内雅史, 松本泰治, 森信芳, 高橋潤, 杉村宏一郎, 三浦正暢, 川本俊輔, 熊谷紀一郎, 上月正博, 齋木佳克, 下川宏明

日本心臓病学会学術集会抄録　64回　JS5-4　2016年9月
出版者・発行元： (一社)日本心臓病学会
Non-invasive evaluation of the severity of chronic thromboembolic pulmonary hypertension with ventilatory gas analysis 査読有り

Akizuki Mina, Sugimura Koichiro, Aoki Tatsuo, Kakihana Takaaki, Mori Nobuyoshi, Ito Osamu, Shimokawa Hiroaki, Kohzuki Masahiro

EUROPEAN RESPIRATORY JOURNAL　48　2016年9月1日

DOI： 10.1183/13993003.congress-PA2460 　

ISSN： 0903-1936
Focal Decrease in Cardiac 123I-Meta-Iodobenzylguanidine Uptake in Patients with Anderson-Fabry Disease

Saori Yamamoto, Hideaki Suzuki, Koichiro Sugimura, Syunsuke Tatebe, Tatsuo Aoki, Masanobu Miura, Nobuhiro Yaoita, Kentaro Takanami, Kei Takase, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　22　(9)　S178-S178　2016年9月

ISSN： 1071-9164

eISSN： 1532-8414
二次性心筋症の診断の進歩イメージングとバイオマーカー Fabry病患者における画像診断とバイオマーカー

山本沙織, 杉村宏一郎, 鈴木秀明, 青木竜男, 建部俊介, 三浦正暢, 矢尾板信裕, 佐藤遥, 神津克也, 佐藤公雄, 高浪健太郎, 下川宏明

日本心臓病学会学術集会抄録　64回　S13-6　2016年9月
出版者・発行元： (一社)日本心臓病学会
東日本大震災から学んだこと

青木竜男, 中野誠, 二瓶太郎, 羽尾清貴, 小野瀬剛生, 杉村宏一郎, 高橋潤, 福田浩二, 宮田敏, 坂田泰彦, 下川宏明

日本心臓病学会学術集会抄録　64回　SS9-2　2016年9月
出版者・発行元： (一社)日本心臓病学会
血漿中Cyclophilin Aによる冠動脈疾患の長期予後予測

大槻知広, 佐藤公雄, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 二瓶太郎, 高橋潤, 宮田敏, 下川宏明

日本心臓病学会学術集会抄録　64回　O-084　2016年9月
出版者・発行元： (一社)日本心臓病学会
血漿中Adipsin濃度による冠動脈疾患の長期予後予測

大槻知広, 佐藤公雄, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 二瓶太郎, 高橋潤, 宮田敏, 下川宏明

日本心臓病学会学術集会抄録　64回　O-085　2016年9月
出版者・発行元： (一社)日本心臓病学会
Mexiletine -Induced Hypersensitivity Syndrome Complicated by Fulminant Myocarditis

Ryo Konno, Tatsuo Aoki, Koichiro Sugimura, Syunsuke Tatebe, Saori Yamamoto, Nobuhiro Yaoita, Katsuya Kozu, Masatoshi Akiyama, Yoshikatsu Saiki, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　22　(9)　S220-S220　2016年9月

ISSN： 1071-9164

eISSN： 1532-8414
Pulmonary Hypertension in Severe Heart Failure Patients With Implantable Ventricular Assist Device

Tatsuo Aoki, Koichiro Sugimura, Shunsuke Tatebe, Saori Yamamoto, Nobuhiro Yaoita, Kimio Satoh, Masatoshi Akiyama, Shunsuke Kawamoto, Yoshikatsu Saiki, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　22　(9)　S157-S157　2016年9月

ISSN： 1071-9164

eISSN： 1532-8414
Importance of acute hemodynamic effects of inhaled nitric oxide in optimization of heart failure treatment in patients with pulmonary hypertension owing to left heart disease

S. Tatebe, K. Sugimura, T. Aoki, M. Miura, S. Yamamoto, N. Yaoita, H. Suzuki, H. Sato, K. Kozu, K. Satoh, H. Shimokawa

EUROPEAN HEART JOURNAL　37　125-125　2016年8月

ISSN： 0195-668X

eISSN： 1522-9645
Basigin promotes cardiac fibrosis and failure in response to chronic pressure-overload in mice

K. Suzuki, K. Satoh, S. Ikeda, S. Sunamura, T. Otsuki, T. Satoh, J. Omura, R. Kurosawa, M. Nogi, K. Numano, K. Sugimura, S. Miyata, H. Shimokawa

EUROPEAN HEART JOURNAL　37　409-409　2016年8月

ISSN： 0195-668X

eISSN： 1522-9645
Diastolic pulmonary gradientによるGroup2PH患者の予後予測

建部俊介, 杉村宏一郎, 青木竜男, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 佐藤公雄, 下川宏明

呼吸と循環　64　(5)　S25-S25　2016年5月15日
出版者・発行元： (株)医学書院
ISSN： 0452-3458

eISSN： 1882-1200
慢性血栓塞栓性肺高血圧症におけるOFDIを用いた病変形態の観察

青木竜男, 杉村宏一郎, 三浦正暢, 建部俊介, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 佐藤公雄, 下川宏明

呼吸と循環　64　(5)　S29-S29　2016年5月15日
出版者・発行元： (株)医学書院
ISSN： 0452-3458

eISSN： 1882-1200
先天性心疾患に関連した肺高血圧症に対する肺移植

渡邉龍秋, 星川康, 安達理, 新井川弘道, 松田安史, 野田雅史, 建部俊介, 杉村宏一郎, 下川宏明, 斉木佳克, 岡田克典

呼吸と循環　64　(5)　S21-S22　2016年5月
出版者・発行元： (株)医学書院
ISSN： 0452-3458
新規病因蛋白セレノプロテインPによる肺高血圧症促進機構

菊地順裕, 佐藤公雄, 大村淳一, 佐藤大樹, 黒澤亮, 野木正道, 大槻知広, 建部俊介, 青木竜男, 杉村宏一郎, 下川宏明

呼吸と循環　64　(5)　S28-S28　2016年5月
出版者・発行元： (株)医学書院
ISSN： 0452-3458

eISSN： 1882-1200
Efficacy And Safety Of Balloon Pulmonary Angioplasty In Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension

T. Aoki, K. Sugimura, M. Miura, S. Tatebe, S. Yamamoto, N. Yaoita, H. Suzuki, H. Sato, K. Kozu, K. Satoh, H. Shimokawa

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE　193　2016年

ISSN： 1073-449X

eISSN： 1535-4970
OCTによるPHの診断

建部俊介, 杉村宏一郎, 青木竜男, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 佐藤公雄, 下川宏明

呼吸と循環　64　(5)　S7-S8　2016年
出版者・発行元： (株)医学書院
ISSN： 0452-3458

eISSN： 1882-1200
心移植患者における心エコーによる左室拡張末期圧推定指標の有用性

藤原淳子, 青木竜男, 船水康陽, 三木俊, 西條芳文, 杉村宏一郎, 坂田泰彦, 秋山正年, 齋木佳克, 下川宏明

超音波医学　43　(Suppl.)　S602-S602　2016年
出版者・発行元： (公社)日本超音波医学会
ISSN： 1346-1176

eISSN： 1881-9311
当院におけるPTPAの成績と問題点

杉村宏一郎, 青木竜男, 三浦正暢, 建部俊介, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 佐藤公雄, 下川宏明

呼吸と循環　64　(5)　S12-S12　2016年
出版者・発行元： (株)医学書院
ISSN： 0452-3458

eISSN： 1882-1200
慢性血栓塞栓性肺高血圧症に対するバルーン肺動脈形成術の長期予後改善効果

建部俊介, 杉村宏一郎, 青木竜男, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 佐藤公雄, 下川宏明

日本心臓病学会学術集会(Web)　64th　ROMBUNNO.P‐560 (WEB ONLY)-560　2016年
出版者・発行元： (一社)日本心臓病学会
サイクロフィリンAによる冠動脈疾患の長期予後予測

大槻知広, 佐藤公雄, 杉村宏一郎, 青木竜男, 建部俊介, 二瓶太郎, 高橋潤, 宮田敏, 下川宏明

血管　39　(1)　32-32　2016年1月
出版者・発行元：日本心脈管作動物質学会
ISSN： 0911-4637
Takotsubo Cardiomyopathy in a Case of Recurrent Pheochromocytoma

Ryuzaburo Kochi, Tatsuo Aoki, Koichiro Sugimura, Shunsuke Tatebe, Masanobu Miura, Nobuhiro Yaoita, Jun Takahashi, Yasuharu Matsumoto, Kimio Satou, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　21　(10)　S169-S170　2015年10月

ISSN： 1071-9164

eISSN： 1532-8414
Crucial Roles of Rho-kinase, Cyclophilin A and its Receptor, Basigin, for Cardiac Hypertrophy, Fibrosis and Failure-Novel Therapeutic Targets

Kimio Satoh, Kota Suzuki, Shinichiro Sunamura, Tomohiro Otsuki, Toru Shimizu, Shohei Ikeda, Tatsuo Aoki, Shunsuke Tatebe, Koichiro Sugimura, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　21　(10)　S158-S158　2015年10月

ISSN： 1071-9164

eISSN： 1532-8414
Mechanical Circulatory Support for Acute Fulminant Myocarditis: Retrospective Analysis of a Single Center Experience

Masatoshi Akiyama, Shintaro Katahira, Satoshi Kawatsui, Hideki Fujiwara, Shunsuke Kawamoto, Koji Fukuda, Koichiro Sugimura, Hiroaki Shimokawa, Yoshikatsu Saiki

JOURNAL OF CARDIAC FAILURE　21　(10)　S155-S155　2015年10月

ISSN： 1071-9164

eISSN： 1532-8414
Prognostic Impacts of Plasma Levels of Cyclophilin A in Patients with Heart Failure

Tomohiro Otsuki, Kimio Satoh, Koichiro Sugimura, Tatsuo Aoki, Shunsuke Tatebe, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Satoshi Miyata, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　21　(10)　S146-S146　2015年10月

DOI： 10.1016/j.cardfail.2015.08.008 　

ISSN： 1071-9164

eISSN： 1532-8414
Prognostic Impacts of Diuretics in Japanese Patients with Chronic Heart Failure

Koichiro Sugimura, Masanobu Miura, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Nobuhiro Yaoita, Kimio Satoh, Satoshi Miyata, Yasuhiko Sakata, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　21　(10)　S203-S204　2015年10月

DOI： 10.1016/j.cardfail.2015.08.331 　

ISSN： 1071-9164

eISSN： 1532-8414
PET、MRI時代においてガリウムシンチが心サルコイドーシス診療に果たす役割

瀬川将人, 福田浩二, 青木竜男, 中野誠, 近藤正輝, 平野道基, 杉村宏一郎, 下川宏明

日本心臓病学会学術集会抄録　63回　1266-1266　2015年9月
出版者・発行元： (一社)日本心臓病学会
血漿中サイクロフィリンAによる冠動脈疾患の長期予後予測

大槻知広, 佐藤公雄, 杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 二瓶太郎, 高橋潤, 宮田敏, 下川宏明

日本心臓病学会学術集会抄録　63回　797-797　2015年9月
出版者・発行元： (一社)日本心臓病学会
原発性胆汁性肝硬変の生体肝移植後に発症した肺高血圧症の一例

矢尾板信裕, 杉村宏一郎, 後岡広太郎, 三浦正暢, 青木竜男, 建部俊介, 山本沙織, 佐藤遥, 佐藤公雄, 下川宏明

呼吸と循環　63　(8)　S45-S45　2015年8月15日
出版者・発行元： (株)医学書院
ISSN： 0452-3458

eISSN： 1882-1200
肺動脈バルーン形成術がCTEPH患者の代謝腎機能へ及ぼす効果

建部俊介, 杉村宏一郎, 後岡広太郎, 青木竜男, 三浦正暢, 山本沙織, 矢尾板信, 佐藤遥, 佐藤公雄, 下川宏明

呼吸と循環　63　(8)　S32-S32　2015年8月15日
出版者・発行元： (株)医学書院
ISSN： 0452-3458

eISSN： 1882-1200
Selenoprotein p promotes vascular smooth muscle cell proliferation and pulmonary hypertension - a possible novel therapeutic target

N. Kikuchi, K. Satoh, J. Omura, T. Satoh, R. Kurosawa, M. Nogi, S. Tatebe, T. Aoki, K. Sugimura, H. Shimokawa

EUROPEAN HEART JOURNAL　36　1206-1206　2015年8月

ISSN： 0195-668X

eISSN： 1522-9645
Novel strategy for catheter interventional treatment of chronic thromboembolic pulmonary hypertension guided by optical coherence tomography imaging

K. Sugimura, T. Aoki, M. Miura, S. Tatebe, N. Yaoita, H. Satoh, K. Satoh, H. Shimokawa

EUROPEAN HEART JOURNAL　36　1040-1041　2015年8月

ISSN： 0195-668X

eISSN： 1522-9645
成人期に肺動脈性肺高血圧症を発症した肝外性門脈閉塞症シャント術後の1例

建部俊介, 杉村宏一郎, 青木竜男, 三浦正暢, 矢尾板信裕, 佐藤遥, 後岡広太郎, 山本沙織, 佐藤公雄, 下川宏明

日本小児循環器学会雑誌　31　(Suppl.1)　s1-375　2015年7月
出版者・発行元： (NPO)日本小児循環器学会
ISSN： 0911-1794

eISSN： 2187-2988
経カテーテル大動脈弁留置術における心臓リハビリの役割~フレイル(Frailty)の認識と呼吸・運動機能管理の重要性~

松本泰治, 竹内雅史, 高橋潤, 杉村宏一郎, 三浦正暢, 上月正博, 下川宏明

日本心臓病学会学術集会(Web)　63rd　2015年
Basiginは血管平滑筋細胞増殖を促進し,肺高血圧症を悪化させる

佐藤公雄, 鈴木康太, 大村淳一, 菊池順裕, 矢尾板信裕, 杉村宏一郎, 福本義弘, 中村一文, 伊藤浩, 下川宏明

呼吸と循環　63　(8)　S35-S36　2015年
出版者・発行元： (株)医学書院
ISSN： 0452-3458

eISSN： 1882-1200
サイクロフィリンA受容体Basiginによる肺高血圧症促進機構~基礎研究の臨床応用~

佐藤公雄, 鈴木康太, 大村淳一, 菊池順裕, 佐藤大樹, 黒澤亮, 矢尾板信裕, 杉村宏一郎, 福本義弘, 中村一文, 伊藤浩, 下川宏明

血管　38　(1)　42-42　2015年
出版者・発行元：日本心脈管作動物質学会
ISSN： 0911-4637
慢性血栓塞栓性肺高血圧症の新規病因蛋白TAFIの発見とその機能的意義

矢尾板信裕, 佐藤大樹, 佐藤公雄, 杉村宏一郎, 大村淳一, 福本義弘, 下川宏明

血管　38　(1)　32-32　2015年
出版者・発行元：日本心脈管作動物質学会
ISSN： 0911-4637
当院補助人工心臓センター開設までの経緯から振り返る重症心不全治療チーム体制の構築

秋山正年, 片平晋太郎, 河津聡, 藤原英記, 川本俊輔, 杉村宏一郎, 福田浩二, 高橋潤, 下川宏明, 齋木佳克

人工臓器(日本人工臓器学会)　44　(2)　S-23　2015年
出版者・発行元： (一社)日本人工臓器学会
ISSN： 0300-0818

eISSN： 1883-6097
当院におけるFabry病診療の現状

杉村宏一郎, 青木竜男, 建部俊介, 三浦正暢, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会(Web)　63rd　334-334　2015年
出版者・発行元： (一社)日本心臓病学会
多核巨細胞を認めた劇症型心筋炎の一例

田中祥朗, 青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 矢尾板信裕, 佐藤遥, 下川宏明

日本心臓病学会学術集会(Web)　63rd　ROMBUNNO.P‐565 (WEB ONLY)-1150　2015年
出版者・発行元： (一社)日本心臓病学会
末梢型慢性血栓塞栓性肺高血圧症の病変形態―OFDIによる検討―

神津克也, 青木竜男, 杉村宏一郎, 三浦正暢, 建部俊介, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 佐藤公雄, 下川宏明

日本循環器学会東北地方会(Web)　161st　(Suppl.)　TOHOKU161,81 (WEB ONLY)-S159　2015年
出版者・発行元： (一社)日本脈管学会
ISSN： 0387-1126

eISSN： 1880-8840
慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術の効果-画像診断を用いた評価-

青木竜男, 杉村宏一郎, 建部俊介, 三浦正暢, 山本沙織, 矢尾板信裕, 鈴木秀明, 佐藤遥, 神津克也, 佐藤公雄, 大田英揮, 下川宏明

脈管学(Web)　55　(supplement)　2015年

ISSN： 1880-8840
Percutaneous Transluminal Pulmonary Angioplasty Improves Hemodynamics and Right Ventricular Function in Patients with Chronic Thromboembolic Pulmonary Hypertension -One Year Follow-up Study

Masanobu Miura, Koichiro Sugimura, Kotaro Nochioka, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Nobuhiro Yaoita, Haruka Sato, Kimio Sato, Hiroaki Shimokawa

CIRCULATION　130　2014年11月

ISSN： 0009-7322

eISSN： 1524-4539
Importance of Acute Hemodynamic Effects of Inhaled Nitric Oxide in Optimization of Heart Failure Treatment in Patients with Pulmonary Hypertension due to Left Heart Disease

Shunsuke Tatebe, Koichiro Sugimura, Kotaro Nochioka, Tatsuo Aoki, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Haruka Sato, Kimio Satoh, Hiroaki Shimokawa

CIRCULATION　130　2014年11月

ISSN： 0009-7322

eISSN： 1524-4539
Cyclophilin a and Basigin Promotes Pulmonary Hypertension by Inducing Inflammation and Vascular Smooth Muscle Cell Proliferation

Kimio Satoh, Kota Suzuki, Junichi Omura, Nobuhiro Kikuchi, Satoshi Miyata, Tatsuro Minami, Koichiro Sugimura, Tatsuo Aoki, Kotaro Nochioka, Shunsuke Tatebe, Masanobu Miura, Saori Yamamoto, Toru Shimizu, Shohei Ikeda, Nobuhiro Yaoita, Yoshihiro Fukumoto, Kazufumi Nakamura, Hiroshi Ito, Kenji Kadomatsu, Hiroaki Shimokawa

CIRCULATION　130　2014年11月

ISSN： 0009-7322

eISSN： 1524-4539
Percutaneous Transluminal Balloon Angioplasty Ameliorates Metabolic and Renal Dysfunctions Associated With Hemodynamic Improvement in Patients With Chronic Thromboembolic Pulmonary Hypertension

Shunsuke Tatebe, Koichiro Sugimura, Kotaro Nochioka, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Haruka Sato, Kimio Satoh, Hiroaki Shimokawa

CIRCULATION　130　2014年11月

ISSN： 0009-7322

eISSN： 1524-4539
Effects of Conventional Medical Therapy Prior to Percutaneous Transluminal Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension

Tatsuo Aoki, Koichiro Sugimura, Nobuhiro Yaoita, Saori Yamamoto, Shunsuke Tatebe, Masanobu Miura, Kotaro Nochioka, Haruka Sato, Kimio Sato, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　20　(10)　S163-S163　2014年10月

ISSN： 1071-9164

eISSN： 1532-8414
A Case Report of Successful Immunosuppressive Therapy for Chronic Myocarditis

Haruka Sato, Tatsuo Aoki, Koichiro Sugimura, Kotaro Nochioka, Shunsuke Tatebe, Saori Yamamoto, Masanobu Miura, Nobuhiro Yaoita, Kimio Satoh, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　20　(10)　S206-S206　2014年10月

ISSN： 1071-9164

eISSN： 1532-8414
Two Cases of Pulmonary Hypertension Associated with Portosystemic Shunt

Haruka Sato, Tatsuo Aoki, Masanobu Miura, Nobuhiro Yaoita, Saori Yamamoto, Syunsuke Tatebe, Kotaro Nochioka, Kimio Satoh, Koichiro Sugimura, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　20　(10)　S196-S196　2014年10月

ISSN： 1071-9164

eISSN： 1532-8414
Impact of Implantable Ventricular Assist Devices on Long-term Prognosis of Patients with Advanced Heart Failure

Tatsuo Aoki, Koichiro Sugimura, Kotaro Nochioka, Shunsuke Tatebe, Saori Yamamoto, Masanobu Miura, Kimio Sato, Masatoshi Akiyama, Yoshikatsu Saiki, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　20　(10)　S203-S204　2014年10月

ISSN： 1071-9164

eISSN： 1532-8414
肺高血圧症の診断と治療における光干渉断層法の有用性

杉村宏一郎, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 三浦正暢, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録(CD-ROM)　62nd　ROMBUNNO.VW4-5-5　2014年9月2日
出版者・発行元： (一社)日本心臓病学会
慢性心筋炎に免疫抑制療法が著効した一例

佐藤遥, 青木竜男, 杉村宏一郎, 後岡広太郎, 建部俊介, 山本沙織, 三浦正暢, 矢尾板信裕, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録(CD-ROM)　62nd　ROMBUNNO.P-661-661　2014年9月2日
出版者・発行元： (一社)日本心臓病学会
慢性肺血栓塞栓性肺高血圧症に対する薬物療法の効果

青木竜男, 杉村宏一郎, 矢尾板信裕, 山本沙織, 建部俊介, 三浦正暢, 後岡広太郎, 佐藤遥, 佐藤公雄, 下川宏明

日本心臓病学会学術集会抄録(CD-ROM)　62nd　ROMBUNNO.P-362-362　2014年9月2日
出版者・発行元： (一社)日本心臓病学会
Usefulness of optical coherence tomography imaging in chronic thromboembolic pulmonary hypertension

K. Sugimura, K. Nochioka, S. Tatebe, S. Yamamoto, M. Miura, T. Kato, K. Satoh, H. Shimokawa

EUROPEAN HEART JOURNAL　35　917-917　2014年9月

ISSN： 0195-668X

eISSN： 1522-9645
Percutaneous transluminal pulmonary angioplasty ameliorates metabolic and renal dysfunctions associated with hemodynamic improvement in patients with chronic thromboembolic pulmonary hypertension

S. Tatebe, K. Sugimura, K. Nochioka, M. Miura, Y. Yamamoto, K. Satoh, H. Shimokawa

EUROPEAN HEART JOURNAL　35　915-915　2014年9月

ISSN： 0195-668X

eISSN： 1522-9645
重症心不全の治療の進歩植込み型補助人工心臓治療の現況植込み後再入院を要する治療の現状と対策

秋山正年, 秋場美紀, 河津聡, 川本俊輔, 後岡広太郎, 杉村宏一郎, 福田浩二, 齋木佳克, 下川宏明

日本心臓病学会学術集会抄録　62回　S10-2　2014年9月
出版者・発行元： (一社)日本心臓病学会
Decreased cerebral blood flow and BDNF levels are associated with depression and memory impairment in patients with heart failure -Brain Assessment and Investigation in Heart Failure Trial (B-HeFT)-

H. Suzuki, Y. Matsumoto, H. Ota, K. Sugimura, J. Takahashi, K. Ito, Y. Fukumoto, R. Kawashima, Y. Taki, H. Shimokawa

EUROPEAN HEART JOURNAL　35　13-13　2014年9月

ISSN： 0195-668X

eISSN： 1522-9645
慢性血栓塞栓性肺高血圧症におけるThrombin Activated Fibrinolysis Inhibitorの関与

矢尾板信裕, 福本義弘, 杉村宏一郎, 河村剛至, 堀内久徳, 下川宏明

心臓　46　(7)　985-985　2014年7月
出版者・発行元： (公財)日本心臓財団
DOI： 10.11281/shinzo.46.985 　

ISSN： 0586-4488
Basigin Promotes Vascular Smooth Muscle Proliferation and Pulmonary Hypertension

Kimio Satoh, Kota Suzuki, Junichi Omura, Nobuhiro Kikuchi, Satoshi Miyata, Tatsuro Minami, Koichiro Sugimura, Tatsuo Aoki, Kotaro Nochioka, Shunsuke Tatebe, Masanobu Miura, Saori Yamamoto, Toru Shimizu, Nobuhiro Yaoita, Yoshihiro Fukumoto, Kazufumi Nakamura, Hiroshi Ito, Kenji Kadomatsu, Hiroaki Shimokawa

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY　34　2014年5月

ISSN： 1079-5642

eISSN： 1524-4636
肺動脈リモデリングは肺高血圧症発症前から出現する:光干渉断層疱を用いた検討

戴哲皓, 福本義弘, 建部俊介, 杉村宏一郎, 三浦裕, 後岡広太郎, 青木竜男, 山本沙織, 矢尾板信裕, 佐藤公雄, 下川宏明

東北医学雑誌　126　(1)　100-101　2014年
出版者・発行元：東北医学会
ISSN： 0040-8700
Percutaneous Transluminal Balloon Angioplasty Ameliorates Metabolic And Renal Dysfunctions Associated With Hemodynamic Improvement In Patients With Chronic Thromboembolic Pulmonary Hypertension

S. Tatebe, Y. Fukumoto, K. Sugimura, K. Nochioka, M. Miura, S. Yamamoto, K. Satoh, H. Shimokawa

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE　189　2014年

ISSN： 1073-449X

eISSN： 1535-4970
肺高血圧症を合併したACHD診療の治療戦略

建部俊介, 杉村宏一郎, 後岡広太郎, 三浦正暢, 山本沙織, 佐藤公雄, 安達理, 岡田克典, 木村正人, 秋葉美紀, 齋木佳克, 近藤丘, 下川宏明

日本心臓病学会学術集会抄録(CD-ROM)　62nd　S11-2　2014年
出版者・発行元： (一社)日本心臓病学会
末梢型慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術の有用性

青木竜男, 杉村宏一郎, 後岡広太郎, 三浦正暢, 建部俊介, 山本沙織, 佐藤公雄, 下川宏明

日本循環器学会東北地方会(Web)　158th　2014年
慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術と右室機能に関する検討

砂村慎一郎, 三浦正暢, 杉村宏一郎, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 矢尾板信裕, 佐藤遥, 佐藤公雄, 下川宏明

脈管学(Web)　54　(Supplement)　2014年

ISSN： 1880-8840
Basigin Promotes Inflammation and Pulmonary Hypertension Through Synergistic Cooperation With Extracellular Cyclophilin A

Kimio Satoh, Yoshihiro Fukumoto, Koichiro Sugimura, Tatsuo Aoki, Kotaro Nochioka, Shunsuke Tatebe, Masanobu Miura, Saori Yamamoto, Toru Shimizu, Nobuhiro Yaoita, Tatsuro Minami, Satoshi Miyata, Kota Suzuki, Nobuhiro Kikuchi, Kazufumi Nakamura, Hiroshi Ito, Kenji Kadomatsu, Hiroaki Shimokawa

CIRCULATION　128　(22)　2013年11月

ISSN： 0009-7322

eISSN： 1524-4539
Percutaneous Transluminal Balloon Angioplasty Improves Metabolic and Renal Dysfunctions Associated with Hemodynamic Improvement in Patients with Chronic Thromboembolic Pulmonary Hypertension

Shunsuke Tatebe, Yoshihiro Fukumoto, Koichiro Sugimura, Kotaro Nochioka, Masanobu Miura, Saori Yamamoto, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　19　(10)　S146-S146　2013年10月

ISSN： 1071-9164

eISSN： 1532-8414
Potential Involvement of Functional Tricuspid Regurgitation in the Diagnostic Error to Assess Pulmonary Arterial Pressure by Doppler Echocardiography

Saori Yamamoto, Yasuharu Matsumoto, Yoshihiro Fukumoto, Kotaro Nochioka, Masanobu Miura, Shunsuke Tetebe, Koichiro Sugimura, Tomoyuki Suzuki, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　19　(10)　S174-S174　2013年10月

ISSN： 1071-9164

eISSN： 1532-8414
原発性副甲状腺機能亢進症の術後に心不全を呈し、心臓にび漫性の石灰化を認めた1例

高木英誠, 大田英揮, 青木竜夫, 杉村宏一郎, 福本義宏, 高瀬圭, 下川宏明, 高橋昭喜

日独医報　58　(1)　135-136　2013年10月
出版者・発行元：バイエル薬品(株)
ISSN： 0912-0351
Interactions between the Heart and the Brain in Heart Failure Patients Assessed by MRI -Interim Results from the B-HeFT Study-

Hideaki Suzuki, Yasuharu Matsumoto, Jun Takahashi, Ryuji Tsuburaya, Koichiro Sugimura, Kenta Ito, Yoshihiro Fukumoto, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　19　(10)　S132-S132　2013年10月

ISSN： 1071-9164

eISSN： 1532-8414
Triglyceride Deposit Cardiomyovasculopathy with Severe Heart Failure

Naoko Takada, Koichiro Sugimura, Yoshihiro Fukumoto, Kotaro Nochioka, Shunsuke Tatebe, Saori Yamamoto, Masanobu Miura, Kimio Satoh, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　19　(10)　S175-S175　2013年10月

ISSN： 1071-9164

eISSN： 1532-8414
Usefulness of optical coherence tomography for diagnosis and treatment in chronic thromboembolic pulmonary hypertension

Koichiro Sugimura, Yoshihiro Fukumoto, Yutaka Miura, Kotaro Nochioka, Shunsuke Tatebe, Saori Yamamoto, Masanobu Miura, Kimio Satoh, Hiroaki Shimokawa

EUROPEAN RESPIRATORY JOURNAL　42　2013年9月

ISSN： 0903-1936

eISSN： 1399-3003
Enhanced [18F]fluorodeoxyglucose accumulation in the right ventricular free wall predicts long-term prognosis of patients with pulmonary hypertension

S. Tatebe, Y. Fukumoto, K. Sugimura, K. Satoh, Y. Miura, K. Nochioka, M. Miura, M. Oikawa-Wakayama, Y. Kagaya, H. Shimokawa

EUROPEAN HEART JOURNAL　34　35-35　2013年8月

ISSN： 0195-668X

eISSN： 1522-9645
慢性活動性Epstein-Barr感染症に合併した肺高血圧症の一例

杉村宏一郎, 後岡広太郎, 建部俊介, 山本沙織, 三浦正暢, 佐藤公雄, 下川宏明

日本心臓病学会誌　8　(Supplement 1)　412-412　2013年
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
肺高血圧の重症度と予後予測のための新規バイオマーカー・サイクロフィリンA

佐藤公雄, 福本義弘, 杉村宏一郎, 三浦裕, 青木竜男, 後岡広太郎, 建部俊介, 山本沙織, 清水亨, 矢尾板信裕, 中村一文, 伊藤浩, 下川宏明

血管　36　(1)　32-32　2013年
出版者・発行元：日本心脈管作動物質学会
ISSN： 0911-4637
Prognostic Impact Of Enhanced [18f]fluorodeoxyglucose Accumulation In The Right Ventricular Free Wall In Patients With Pulmonary Hypertension

S. Tatebe, Y. Fukumoto, K. Sugimura, K. Satoh, Y. Miura, K. Nochioka, T. Aoki, M. Miura, Y. Kagaya, S. Yamamoto, M. Wakayama, H. Shimokawa

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE　187　2013年

ISSN： 1073-449X

eISSN： 1535-4970
慢性血栓塞栓性肺高血圧症の末梢肺動脈における光干渉断層法を用いた評価

杉村宏一郎, 福本義弘, 三浦裕, 後岡広太郎, 建部俊介, 三浦正暢, 佐藤公雄, 下川宏明

日本循環器学会東北地方会(Web)　156th　2013年
Prognostic Significance of Enhanced [F-18]Fluorodeoxyglucose Accumulation in the Right Ventricular Free Wall in Patients With Pulmonary Hypertension

Shunsuke Tatebe, Yoshihiro Fukumoto, Koichiro Sugimura, Kimio Satoh, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Saori Yamamoto, Minako Oikawa-Wakayama, Yutaka Kagaya, Hiroaki Shimokawa

CIRCULATION　126　(21)　2012年11月

ISSN： 0009-7322

eISSN： 1524-4539
Plasma Cyclophilin A as a Novel Biomarker for Pulmonary Hypertension in Humans

Kimio Satoh, Yoshihiro Fukumoto, Koichiro Sugimura, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Toru Shimizu, Kazufumi Nakamura, Hiroshi Ito, Hiroaki Shimokawa

CIRCULATION　126　(21)　2012年11月

ISSN： 0009-7322

eISSN： 1524-4539
Percutaneous Transluminal Pulmonary Angioplasty Markedly Improves Pulmonary Hemodynamics and Long-Term Prognosis of Patients with Distal-Type Chronic Thromboembolic Pulmonary Hypertension

Yutaka Miura, Koichiro Sugimura, Yoshihiro Fukumoto, Kimio Satoh, Kotaro Nochioka, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Hiroaki Shimokawa

CIRCULATION　126　(21)　2012年11月

ISSN： 0009-7322

eISSN： 1524-4539
A Rare Case with Fatal Pulmonary Tumor Thrombotic Microangiopathy

Yutaka Miura, Yoshihiro Fukumoto, Koichiro Sugimura, Kimio Sato, Kotaro Nochioka, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　18　(10)　S184-S184　2012年10月

ISSN： 1071-9164
Prognostic Impact of Enhanced [F-18]Fluorodeoxyglucose Accumulation in the Right Ventricular Free Wall in Patients with Pulmonary Hypertension

Shunsuke Tatebe, Yoshihiro Fukumoto, Koichiro Sugimura, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Saori Yamamoto, Minako Oikawa-Wakayama, Yutaka Kagaya, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　18　(10)　S162-S162　2012年10月

ISSN： 1071-9164
Clinical Profiles of Chronic Heart Failure with Adult Congenital Heart Disease

Shunsuke Tatebe, Yoshihiro Fukumoto, Koichiro Sugimura, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Saori Yamamoto, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　18　(10)　S156-S156　2012年10月

ISSN： 1071-9164
Effects of Corticosteroid Therapy on Long-term Survival of Patients with Cardiac Sarcoidosis

Yutaka Miura, Yoshihiro Fukumoto, Koichiro Sugimura, Kimio Sato, Kotaro Nochioka, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　18　(10)　S158-S158　2012年10月

ISSN： 1071-9164
Prognostic Impact of Pulmonary Circulation in Patients with Left Ventricular Diastolic Dysfunction

Yoshihiro Fukumoto, Shunsuke Tatebe, Koichiro Sugimura, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Saori Yamamoto, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　18　(10)　S132-S132　2012年10月

ISSN： 1071-9164
Percutaneous Transluminal Pulmonary Angioplasty Markedly Ameliorates Severe Right Heart Failure in Patients with Distal-type Chromic Thromboembolic Pulmonary Hypertension

Koichiro Sugimura, Yoshihiro Fukumoto, Kimio Satoh, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　18　(10)　S131-S131　2012年10月

ISSN： 1071-9164
Rho-kinase Activity in Circulating Leukocytes as a Novel Biomarker of Heart Failure

Zhulanqiqge Do E, Yoshihiro Fukumoto, Koichiro Sugimura, Yutaka Miura, Shunsuke Tatebe, Saori Yamamoto, Tatsuo Aoki, Kotaro Nochioka, Kimio Satoh, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　18　(10)　S149-S149　2012年10月

ISSN： 1071-9164
Remarkable effectiveness of percutaneous transluminal pulmonary angioplasty for hemodynamics and long-term prognosis in patients with distal-type chronic thromboembolic pulmonary hypertension

K. Sugimura, Y. Fukumoto, K. Satoh, Y. Miura, K. Nochioka, T. Aoki, S. Tatebe, S. Yamamoto, H. Shimokawa

EUROPEAN HEART JOURNAL　33　47-47　2012年8月

ISSN： 0195-668X
心内修復術後に肺高血圧症を合併した成人先天性心疾患患者の臨床像

建部俊介, 福本義弘, 杉村宏一郎, 佐藤公雄, 三浦裕, 後岡広太郎, 青木竜男, 山本沙織, 下川宏明

日本心臓病学会誌　7　(Supplement 1)　171-171　2012年
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
成人先天性心疾患患者に合併した慢性心不全の臨床的特徴

建部俊介, 福本義弘, 杉村宏一郎, 佐藤公雄, 三浦裕, 後岡広太郎, 青木竜男, 山本沙織, 下川宏明

日本小児循環器学会雑誌　28　(Supplement)　s348-s348　2012年
出版者・発行元： (NPO)日本小児循環器学会
ISSN： 0911-1794

eISSN： 2187-2988
左心系心疾患による肺高血圧症の診断ポイント

建部俊介, 福本義弘, 杉村宏一郎, 佐藤公雄, 三浦裕, 後岡広太郎, 青木竜男, 山本沙織, 下川宏明

Therapeutic Research　33　(10)　1529-1531　2012年
出版者・発行元：ライフサイエンス出版(株)
ISSN： 0289-8020

詳細を見る詳細を閉じる

左心系心疾患による肺高血圧症(pc-PH)の診断ポイントについて検討した。右心カテーテルにて血行動態評価を行った1685例中、左心系心疾患を有しNYHA2度以上である安定慢性心不全患者676例を対象とした。58例にpc-PHを認め、58例がreactive pc-PH、残り100例がpassive pc-PHであった。単変量ロジスティック回帰では、年齢、性別、BMI、高血圧の有無、カルシウム拮抗薬の有無がreactive pc-PHと関連したが、多変量解析では女性が唯一の独立した規定因子であった。125例が死亡し、22例がreactive pc-PH、24例がpassive pc-PHであった。多変量COX比例ハザード解析ではPVRの上昇が死亡の独立した予後規定因子であった。pc-PHはnon-PH群より有意に予後不良で、reactive pc-PHはpassive pc-PHより予後不良であった。
肺高血圧症を合併したCombined Pulmonary Fibrosis and Emphysema Syndrome(CPFE)の3症例

青木竜男, 杉村宏一郎, 福本義弘, 佐藤公雄, 三浦裕, 後岡広太郎, 建部俊介, 山本沙織, 下川宏明

日本循環器学会東北地方会(Web)　154th　2012年
重症肺高血圧症を来したpulmonary tumor thrombotic microangiopathy(PTTM)の一例

青木竜男, 佐藤公雄, 杉村宏一郎, 三浦裕, 後岡広太郎, 建部俊介, 山本沙織, 福本義弘, 下川宏明, 笠島敦子

日本循環器学会東北地方会(Web)　154th　2012年
9年間のエポプロステノール治療後に門脈圧亢進症を呈した難治性肺動脈性肺高血圧症の1例

杉村宏一郎, 青木竜男, 福本義弘, 三浦裕, 後岡広太郎, 建部俊介, 山本沙織, 佐藤公雄, 下川宏明

日本循環器学会東北地方会(Web)　155th　2012年
Cyclophilin A Plays an Important Role in the Pathogenesis of Pulmonary Arterial Hypertension in Humans - Involvement of Rho-Kinase Pathway

Kimio Satoh, Yoshihiro Fukumoto, Koichiro Sugimura, Yutaka Miura, Kotaro Nochioka, Tatsuo Aoki, Shunsuke Tatebe, Saori Yamamoto, Toru Shimizu, Kazufumi Nakamura, Hiroaki Shimokawa

CIRCULATION　124　(21)　2011年11月

ISSN： 0009-7322
Prognostic Impact of Myocardial Fibrosis in Patients with Heart Failure - Comparison between Preserved and Reduced Ejection Fraction Heart Failure

Tatsuo Aoki, Yoshihiro Fukumoto, Koichiro Sugimura, Kimio Satoh, Yutaka Miura, Kotaro Nochioka, Shunsuke Tatebe, Saori Miyamichi-Yamamoto, Masaharu Nakayama, Hiroaki Shimokawa

CIRCULATION　124　(21)　2011年11月

ISSN： 0009-7322
Percutaneous Transluminal Pulmonary Angioplasty Markedly Improves Pulmonary Hemodynamics in Patients with Distal-Type Chronic Thromboembolic Pulmonary Hypertension

Tatsuo Aoki, Yoshihiro Fukumoto, Koichiro Sugimura, Kimio Satoh, Yutaka Miura, Kotaro Nochioka, Shunsuke Tatebe, Saori Miyamichi-Yamamoto, Hiroaki Shimokawa

CIRCULATION　124　(21)　2011年11月

ISSN： 0009-7322
当科における心サルコイドーシスの特徴

三浦裕, 福本義弘, 杉村宏一郎, 佐藤公雄, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 下川宏明

日本サルコイドーシス/肉芽腫性疾患学会雑誌　31　(サプリメント号)　41-41　2011年10月
出版者・発行元：日本サルコイドーシス
ISSN： 1883-1273
Clinical characteristics and prognosis of patients with post-capillary reactive pulmonary hypertension caused by left heart disease

S. Tatebe, Y. Fukumoto, K. Sugimura, K. Satoh, Y. Miura, K. Nochioka, S. Yamamoto, H. Shimokawa

EUROPEAN HEART JOURNAL　32　917-917　2011年8月

ISSN： 0195-668X
Optical coherence tomography is superior to intravascular ultrasound for diagnosis of distal-type chronic thromboembolic pulmonary hypertension

S. Tatebe, Y. Fukumoto, K. Sugimura, K. Satoh, Y. Miura, K. Nochioka, S. Yamamoto, H. Shimokawa

EUROPEAN HEART JOURNAL　32　447-447　2011年8月

ISSN： 0195-668X
Marked effectiveness of percutaneous transluminal pulmonary angioplasty in patients with distal-type chronic thromboembolic pulmonary hypertension

K. Sugimura, Y. Fukumoto, K. Satoh, Y. Miura, S. Tatebe, S. Yamamoto, H. Shimokawa

EUROPEAN HEART JOURNAL　32　445-445　2011年8月

ISSN： 0195-668X
膠原病性肺動脈性肺高血圧症に対する積極的免疫抑制療法の有効性

山本沙織, 福本義弘, 杉村宏一郎, 石井智徳, 佐藤公雄, 後岡広太郎, 三浦裕, 建部俊介, 青木竜男, 下川宏明

日本心臓病学会誌　6　(Supplement 1)　281-281　2011年
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
新規酸化ストレス増幅蛋白サイクロフィリンAによる心血管病促進機構

佐藤公雄, 福本義弘, 杉村宏一郎, 三浦裕, 後岡広太郎, 建部俊介, 山本沙織, 青木竜男, 下川宏明

脈管学　51　(Supplement)　S99-S99　2011年
出版者・発行元： (一社)日本脈管学会
ISSN： 0387-1126

eISSN： 1880-8840
心内修復術後の肺高血圧合併成人先天性心疾患患者の臨床像と予後

建部俊介, 福本義弘, 杉村宏一郎, 佐藤公雄, 三浦裕, 山本沙織, 下川宏明

日本小児循環器学会雑誌　27　(Supplement)　s217-s217　2011年
出版者・発行元： (NPO)日本小児循環器学会
ISSN： 0911-1794

eISSN： 2187-2988
末梢型慢性血栓塞栓性肺高血圧症に対する経皮的肺動脈形成術の著明な治療効果

杉村宏一郎, 福本義弘, 佐藤公雄, 三浦裕, 後岡広太郎, 建部俊介, 山本沙織, 下川宏明

日本心臓病学会誌　6　(Supplement 1)　259-259　2011年
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
光干渉断層撮影(OCT)による末梢型慢性血栓塞栓性肺高血圧症(CTEPH)の診断

福本義弘, 杉村宏一郎, 佐藤公雄, 建部俊介, 三浦裕, 後岡広太郎, 山本沙織, 下川宏明

Therapeutic Research　32　(10)　1276-1278　2011年
出版者・発行元：ライフサイエンス出版(株)
ISSN： 0289-8020

詳細を見る詳細を閉じる

2009年2月〜2010年12月に入院し、肺高血圧が疑われた連続44例の診断に対するoptical coherence tomography(OCT)の有用性について検討した。対象の内訳は肺動脈性肺高血圧症(PAH)が26例、末梢型慢性血栓塞栓症肺高血圧症(CTEPH)が13例、コントロールが5例で、全例に右心カテーテル検査と肺動脈OCTが施行された。その結果、血行動態に関してはPAHとCTEPHでは肺動脈楔入圧、平均肺動脈圧、心係数、肺血管抵抗に有意差はみられなかった。また、OCT所見ではコントロールとPAH群では1mm以上の血管に閉塞は認められなかった。一方、対照的にCTEPH群のOCT所見では残り2群と違い、CTEPH群で血栓と考えられた血管閉塞が44%認められ、血管内腔のflapが67%認められた。尚、ほかに網膜様構造や血栓内膜摘除後の残存血栓の存在などが証明された。
経皮的肺動脈形成術にてPGI2持続静注療法から離脱しえた慢性血栓塞栓性肺高血圧症の一例

杉村宏一郎, 福本義弘, 佐藤公雄, 三浦裕, 後岡広太郎, 青木竜男, 建部俊介, 山本沙織, 下川宏明, 宮本卓也, 久保田功

日本循環器学会東北地方会(Web)　153rd　2011年
第4回心不全陽圧治療研究会当科におけるAutoSVの検討

杉村宏一郎, 建部, 俊介, 福本, 義弘, 及川, 美奈子, 佐藤, 公雄, 中野, 誠, 宮道, 沙織, 下川宏明

心臓　42　(11)　1519-1524　2010年11月

DOI： 10.11281/shinzo.42.1519 　
Intensive Immunosuppressive Therapy Improves Pulmonary Hemodynamics in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Saori Miyamichi, Yoshihiro Fukumoto, Koichiro Sugimura, Kimio Satoh, Makoto Nakano, Yutaka Miura, Shunsuke Tatebe, Minako Oikawa, Tomonori Ishii, Hiroaki Shimokawa

CIRCULATION　122　(21)　2010年11月

ISSN： 0009-7322
Clinical Characteristics and Prognostic Impacts of Post-Capillary Reactive Pulmonary Hypertension in Patients with Left Heart Disease

Shunsuke Tatebe, Yoshihiro Fukumoto, Koichiro Sugimura, Kimio Satoh, Yutaka Miura, Saori Miyamichi, Minako Oikawa, Hiroaki Shimokawa

CIRCULATION　122　(21)　2010年11月

ISSN： 0009-7322
Cyclophilin a Mediates Pulmonary Vascular Remodeling by Rho-Kinase Activation in Patients With Pulmonary Hypertension

Kimio Satoh, Yoshihiro Fukumoto, Koichiro Sugimura, Shunsuke Tatebe, Yutaka Miura, Saori Miyamichi, Kazufumi Nakamura, Patrizia Nigro, Bradford C. Berk, Hiroaki Shimokawa

CIRCULATION　122　(21)　2010年11月

ISSN： 0009-7322
心筋の線維化が予後に与える影響

青木竜男, 福本義弘, 杉村宏一郎, 及川美奈子, 佐藤公雄, 中野誠, 中山雅晴, 下川宏明

心臓　42　(10)　1368-1368　2010年10月
出版者・発行元： (公財)日本心臓財団
ISSN： 0586-4488

eISSN： 2186-3016
Optical coherence tomography as a novel differential diagnostic tool for chronic thromboembolic pulmonary hypertension from pulmonary arterial hypertension

S. Tatebe, Y. Fukumoto, K. Sugimura, M. Nakano, S. Miyamichi, K. Satoh, M. Oikawa, H. Shimokawa

EUROPEAN HEART JOURNAL　31　630-630　2010年9月

ISSN： 0195-668X
血栓内膜摘除術後の残存肺高血圧に肺動脈バルーン拡張術が有効であった慢性肺血栓塞栓性肺高血圧の一例

佐藤公雄, 福本義弘, 杉村宏一郎, 三浦裕, 建部俊介, 宮道沙織, 下川宏明

日本心臓病学会誌　5　(Supplement 1)　420-420　2010年
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
長期入院加療を必要とした重症慢性血栓塞栓性肺高血圧症に経皮的肺動脈形成術が著効した一例

杉村宏一郎, 福本義弘, 佐藤公雄, 建部俊介, 宮道沙織, 中野誠, 及川美奈子, 下川宏明

日本心臓病学会誌　5　(Supplement 1)　390-390　2010年
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
大動脈炎症候群による肺動脈狭窄に両側肺動脈バイパス施行後,再狭窄に対する肺動脈バルーン形成術が有効であった1例

建部俊介, 福本義弘, 杉村宏一郎, 佐藤公雄, 中野誠, 三浦裕, 宮道沙織, 下川宏明

日本心臓病学会誌　5　(Supplement 1)　230-230　2010年
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
重症慢性血栓塞栓性肺高血圧症に経皮的肺動脈形成術が著効した一例

杉村宏一郎, 福本義弘, 佐藤公雄, 及川美奈子, 中野誠, 建部俊介, 宮道沙織, 下川宏明

日本循環器学会東北地方会(Web)　150th　2010年
末梢型慢性血栓塞栓性肺高血圧症(CTEPH)に対する経皮的肺動脈形成術(PTPA)の有効性

杉村宏一郎, 福本義弘, 佐藤公雄, 三浦裕, 建部俊介, 宮道沙織, 下川宏明

日本循環器学会東北地方会(Web)　151st　2010年
肺循環の最新の治療肺高血圧症の新たな予後規定因子の検索臨床的知見から

三浦裕, 福本義弘, 中野誠, 佐藤公雄, 杉村宏一郎, 及川美奈子, 下川宏明

日本臨床生理学会雑誌　39　(5)　74-74　2009年9月
出版者・発行元：日本臨床生理学会
ISSN： 0286-7052

eISSN： 2435-1695
肺高血圧症の診断における一酸化窒素吸入試験の意義

杉村宏一郎, 福本義弘, 及川美奈子, 佐藤公雄, 中野誠, 三浦裕, 下川宏明

日本心臓病学会誌　4　(Suppl.I)　416-416　2009年8月
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
PJ-477 Diagnostic Usefulness of Vasodilator Test with Inhaled Nitric Oxide in Patients with Pulmonary Veno-Occlusive Disease(PJ080,Pulmonary Circulation 1 (H),Poster Session (Japanese),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)

Sugimura Koichiro, Fukumoto Yoshihiro, Oikawa Minako, Satoh Kimio, Nakano Makoto, Miura Yutaka, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　73　666-666　2009年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PE-349 Gender Difference in the Responsiveness to Corticosteroid Therapy in Patients with Cardiac Sarcoidosis(PE059,Heart Failure (Treatment) 2 (M),Poster Session (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)

Nakayama Masaharu, Osaki Shizuka, kato Takeshi, Sugimura Koichiro, Oikawa Minako, Fukumoto Yoshihiro, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　73　487-487　2009年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PE-444 Prognostic Impact of Myocardial Fibrosis in Systolic Heart Failure : New Aspect of Usefulness of Myocardial Biopsy(PE075,Heart Failure (Pathophysiology) (M),Poster Session (English),The 73rd Annual Scientific Meeting of the Japanese Circulation Society)

Aoki Tatsuo, Fukumoto Yoshihiro, Sugimura Koichiro, Oikawa Minako, Sato Kimio, Nakano Makoto, Nakayama Masaharu, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　73　511-511　2009年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OJ-046 Evidence for Rho-kinase Activation in Patients with Pulmonary Arterial Hypertension(OJ08,Pulmonary Circulation (H),Oral Presentation (Japanese),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)

qiqige Zhulan, Fukumoto Yoshihiro, Takaki Aya, Tawara Shunsuke, Ohashi Junko, Nakano Makoto, Tada Tomohiro, Saji Kenya, Sugimura Koichiro, Fujita Hiroshi, Hoshikawa Yasushi, Nawata Jun, Kondo Takashi, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　73　297-297　2009年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OE-111 New Additional Prognostic Factors of Pulmonary Hypertension : Lessons from Long-Term Follow-Up Study(OE19,Pulmonary Circulation (H),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)

Miura Yutaka, Fukumoto Yoshihiro, Fukui Shigefumi, Satoh Kimio, Sugimura Koichiro, Oikawa Minako, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　73　202-202　2009年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
肺静脈閉塞症の診断における一酸化窒素吸入試験の有用性

杉村宏一郎, 福本義弘, 及川美奈子, 佐藤公雄, 中野誠, 三浦裕, 下川宏明

日本内科学会雑誌　98　(Suppl.)　127-127　2009年2月
出版者・発行元： (一社)日本内科学会
ISSN： 0021-5384

eISSN： 1883-2083
左房へのシャントを認めた肺動脈原発血管肉腫の1例

清水亨, 杉村宏一郎, 福本義弘, 及川美奈子, 佐藤公雄, 中野誠, 下川宏明

日本心臓病学会誌　4　(Supplement 1)　266-266　2009年
出版者・発行元： (一社)日本心臓病学会
ISSN： 1882-4501
鉄剤とErythropoietinにより右心不全の改善をみた慢性血栓塞栓性肺高血圧症の1例

太田淳, 佐藤公雄, 福本義弘, 杉村宏一郎, 及川美奈子, 中野誠, 三浦裕, 下川宏明

日本循環器学会東北地方会(Web)　148th　2009年
巨大冠動脈-肺動脈瘻/瘤の一例

金子仁彦, 福本義弘, 杉村宏一郎, 中野誠, 宮道沙織, 建部俊介, 及川美奈子, 佐藤公雄, 下川宏明

日本循環器学会東北地方会(Web)　149th　2009年
左室拡張不全の病態におけるRhoキナーゼ経路の重要性ダール食塩感受性高血圧ラットにおける検討

福井重文, 福本義弘, 鈴木潤, 佐治賢哉, 田原俊介, 杉村宏一郎, 縄田淳, 加賀谷豊, 下川宏明

血管　31　(4)　105-110　2008年12月
出版者・発行元：日本心脈管作動物質学会
ISSN： 0911-4637

詳細を見る詳細を閉じる

拡張不全の動物モデルであるダール食塩感受性高血圧ラットを用いて、高血圧性心疾患に起因する拡張不全およびその拡張機能障害の病態におけるRhoキナーゼ経路の役割について検討した。未治療の拡張不全群(DHF)、低用量ファスジル治療群および高用量ファスジル治療群に分けた。未治療のDHF群では、心エコー上コントロール群に比して11週齢から17週齢にかけて左室壁厚が進行性に増大したが、高用量のファスジル投与群では左室壁厚の増大が有意に抑制された。ファスジルによる治療、は血圧に影響することなく、左室肥大および肺水腫の状態を有意に改善した。左室間質の線維化は、ファスジル治療により用量依存的に抑制された。左室局所のスーパーオキサイドの産生は、コントロール群に比して未治療のDHF群において有意に亢進していたが、ファスジル治療により有意に改善した。
Diabetes mellitus exacerbates left ventricular diastolic dysfunction through activation of renin-angiotensin system in hypertensive rats

S. Fukui, Y. Fukumoto, J. Suzuki, K. Saji, J. Nawata, K. Sugimura, T. Shinozaki, Y. Kagaya, H. Shimokawa

EUROPEAN HEART JOURNAL　29　383-383　2008年9月

ISSN： 0195-668X
Diabetes mellitus exacerbates diastolic dysfunction through activation of renin-angiotensin system in hypertensive rats

Shigefumi Fukui, Yoshihiro Fukumoto, Jun Suzuki, Kenya Saji, Jun Nawata, Koichiro Sugimura, Yutaka Miura, Tsuyoshi Shinozaki, Yutaka Kagaya, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　14　(7)　S151-S151　2008年9月

ISSN： 1071-9164
重症心不全を合併した褐色細胞腫の一例

岩根尊, 関口悟, 川岸直樹, 赤松順寛, 渡辺道雄, 中島範昭, 佐藤和重, 宮城重人, 武田郁央, 中村篤司, 福本義弘, 縄田淳, 杉村宏一郎, 福井重文, 阿部高明, 阿部倫明, 藤盛啓成, 大内憲明, 里見進

日本内分泌外科学会総会プログラム・抄録集　20回　74-74　2008年6月
出版者・発行元： (一社)日本内分泌外科学会
PJ-171 Pravastatin Ameliorates Hypoxia-Induced Pulmonary Arterial Hypertension Through Down-regulation of Stromal Cell-Derived Factor-1 in Mice(Pulmonary circulation(03)(H),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Nakano Makoto, Satoh Kimio, Fukumoto Yoshihiro, Sugimura Koichiro, Nawata Jun, Demachi Jun, Karibe Akihiko, Kagaya Yutaka, Watanabe Jun, Shirato Kunio, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　72　554-554　2008年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PE-563 Acute Vasodilator Effects of Inhaled Fasudil, a Specific Rho-Kinase Inhibitor, in Ptients with Pulmonary Arterial Hypertension(Pulmonary circulation(02)(H),Poster Session(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Fukumoto Yoshihiro, Fujita Hiroshi, Saji Kenya, Sugimura Koichiro, Demachi Jun, Nawata Jun, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　72　501-501　2008年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PE-567 Prognostic Impact of Main Pulmonary Artery Remodeling in Patients with Pulmonary Arterial Hypertension(Pulmonary circulation(02)(H),Poster Session(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Sugimura Koichiro, Fukumoto Yoshihiro, Nawata Jun, Saji Kenya, Fukui Shigefumi, Miura Yutaka, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　72　502-502　2008年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PJ-744 Evidence for Rho-kinase Activation in Patients with Pulmonary Arterial Hypertention(Pulmonary circulation(04)(H),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Doe Zhulanqiqige, Nawata Jun, Tawara Shunsuke, Tada Tomohiro, Sugimura Koichiro, saji kenya, Fujita Hiroshi, Fukumoto Yoshihiro, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　72　699-699　2008年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OE-293 Enhanced Pulsatile Pressure Accelerates Vascular Smooth Muscle Migration : Implications for Atherogenesis of Hypertension(Vascular smooth muscle (IHD),Oral Presentation(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Tada Tomohiro, Nawata Jun, Wang Huan, Onoue Noriko, Doe ZhulanQiqige, Ito Kenta, Sugimura Koichiro, Fukumoto Yoshihiro, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　72　254-254　2008年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
Pravastatin ameliorates hypoxia-induced pulmonary arterial hypertension associated through down-regulation of stromal cell-derived factor-1 in mice

Makoto Nakano, Kimio Satoh, Yoshihiro Fukumoto, KoiChiro Sugimura, Jun Nawata, Jun Demachi, Akihiko Karibe, Yutaka Kagaya, Jun Watanabe, Kunio Shirato, Nacto Ishii, Kazuo Sugamura, Hiroaki Shimokawa

CIRCULATION　116　(16)　122-122　2007年10月

ISSN： 0009-7322
東北大学病院における熱傷治療の現況

篠澤洋太郎, 赤石敏, 田熊清継, 佐々木淳一, 黒田宙, 山内聡, 杉村宏一郎, 遠藤智之, 中川敦寛, 野村亮介, 小林道生, 工藤大介, 北條伸子, 安藤亮, 赤松順寛, 関根祐樹

熱傷　33　(2)　105-105　2007年6月
出版者・発行元： (一社)日本熱傷学会
ISSN： 0285-113X
熱傷初期診療の標準化 ABLS(advanced burn life support)コースの日本導入に向けて

田熊清継, 佐々木淳一, 赤石敏, 黒田宙, 山内聡, 杉村宏一郎, 遠藤智之, 中川敦寛, 野村亮介, 小林道生, 工藤大介, 北條伸子, 安藤亮, 赤松順寛, 関根祐樹, 篠澤洋太郎

熱傷　33　(2)　105-105　2007年6月
出版者・発行元： (一社)日本熱傷学会
ISSN： 0285-113X
Sleep apnea predicts lethal arrhythmic events in patients with chronic heart failure

Tsuvoshi Shinozaki, Koichiro Sugimura, Shigefumi Fukui, Hiromasa Ogawa, Hiroaki Shimokawa

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY　49　(9)　54A-54A　2007年3月

ISSN： 0735-1097
PJ-826 Characteristics of the Responders to Epoprostenol Infusion Therapy in Patients with Severe Pulmonary Arterial Hypertension(Pulmonary circulation-3, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Demachi Jun, Fukumoto Yoshihiro, Nawata Jun, Sugimura Koichiro, Saji Kenya, Fujita Hiroshi, Sakuma Masahito, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　71　679-679　2007年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PJ-834 Identification of Non-Invasive Predictors of High-risk Patients with Pulmonary Arterial Hypertension(Pulmonary circulation-4, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Sugimura Koichiro, Fukumoto Yoshihiro, Demachi Jun, Nawata Jun, Oikawa Minako, Kagaya Yutaka, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　71　680-681　2007年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PE-043 Hemodynamic Factors Accelerate Vascular Smooth Muscle Migration Through IP3-Receptor : Implication for Atherogenesis of Hypertension(Atherosclerosis, basic-5, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Tada Tomohiro, Nawata Jun, Wang Huan, Onoue Noriko, Qiqige Zhulan, Ito Kenta, Sugimura Koichiro, Fukumoto Yoshihiro, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　71　335-335　2007年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OE-182 Increased Static Pressure Promotes Migration of Vascular Smooth Muscle Cells : Involvement of Rho-kinase Pathway(Vascular smooth muscle-1, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Onoue Noriko, Nawata Jun, Tada Tomohiro, Qiqige Zhulan, Wang Huan, Sugimura Koichiro, Fukumoto Yoshihiro, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　71　196-197　2007年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PJ-379 Sleep Apnea Predicts Lethal Arrhythmic Events in Patients with Chronic Heart Failure(Heart failure, clinical-11, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Shinozaki Tsuyoshi, Fukui Shigefumi, Sugimura Koichiro, Ogawa Hiromasa, Okabe Shinichi, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　71　566-566　2007年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OE-345 Determinants of Left Ventricular Reverse Remodeling after Cardiac Resynchronization Therapy : Evaluation Using Quantitative Gated Myocardial Perfusion SPECT(Heart failure, clinical-03, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Wakayama Yuji, Kumagai Koji, Fukuda Koji, Sugai Yoshinao, Hirose Masanori, Oikawa Minako, Sugimura Koichiro, Kagaya Yutaka, Kaneta Tomohiro, Fukuda Hiroshi, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　71　237-237　2007年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OE-348 Reverse Remodeling after Cardiac Resynchronization Therapy Influences Cardiac Events due to Heart Failure but not Ventricular Arrhythmias(Heart failure, clinical-03, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Wakayama Yuji, Kumagai Koji, Fukuda Koji, Sugai Yoshinao, Hirose Masanori, Oikawa Minako, Sugimura Koichiro, Kagaya Yutaka, Kaneta Tomohiro, Fukuda Hiroshi, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　71　238-238　2007年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
肺動脈性肺高血圧症患者におけるPGI2投与の中止・減量の検討

縄田淳, 出町順, 杉村宏一郎, 佐藤公雄, 佐久間聖仁, 福本義弘, 下川宏明

Therapeutic Research　27　(10)　1937-1939　2006年10月
出版者・発行元：ライフサイエンス出版(株)
ISSN： 0289-8020

詳細を見る詳細を閉じる

症例1(51歳女)。歩行時の胸痛が出現し肺動脈性肺高血圧症(IPAH)と診断され、エポフロステノール投与を開始した。その後、血圧上昇、胸部不快、めまいの出現で再入院となり精神状態悪化で症状精神病と診断され、在宅でエポプロステノールの自己管理が困難となり漸減を開始したが肺血管抵抗の増悪は認めず、ベラプロスト、Ca拮抗薬とワルファリンを加えた後中止したが肺高血圧の増悪は認めなかった。症例2(36歳女)。労作時の息切れ、浮腫出現によりIPAHと診断されベラプロスト投与で退院した。内服薬の自己中断もあり浮腫の再出現で入院しエポプロステノール投与開始後、血行動態、運動耐用態の改善が見られたが、本人希望によりボセンタンに切り替えた。頭痛、顔面紅潮の出現でPGI2を急速に減量し、その後1週間1ng/kg/minで減量し中止した。血行動態は再入院当時と同等まで増悪しており、6分間歩行、BNP値も増悪を認めた。エポプロステノールの減量・中止には安定状態における平均肺動脈や投与量が重要であると考えられた。
Chronic effects of home oxygen therapy on brain-natriuretic peptide in chronic heart failure complicated with central sleep apnea

Shigefumi Fukui, Shinozaki Tsuyoshi, Sugimura Koichiro, Ogawa Hiromasa, Fukumoto Yoshihiro, Shimokawa Hiroaki

JOURNAL OF CARDIAC FAILURE　12　(8)　S184-S184　2006年10月

ISSN： 1071-9164
Usefulness of quantitative gated myocardial perfusion SPECT to evaluate the initial effectiveness of cardiac resynchronization therapy and to predict left ventricular reverse remodeling

Yuji Wakayama, Minako Oikawa, Yutaka Kagaya, Koji Kumagai, Koji Fukuda, Yoshinao Sugai, Koichiro Sugimura, Tomohiro Kaneta, Hiroshi Fukuda, Hiroaki Shimokawa

CIRCULATION　114　(18)　637-637　2006年10月

ISSN： 0009-7322
CRT improves abnormal left ventricular wall thickening and remodeling evaluated by quantitative gated myocardial perfusion SPECT

Wakayama Yuji, Koji Kumagai, Koji Fukuda, Yoshinao Sugai, Koichiro Sugimura, Tomohiro Kaneta, Hiroshi Fukuda, Yutaka Kagaya, Hiroaki Shimokawa

JOURNAL OF CARDIAC FAILURE　12　(8)　S180-S180　2006年10月

ISSN： 1071-9164
著明な近位部肺動脈拡大を認める特発性肺動脈性肺高血圧症の3例

出町順, 縄田淳, 杉村宏一郎, 鈴木潤, 福本義弘, 佐藤公雄, 佐久間聖仁, 白土邦男, 下川宏明

Journal of Cardiology　48　(Suppl.I)　663-663　2006年9月
出版者・発行元： (一社)日本心臓病学会
ISSN： 0914-5087
肺高血圧症に対するボセンタンの効果と安全性

縄田淳, 出町順, 福本義弘, 杉村宏一郎, 佐藤公雄, 佐久間聖仁, 下川宏明

Journal of Cardiology　48　(Suppl.I)　662-662　2006年9月
出版者・発行元： (一社)日本心臓病学会
ISSN： 0914-5087
OJ-385 End-tidal Carbon Dioxide Predicts the Responsiveness of Patients with Chronic Heart Failure Associated with Central Sleep Apnea to Oxygen Therapy(Heart failure, clinical-6 (M) OJ65,Oral Presentation (Japanese),The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society)

Sugimura Koichiro, Shinozaki Tsuyoshi, Fukui Shigefumi, Ogawa Hiromasa, Watanabe Jun, Shirato Kunio, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　70　330-330　2006年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OE-072 Pathogenetic Link between Microtubule Polymerization and Myocyte Apoptisis : Implication for Heart Failure(Cell death, apoptosis/necrosis (M) OE12,Oral Presentation (English),The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society)

Saji Kenya, Suzuki Jun, Nawata Jun, Demachi Jun, Oikawa Minako, Sugimura Koichiro, Fukui Shigefumi, Tada Tomohiro, Sakuma Masahito, Shirato Kunio, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　70　166-166　2006年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OE-218 Risk Factors and Incidence of Pulmonary Embolism in Japan 2004(Thromboembolism/Antithrombotic therapy/Thrombolysis-1 (H) OE37,Oral Presentation (English),The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society)

Sugimura Koichiro, Sakuma Masahito, Shirato Kunio, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　70　203-203　2006年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PE-483 Prognostic Impact of Central Sleep Apnea in Patients with Chronic Heart Failure(Heart failure, clinical-9 (M) PE81,Poster Session (English),The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society)

Fukui Shigefumi, Shinozaki Tsuyoshi, Sugimura Koichiro, Ogawa Hiromasa, Kagaya Yutaka, Watanabe Jun, Shirato Kunio, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　70　454-454　2006年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PE-537 Evidence for Mobilization of Vascular Progenitor Cells in Patients with Pulmonary Hypertension(Regeneration (angionenesis/myocardial regeneration)-4 (M) PE90,Poster Session (English),The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society)

Nakano Makoto, Satoh Kimio, Do.e Zhulanqiqige, Nawata Jun, Ito Yoshitaka, Sugimura Koichiro, Kagaya Yutaka, Shimokawa Hiroaki

Circulation journal : official journal of the Japanese Circulation Society　70　467-467　2006年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
肺高血圧症を伴った片側肺動脈無形成症の一症例

杉村宏一郎, 及川美奈子, 出町順, 福本義弘, 縄田淳, 佐藤公雄, 佐久間聖仁, 下川宏明

Circulation Journal　70　(Supplement 3)　2006年

ISSN： 1346-9843
原発性肺高血圧症合併した肺動脈仮性瘤にコイル塞栓術が有効であった一例(第139回日本循環器学会東北地方会)

相馬真子, 佐久間聖仁, 出町順, 鈴木潤, 縄田淳, 杉村宏一郎, 多田智洋, 福井重文, 白土邦男

Circulation journal : official journal of the Japanese Circulation Society　69　899-899　2005年10月20日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
The Outcome of Long-term Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension (Pulmonary Circulation 4 (H), The 69th Annual Scientific Meeting of the Japanese Circulation Society)

Sugimura Koichiro, Sakuma Masahito, Suzuki Jun, Demachi Jun, Nawata Jun, Saji Kenya, Soma Shinko, Tada Tomonori, Fukui Shigefumi, Shirato Kunio

Circulation journal : official journal of the Japanese Circulation Society　69　642-642　2005年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
Central Sleep Apnea Predicts the Prognosis of Patients with Chronic Heart Failure Independent of Brain Natriuretic Peptide(Heart Failure, Clinical 11 (M), The 69th Annual Scientific Meeting of the Japanese Circulation Society)

Fukui Shigefumi, Shinozaki Tsuyoshi, Sugimura Koichiro, Ogawa Hiromasa, Kagaya Yutaka, Watanabe Jun, Shirato Kunio

Circulation journal : official journal of the Japanese Circulation Society　69　412-412　2005年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
Oxygen Therapy Decreases Sympathetic Nerve Activity and Brain Natriuretic Peptide in Patients with Chronic Heart Failure and Central Sleep Apnea(Heart Failure, Clinical 11 (M), The 69th Annual Scientific Meeting of the Japanese Circulation Society)

Sugimura Koichiro, Shnozaki Tsuyoshi, Ogawa Hiromasa, Kagaya Yutaka, Watanabe Jun, Shirato Kunio

Circulation journal : official journal of the Japanese Circulation Society　69　413-413　2005年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
An Analysis of Pulmonary Embolism Associated with Pregnancy, Deliverly and Infection in 396, 982 Autopsies(Thrombosis/Thrombolysis 3 (IHD), The 69th Annual Scientific Meeting of the Japanese Circulation Society)

Sugimura Koichiro, Sakuma Masahito, Takahahshi Tohru, Kitamukai Osamu, Shirato Kunio, Nakamura Mashio, Yazu Takahiro, Yamada Norikazu, Nakano Takeshi

Circulation journal : official journal of the Japanese Circulation Society　69　248-248　2005年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
OE-095 Hypertension Promotes the Phosphorylation of FAK and PYK2 in a Pressure Dependent Manner in Rat Aorta(Molecular Biology, Vascular 1 (H) : OE12)(Oral Presentation (English))

Sugimura Koichiro, Nawata Jun, Wang Huan, Kakudoh Noriko, Suzuki Jun, Sakuma Masahito, Shirato Kunio

Circulation journal : official journal of the Japanese Circulation Society　68　164-164　2004年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PJ-623 Increased Static Pressure Promotes Collagen Gel Contraction by Cardiac Fibroblasts without Cell Proliferation(Cardiac Hypertrophy, Basic and Clinical 2 (M) : PJ104)(Poster Session (Japanese))

Nawata Jun, Wang Huan, Kakudoh Noriko, Sugimura Koichiro, Suzuki Jun, Sakuma Masahito, Shirato Kunio

Circulation journal : official journal of the Japanese Circulation Society　68　632-633　2004年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
PE-297 Oxygen Therapy Decreases Central Sleep Apnea and Excretion of Nocturnal Urinary Norepinephrine in Patients with Chronic Heart Failure(Heart Failure, Clinical 12 (M) : PE51)(Poster Session (English))

Sugimura Koichiro, Shinozaki Tsuyoshi, Takahashi Takanori, Ogawa Hiromasa, Okabe Shinichi, Watanabe Jun, Shirato Kunio

Circulation journal : official journal of the Japanese Circulation Society　68　434-434　2004年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
2 Nocturnal Oxygen Therapy to Patients With Chronic Heart Failure and Central Sleep Apnea(Meet the Expert 2 (ME2) (M) : Therapeutic Strategy for Chronic Heart Failure)(Special Program)

Shinozaki Tsuyoshi, Ogawa Hiromasa, Takahashi Takanori, Sugimura Koichiro, Okabe Shinichi, Kagaya Yutaka, Watanabe Jun, Shirato Kunio

Circulation journal : official journal of the Japanese Circulation Society　68　69-70　2004年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843
Hypersensltivity of Central Chemoreceptors Contribute to Central Sleep Apnea in Patients with Congestive Heart Failure

Sugimura Koichiro, Shinozaki Tsuyoshi, Okabe Shinichi, Sakuma Masahito, Ogawa Hiromasa, Takahashi Takanori, Oikawa Minako, Watanabe Jun, Shirato Kunio

Circulation journal : official journal of the Japanese Circulation Society　67　468-468　2003年3月1日
出版者・発行元：社団法人日本循環器学会
ISSN： 1346-9843

︎全件表示 ︎最初の5件までを表示

共同研究・競争的資金等の研究課題 10

乳がん患者における網羅的ゲノム・オミックス解析に基づく心毒性発症機序の解明

杉村宏一郎, 後岡広太郎, 黒住献, 堀口淳

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：International University of Health and Welfare

2021年4月1日～ 2024年3月31日

詳細を見る詳細を閉じる

本研究課題では、乳がん治療におけるアドリアマイシン及びトラスツズマブ投与に関連する心臓合併症の問題点を克服するために、1年目の令和3年度は以下の研究を行った。 ①国際医療福祉大学成田病院における化学療法を受ける乳がん患者について乳腺外科と循環器内科において心臓の画像診断を行っていく体制を確立した。 ②CHECKHEART BC研究（2018年5月～2020年3月31日 AMED管理番号：19ek0210084h0003）と CHECKHEART BC OMICS研究(2019年11月11日～2021年9月30日 AMED管理番号：20ck0106529h0002）におけるデータベースより67名の患者に対して心臓MRI（CMR）のデータより解析を行った。左心室の収縮の指標である左室駆出率（LVEF）とglobal lomgitudinal strain(GLS)は化学療法前後で有意に低下した。同様に心筋障害のマーカーとなるnativeT1値は有意に上昇した。心毒性発生に化学療法前のNativeT1値が最も関与していた。また、CHECKHEART-BC OMICS試験においては、最終でデータベース上288名の患者が登録され、OMICSデータ利用可能な患者数は174名に至った。解析可能な174名中、心収縮低下の発生は37名（21％）であった。 ③33症例のオミックス解析を行った。有意差のあるメタボローム19種の同定を行うことができた。上位６つではsphingomyelinのSM24:0 SM24：1 SM(C26:0) SM(OH)C22:1、Cholesterol esterのCE(18:3)、phosphatidylcholineの PCae(C38:1)があげられる。現在は、各メタボロームに関して経時的な変化を合わせて心毒性のリスクになりうるのか検討を行う予定である。
心臓MRIの画質改善・定量性向上を目的としたDLRを用いたデノイズ手法の開発

森田佳明, 藤島史喜, 大田英揮, 杉村宏一郎, 福田哲也

2019年4月1日～ 2022年3月31日

詳細を見る詳細を閉じる

本研究は、心臓MRIの撮影法であるCine MRI, T1 mapping, 冠動脈MRI（MRAおよびプラークイメージング）に対するDeep Learning Reconstruction（DLR）の有用性を検討するものである。まず、分担研究者および共同研究者（キャノンメディカルシステムズ）との間で複数回のミーティングを行い、最適なシーケンスやパルスデザイン、DLRによる後処理に関する検討を行った。その後、キャノンメディカルシステムズ開発センターにて、実機（高傾斜磁場強度3T-MRI）を用いてボランティア撮影における評価を行った。冠動脈MRAに関しては、データサンプリングおよび呼吸同期の効率を改善した高速撮影法を応用することで、これまでの撮影よりも約70％の撮影時間を短縮することが可能となり、さらにDLRを適用することで従来法と同等の画質やコントラスト分解能を維持することが可能であった。この結果を、ISMRM（International Society of Magnetic Resonance in Medicine） 28th Annual Meeting & Exhibition, 2020に投稿し、 oral scientific sessionに採択された。 T1 mappingに関しては、従来使用されているMOLLI法よりも系統誤差が少なく、撮影時間が短縮可能なSASHA法に関してパルスデザインの検討を行い、ファントムおよびボランティア撮影を行い、T1計測の精度に関する検証を行った。冠動脈プラークイメージングに関しては、従来法の問題点を検証し、新たなパルスデザインやDLRの応用に関する議論を行った。
オミックス解析に基づく乳がん患者における化学療法による心毒性発症機序の解明と危険因子の探索

2019年11月～ 2021年9月
形態・機能画像と数値流体力学による慢性血栓塞栓性肺高血圧症の肺血流解析

大田英揮, 太田信, 杉村宏一郎

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2016年4月1日～ 2019年3月31日

詳細を見る詳細を閉じる

本研究では，慢性血栓塞栓性肺高血圧症に対して4D flow MRIとデュアルエナジーCTから，肺血流の解析を行った．具体的には，1）慢性血栓塞栓性肺高血圧症に対する肺動脈血管拡張術前後において，デュアルエナジーCTの画像を解析し，血液分布を反映するCT造影剤の分布が，肺実質内で有意に変化し，肺動脈圧とその分布に相関があることを示した．2）4D flow MRIを用いて，肺動脈血管形成術前後における数値流体力学的パラメータを比較したところ，壁せん断応力が治療後に上昇したことが確認できた．また，その変化度は，肺動脈圧の変化度と相関していた．
乳がん治療における心臓合併症の画像診断を用いた新たなリスク因子探索と心機能評価法標準化に関する研究 ― Cardio-oncologyの実践

2017年4月～ 2019年3月
虚血性心不全の増悪および死亡リスク予測に有用なマイクロRNAの探索

坂田泰彦, 宮田敏, 杉村宏一郎, 三浦正暢, 河原行郎

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2015年4月1日～ 2018年3月31日

詳細を見る詳細を閉じる

世界に先駆けて超高齢化社会に突入した我が国に於いては近年、虚血性心不全患者が急増し、医療経済を圧迫している。本研究ではこのように現在社会問題となっている虚血性心不全症例の生活の質と生命予後改善のため、虚血性心不全の予後予測に有用なマイクロRNAの同定とその作用機序の解明を通じて治療への応用を検討した。具体的には虚血性心不全症例の血清を用い、種々の病態において遺伝子発現制御に関与することが明らかになり、また近年バイオマーカーとしても注目を集めている非コードRNAであるマイクロRNAの網羅的解析を行い、虚血性心不全症例の心不全増悪・および死亡リスク予測に有用なマイクロRNAを同定を試みた。
非手術適応慢性血栓塞栓性肺高血圧症に対する新しい診断・治療・評価法の確立

杉村宏一郎, 佐藤公雄

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2015年4月1日～ 2018年3月31日

詳細を見る詳細を閉じる

われわれは、以下の成果を報告した。 1)肺動脈の血流の改善（Eur Heart J. 2015）2)全身代謝の改善（Circ J. 2016）3)酸素化の改善（Circ J. 2016）4)統合失調症患者におけるCTEPHの頻度（Int J Cardiol. 2016）5)両心室の機能の改善（Circ J. 2016）6)Dual-energy CTによる評価（Eur J Radiol. 2016）7)CTEPHへのTAFIが関与（Arterioscler Thromb Vasc Biol. 2016）8)BPAは長期予後を改善する（Eur Heart J 2017 38:3152-3159.）
慢性血栓塞栓性肺高血圧症肺生検診断による手術適応・予後診断の確立

八巻重雄, 齋木佳克, 川本俊輔, 堀井明, 佐藤公雄, 杉村宏一郎

2014年4月1日～ 2017年3月31日

詳細を見る詳細を閉じる

難病に指定されている慢性血栓閉塞性肺高血圧症の予後改善を目指し、肺生検による手術適応・予後診断基準を確立すべく、東北大学大学院医学系研究科心臓血管外科学分野内に肺血管研究室を整備し、肺血管病理診断の主体を既存の日本肺血管研究所(仙台市)から移し、研究を開始した。まず、これまで集積してきた肺病理標本を後方視的に解析した。特に抗がん剤治療後に肺高血圧を発症した7例に関して、その病理学的特徴として直径100-500μm大の小肺動脈内および肺静脈内の血栓形成を認めることを見いだし、それらが肺高血圧症発生の機序である可能性と考え、これらの症例の予後を含めて学術論文にまとめ、Pulmonary Medicine誌に報告した1)。 (その後、研究代表者が急逝したため、本研究費は初年度途中で執行中止し返納した) 参考文献 1) Kay Maeda, Yoshikatsu Saiki, and Shigeo Yamaki. In Situ Thrombosis of Small Pulmonary Arteries in Pulmonary Hypertension Developing after Chemotherapy for Malignancy. Pulmonary Medicine 2015 (2015), Article ID 230846, 6 pages
末梢型慢性血栓塞栓性肺高血圧症に対する新たな治療法の確立

杉村宏一郎, 福本義弘

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2012年4月1日～ 2015年3月31日

詳細を見る詳細を閉じる

予後不良の疾患である慢性血栓塞栓性肺高血圧症（CTEPH）に対して、経皮的肺動脈形成術(PTPA)を確立することを目標に研究してきた。我々は光干渉断層法（OCT）(Circ J. 2013;77:1081 Eur Heart J. 2013;34:2121)を用い重大な合併症の克服を試みた治療効果と安全性を2013年欧州呼吸器学会議で報告した。また、カテーテル中に採取した血液検体より、CTEPHの原因として、血栓における線溶抵抗性にTAFIが関与することを2013年11月のアメリカ循環器学会で報告した。現在までに61名に加療を行い、その安全性、有効性を論文、学会へ報告する予定である。
新しい原理(低酸素細胞のPETイメージング)に基づく心筋虚血評価法の開発

加賀谷豊, 杉村宏一郎, 高井良尋, 岩田錬, 金田朋洋

2007年～ 2008年

詳細を見る詳細を閉じる

冠動脈造影による冠動脈の狭窄度の評価を行っただけでは、適切な症例に適切に冠動脈インターベンションあるいは冠動脈バイパス術を行うことはできない。従って、主として画像診断による心筋バイアビリティの評価が極めて重要である。FDGを用いたポジトロン断層撮影(PET)はこの目的に頻繁に使用されるが、患者のインスリン分泌能あるいは心筋のインスリン感受性の影響を受けることから、新しいイメージング剤の開発が強く望まれている。東北大学では放射線増感剤1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole(以下RP-170)のフッ素誘導体を^<18>Fで標識した新しい低酸素細胞イメージング剤[^<18>F]FRP-170の合成に成功している。本研究において、[^<18>F]FRP-170を用いたPET検査が心筋バイアビリティの評価に有用であるか否かを検証した。冠動脈に有意狭窄病変がある安定した冠動脈疾患患者において、[^<18>F]FRP-170を用いた運動負荷心臓PETを行った。自転車エルゴメータによる多段階負荷によりエンドポイントに達したところで、予め確保しておいた静脈ラインから[^<18>F]FRP-1705mCiを注射した。注射後約30秒間は運動を続け、PETの撮像は[^<18>F]FRP-170投与後、5分間隔で1時間後まで行った。以前我々が報告したラットを用いた動物実験の結果とは異なり、[^<18>F]FRP-170の集積に関して虚血領域と非虚血領域の違いが明瞭でなかった。今後、さらに投与方法を変更することや心筋虚血のより強い症例において検討を重ねる必要があると考える。

︎全件表示 ︎最初の5件までを表示